Short-Course Chemotherapy for Tuberculosis by Christie, DA & Tansey, EM
Short-Course Chemotherapy for Tuberculosis













Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
SHORT-COURSE CHEMOTHERAPY 
FOR TUBERCULOSIS
The transcript of a Witness Seminar held by the Wellcome Trust Centre 
for the History of Medicine at UCL, London, on 3 February 2004
Edited by D A Christie and E M Tansey
Volume 24 2005
©The Trustee of the Wellcome Trust, London, 2005
First published by the Wellcome Trust Centre 
for the History of Medicine at UCL, 2005
The Wellcome Trust Centre for the History of Medicine 
at University College London is funded by the Wellcome Trust,
which is a registered charity, no. 210183.
ISBN 978 0 85484 104 2
Histmed logo images courtesy of the Wellcome Library, London.
Design and production: Julie Wood at Shift Key Design 020 7241 3704
 
All volumes are freely available online at: www.history.qmul.ac.uk/research/modbiomed/wellcome_witnesses/  
 
Please cite as: Christie D A, Tansey E M. (eds) (2005) Short-Course Chemotherapy forTuberculosis.
Wellcome Witnesses to Twentieth Century Medicine, vol. 24. London: Wellcome Trust Centre for the 
History of Medicine at UCL.
CONTENTS
Illustrations and credits v
Witness Seminars: Meetings and publications;Acknowledgements vii




Edited by D A Christie and E M Tansey 1
Appendix 1 75
Wallace Fox’s contributions to tuberculosis 








Figure 1 Professor Wallace Fox in 1959. Photograph provided 
and reproduced by permission of Mrs Gaye Fox. 4
Figure 2 Sputum conversion in advanced pulmonary tuberculosis 
on treatment with three regimens of chemotherapy. 
Figure provided by Dr Joseph Angel. Reproduced 
by permission of Elsevier, Health Sciences 
Rights Department. 23
Figure 3 Cumulative percentage of patients culture-negative 
at each month during the course of drug treatment. 
Figure provided by Dr Joseph Angel. Reproduced 
by permission of Elsevier, Health Sciences 
Rights Department. 23
Figure 4 Dr Philip D’Arcy Hart in the 1950s. 
Reproduced by permission of Photographics, 
National Institute for Medical Research and 
his son Professor Oliver Hart, 2005. 34

vii
1 The following text also appears in the ‘Introduction’ to recent volumes of Wellcome Witnesses to
Twentieth Century Medicine published by the Wellcome Trust and the Wellcome Trust Centre for the
History of Medicine at University College London.
WITNESS SEMINARS:
MEETINGS AND PUBLICATIONS1
In 1990 the Wellcome Trust created a History of Twentieth Century
Medicine Group, as part of the Academic Unit of the Wellcome Institute for
the History of Medicine, to bring together clinicians, scientists, historians and
others interested in contemporary medical history. Among a number of other
initiatives the format of Witness Seminars, used by the Institute of
Contemporary British History to address issues of recent political history, was
adopted, to promote interaction between these different groups, to emphasize
the potential benefits of working jointly, and to encourage the creation and
deposit of archival sources for present and future use. In June 1999 the
Governors of the Wellcome Trust decided that it would be appropriate for the
Academic Unit to enjoy a more formal academic affiliation and turned the
Unit into the Wellcome Trust Centre for the History of Medicine at
University College London from 1 October 2000. The Wellcome Trust
continues to fund the Witness Seminar programme via its support for the
Wellcome Trust Centre.
The Witness Seminar is a particularly specialized form of oral history, where several
people associated with a particular set of circumstances or events are invited to
come together to discuss, debate, and agree or disagree about their memories. To
date, the History of Twentieth Century Medicine Group has held 40 such
meetings, most of which have been published, as listed on pages xi–xviii.
Subjects are usually proposed by, or through, members of the Programme
Committee of the Group, and once an appropriate topic has been agreed,
suitable participants are identified and invited. This inevitably leads to further
contacts, and more suggestions of people to invite. As the organization of the
meeting progresses, a flexible outline plan for the meeting is devised, usually
with assistance from the meeting’s chairman, and some participants are invited
to ‘set the ball rolling’ on particular themes, by speaking for a short period to
initiate and stimulate further discussion. 
Each meeting is fully recorded, the tapes are transcribed and the unedited
transcript is immediately sent to every participant. Each is asked to check his
or her own contributions and to provide brief biographical details. The editors
turn the transcript into readable text, and participants’ minor corrections and
comments are incorporated into that text, while biographical and
bibliographical details are added as footnotes, as are more substantial
comments and additional material provided by participants. The final scripts
are then sent to every contributor, accompanied by forms assigning copyright
to the Wellcome Trust. Copies of all additional correspondence received
during the editorial process are deposited with the records of each meeting in
Archives and Manuscripts, Wellcome Library, London.
As with all our meetings, we hope that even if the precise details of some of the
technical sections are not clear to the non-specialist, the sense and significance
of the events will be understandable. Our aim is for the volumes that emerge
from these meetings to inform those with a general interest in the history of
modern medicine and medical science; to provide historians with new insights,
fresh material for study, and further themes for research; and to emphasize to
the participants that events of the recent past, of their own working lives, are




Short-course chemotherapy for tuberculosis was suggested as a suitable topic
for a Witness Seminar by Dr Owen McCarthy. He provided many of the
names of individuals to be invited, and helped decide on the topics to be
discussed. We thank him for his input. We are particularly grateful to Professor
Linda Bryder for writing the Introduction to these published proceedings and
to Dr David Girling for his excellent chairing of the occasion and for his help
with the planning of the meeting. Dr Lise Wilkinson kindly read the edited
transcript for general sense and understandability. We thank Dr Joseph Angel,
Sir John Crofton, Dr David Girling and Professor Denny Mitchison for
additional help with the text. Mrs Gaye Fox and Dr Joseph Angel kindly
provided the illustrations. 
As with all our meetings, we depend a great deal on our colleagues at the
Wellcome Trust to ensure their smooth running: the Audiovisual Department,
the Medical Photographic Library and Mrs Tracy Tillotson of the Wellcome
Library; Ms Julie Wood, who has supervised the design and production of this
volume; our indexer, Ms Liza Furnival, and our readers, 
Ms Lucy Moore and Mr Simon Reynolds. Mrs Jaqui Carter is our transcriber,
and Mrs Wendy Kutner and Mrs Lois Reynolds assist us in running the
meetings. Finally we thank the Wellcome Trust for supporting this programme.
Tilli Tansey
Daphne Christie
Wellcome Trust Centre for the History of Medicine at UCL

xi
HISTORY OF TWENTIETH CENTURY MEDICINE
WITNESS SEMINARS, 1993–2005
1993 Monoclonal antibodies
Organizers: Dr E M Tansey and Dr Peter Catterall
1994 The early history of renal transplantation
Organizer: Dr Stephen Lock
Pneumoconiosis of coal workers
Organizer: Dr E M Tansey
1995 Self and non-self: A history of autoimmunity
Organizers: Sir Christopher Booth and Dr E M Tansey
Ashes to ashes: The history of smoking and health
Organizers: Dr Stephen Lock and Dr E M Tansey
Oral contraceptives
Organizers: Dr Lara Marks and Dr E M Tansey
Endogenous opiates
Organizer: Dr E M Tansey
1996 Committee on Safety of Drugs
Organizers: Dr Stephen Lock and Dr E M Tansey
Making the body more transparent: The impact of nuclear 
magnetic resonance and magnetic resonance imaging
Organizer: Sir Christopher Booth
1997 Research in general practice
Organizers: Dr Ian Tait and Dr E M Tansey
Drugs in psychiatric practice
Organizers: Dr David Healy and Dr E M Tansey
The MRC Common Cold Unit
Organizers: Dr David Tyrrell and Dr E M Tansey
The first heart transplant in the UK
Organizer: Professor Tom Treasure
1998 Haemophilia: Recent history of clinical management
Organizers: Professor Christine Lee and Dr E M Tansey
Obstetric ultrasound: Historical perspectives
Organizers: Dr Malcolm Nicolson, Mr John Fleming and 
Dr E M Tansey
Post penicillin antibiotics
Organizers: Dr Robert Bud and Dr E M Tansey
Clinical research in Britain, 1950–1980
Organizers: Dr David Gordon and Dr E M Tansey
1999 Intestinal absorption
Organizers: Sir Christopher Booth and Dr E M Tansey
The MRC Epidemiology Unit (South Wales)
Organizers: Dr Andy Ness and Dr E M Tansey
Neonatal intensive care
Organizers: Professor Osmund Reynolds and Dr E M Tansey
British contributions to medicine in Africa after the Second 
World War
Organizers: Dr Mary Dobson, Dr Maureen Malowany, 
Dr Gordon Cook and Dr E M Tansey
2000 Childhood asthma, and beyond
Organizers: Dr Chris O’Callaghan and Dr Daphne Christie
Peptic ulcer: Rise and fall
Organizers: Sir Christopher Booth, Professor Roy Pounder and 
Dr E M Tansey
Maternal care
Organizers: Dr Irvine Loudon and Dr Daphne Christie
2001 Leukaemia
Organizers: Professor Sir David Weatherall, Professor John 
Goldman, Sir Christopher Booth and Dr Daphne Christie
The MRC Applied Psychology Unit
Organizers: Dr Geoff Bunn and Dr Daphne Christie
Genetic testing
Organizers: Professor Doris Zallen and Dr Daphne Christie
xii
Foot and mouth disease: the 1967 outbreak and its aftermath
Organizers: Dr Abigail Woods, Dr Daphne Christie and 
Dr David Aickin
2002 Environmental toxicology: The legacy of Silent Spring
Organizers: Dr Robert Flanagan and Dr Daphne Christie
Cystic fibrosis
Organizers: Dr James Littlewood and Dr Daphne Christie
Innovation in pain management
Organizers: Professor David Clark and Dr Daphne Christie
2003 Thrombolysis
Organizers: Mr Robert Arnott and Dr Daphne Christie
Beyond the asylum: Anti-psychiatry and care in the community
Organizers: Dr Mark Jackson and Dr Daphne Christie
The Rhesus factor and disease prevention
Organizers: Professor Doris Zallen and Dr Daphne Christie
Platelets in thrombosis and other disorders
Organizers: Professor Gustav Born and Dr Daphne Christie
2004 Short-course chemotherapy for tuberculosis
Organizers: Dr Owen McCarthy and Dr Daphne Christie
Prenatal corticosteroids for reducing morbidity and mortality 
associated with preterm birth
Organizers: Sir Iain Chalmers and Dr Daphne Christie
Public health in the 1980s and 1990s: Decline and rise?
Organizers: Professor Virginia Berridge, Dr Niki Ellis and 
Dr Daphne Christie
2005 The history of cholesterol, atherosclerosis and coronary disease
Organizers: Professor Michael Oliver and Dr Daphne Christie
Development of physics applied to medicine in the UK, 1945–90




“…Few books are so intellectually stimulating or uplifting”.
Journal of the Royal Society of Medicine (1999) 92: 206–8, 
review of vols 1 and 2
“…This is oral history at its best…all the volumes make compulsive
reading…they are, primarily, important historical records”.
British Medical Journal (2002) 325: 1119, review of the series
Technology transfer in Britain: The case of monoclonal antibodies 
Self and non-self: A history of autoimmunity 
Endogenous opiates
The Committee on Safety of Drugs
In: Tansey E M, Catterall P P, Christie D A, Willhoft S V, Reynolds L A.
(eds) (1997) Wellcome Witnesses to Twentieth Century Medicine. Volume 1.
London: The Wellcome Trust, 135pp. ISBN 1 869835 79 4
Making the human body transparent: The impact of NMR and MRI 
Research in general practice
Drugs in psychiatric practice
The MRC Common Cold Unit
In: Tansey E M, Christie D A, Reynolds L A. (eds) (1998) Wellcome
Witnesses to Twentieth Century Medicine. Volume 2. London: The Wellcome
Trust, 282pp. ISBN 1 869835 39 5
Early heart transplant surgery in the UK
In: Tansey E M, Reynolds L A. (eds) (1999) Wellcome Witnesses to 
Twentieth Century Medicine. Volume 3. London: The Wellcome Trust, 
72pp. ISBN 1 841290 07 6
Haemophilia: Recent history of clinical management
In: Tansey E M, Christie D A. (eds) (1999) Wellcome Witnesses to Twentieth
Century Medicine. Volume 4. London: The Wellcome Trust, 90pp. 
ISBN 1 841290 08 4
Looking at the unborn: Historical aspects of obstetric ultrasound
In: Tansey E M, Christie D A. (eds) (2000) Wellcome Witnesses to Twentieth
xv
Century Medicine. Volume 5. London: The Wellcome Trust, 80pp. 
ISBN 1 841290 11 4
Post penicillin antibiotics: From acceptance to resistance? 
In: Tansey E M, Reynolds L A. (eds) (2000) Wellcome Witnesses to Twentieth
Century Medicine. Volume 6. London: The Wellcome Trust, 71pp. 
ISBN 1 841290 12 2
Clinical research in Britain, 1950–1980
In: Reynolds L A, Tansey E M. (eds) (2000) Wellcome Witnesses to Twentieth
Century Medicine. Volume 7. London: The Wellcome Trust, 74pp.
ISBN 1 841290 16 5
Intestinal absorption
In: Christie D A, Tansey E M. (eds) (2000) Wellcome Witnesses to Twentieth
Century Medicine. Volume 8. London: The Wellcome Trust, 81pp. 
ISBN 1 841290 17 3
Neonatal intensive care
In: Christie D A, Tansey E M. (eds) (2001) Wellcome Witnesses to Twentieth
Century Medicine. Volume 9. London: The Wellcome Trust Centre for the
History of Medicine at UCL, 84pp. ISBN 0 854840 76 1
British contributions to medical research and education in Africa after the
Second World War
In: Reynolds L A, Tansey E M. (eds) (2001) Wellcome Witnesses to Twentieth
Century Medicine. Volume 10. London: The Wellcome Trust Centre for the
History of Medicine at UCL, 93pp. ISBN 0 854840 77 X
Childhood asthma and beyond
In: Reynolds L A, Tansey E M. (eds) (2001) Wellcome Witnesses to Twentieth
Century Medicine. Volume 11. London: The Wellcome Trust Centre for the
History of Medicine at UCL, 74pp. ISBN 0 854840 78 8
Maternal care
In: Christie D A, Tansey E M. (eds) (2001) Wellcome Witnesses to Twentieth
Century Medicine. Volume 12. London: The Wellcome Trust Centre for the
History of Medicine at UCL, 88pp. ISBN 0 854840 79 6
Population-based research in south Wales: The MRC Pneumoconiosis
Research Unit and the MRC Epidemiology Unit
In: Ness A R, Reynolds L A, Tansey E M. (eds) (2002) Wellcome Witnesses to
Twentieth Century Medicine. Volume 13. London: The Wellcome Trust
Centre for the History of Medicine at UCL, 74pp. ISBN 0 854840 81 8
Peptic ulcer: Rise and fall
In: Christie D A, Tansey E M. (eds) (2002) Wellcome Witnesses to Twentieth
Century Medicine. Volume 14. London: The Wellcome Trust Centre for the
History of Medicine at UCL, 143pp. ISBN 0 854840 84 2
Leukaemia
In: Christie D A, Tansey E M. (eds) (2003) Wellcome Witnesses to Twentieth
Century Medicine. Volume 15. London: The Wellcome Trust Centre for the
History of Medicine at UCL, 86pp. ISBN 0 85484 087 7
The MRC Applied Psychology Unit
In: Reynolds L A, Tansey E M. (eds) (2003) Wellcome Witnesses to Twentieth
Century Medicine. Volume 16. London: The Wellcome Trust Centre for the
History of Medicine at UCL, 94pp. ISBN 0 85484 088 5
Genetic testing
In: Christie D A, Tansey E M. (eds) (2003) Wellcome Witnesses to Twentieth
Century Medicine. Volume 17. London: The Wellcome Trust Centre for the
History of Medicine at UCL, 130pp. ISBN 0 85484 094 X
Foot and mouth disease: The 1967 outbreak and its aftermath
In: Reynolds L A, Tansey E M. (eds) (2003) Wellcome Witnesses to Twentieth
Century Medicine. Volume 18. London: The Wellcome Trust Centre for the
History of Medicine at UCL, 114pp. ISBN 0 85484 096 6
Environmental toxicology: The legacy of Silent Spring
In: Christie D A, Tansey E M. (eds) (2004) Wellcome Witnesses to Twentieth
Century Medicine. Volume 19. London: The Wellcome Trust Centre for the
History of Medicine at UCL, 132pp. ISBN 0 85484 091 5
Cystic fibrosis
In: Christie D A, Tansey E M. (eds) (2004) Wellcome Witnesses to Twentieth
Century Medicine. Volume 20. London: The Wellcome Trust Centre for the
History of Medicine at UCL, 120pp. ISBN 0 85484 086 9
xvi
Innovation in pain management
In: Reynolds L A, Tansey E M. (eds) (2004) Wellcome Witnesses to Twentieth
Century Medicine. Volume 21. London: The Wellcome Trust Centre for the
History of Medicine at UCL, 125pp. ISBN 0 85484 097 4
The Rhesus factor and disease prevention
In: Zallen D T, Christie D A, Tansey E M. (eds) (2004) Wellcome Witnesses to
Twentieth Century Medicine. Volume 22. London: The Wellcome Trust Centre
for the History of Medicine at UCL, 98pp. ISBN 0 85484 099 0
The recent history of platelets in thrombosis and other disorders
In: Reynolds L A, Tansey E M. (eds) (2005) Wellcome Witnesses to Twentieth
Century Medicine. Volume 23. London: The Wellcome Trust Centre for the
History of Medicine at UCL, 186pp. ISBN 0 85484 103 2
Short-course chemotherapy for tuberculosis 
In: Christie D A, Tansey E M. (eds) (2005) Wellcome Witnesses to Twentieth
Century Medicine. Volume 24. London: The Wellcome Trust Centre for the
History of Medicine at UCL, this volume. ISBN 0 85484 104 0
Prenatal corticosteroids for reducing morbidity and mortality associated
with preterm birth
In: Reynolds L A, Tansey E M. (eds) (2005) Wellcome Witnesses to Twentieth
Century Medicine. Volume 25. London: The Wellcome Trust Centre for the
History of Medicine at UCL. In press.
Public health in the 1980s and 1990s: Decline and rise?
In: Berridge V, Christie D A, Tansey E M. (eds) (2005) Wellcome Witnesses to
Twentieth Century Medicine. Volume 26. London: The Wellcome Trust
Centre for the History of Medicine at UCL. In press.
Volumes 1–12 cost £5 plus postage, with volumes 13–26 at £10 each.
Orders of four or more volumes receive a 20 per cent discount.
All 20 published volumes in the series are available at the special price 
of £115 plus postage.To order a copy contact t.tillotson@wellcome.ac.uk 
or by phone: +44 (0)20 7611 8486; or fax: +44 (0)20 7611 8703.
All volumes are freely available online under publications at www.ucl.ac.uk/histmed
A hard copy of volumes 21–24 can be ordered from www.amazon.co.uk;




Technology transfer in Britain: The case of monoclonal antibodies
In: Tansey E M, Catterall P P. (1993) Contemporary Record 9: 409–44.
Monoclonal antibodies: A witness seminar on contemporary medical history
In: Tansey E M, Catterall P P. (1994) Medical History 38: 322–7.
Chronic pulmonary disease in South Wales coalmines: An eye-witness
account of the MRC surveys (1937–42)
In: P D’Arcy Hart, edited and annotated by E M Tansey. (1998) Social
History of Medicine 11: 459–68.
Ashes to Ashes – The history of smoking and health
In: Lock S P, Reynolds L A, Tansey E M. (eds) (1998) Amsterdam: Rodopi
BV, 228pp. ISBN 90420 0396 0 (Hfl 125) (hardback). Reprinted 2003.
Witnessing medical history. An interview with Dr Rosemary Biggs
Professor Christine Lee and Dr Charles Rizza (interviewers). (1998)
Haemophilia 4: 769–77.
Witnessing the Witnesses: Pitfalls and potentials of the Witness Seminar 
in twentieth century medicine
By E M Tansey. In: Doel R,  Soderqvist T. (eds) (2005) Writing Recent 
Science: The historiography of contemporary science, technology and medicine. 
London: Routledge.
Members of the Programme Committee of the 
History of Twentieth Century Medicine Group, 2004–05
Dr Tilli Tansey – Historian of Modern Medical Science,Wellcome Trust Centre for
the History of Medicine at UCL (WTCHM) and Chair
Sir Christopher Booth – WTCHM, former Director, Clinical Research Centre,
Northwick Park Hospital, London
Dr Robert Bud – Principal Curator of Medicine and Manager of Electronic
Content, Science Museum, London
Dr Daphne Christie – Senior Research Assistant,WTCHM, and Organizing Secretary
Professor Hal Cook – Director, WTCHM
Professor Mark Jackson – Centre for Medical History, Exeter




When Archie Cochrane, the British medical researcher who contributed so
much to the development of epidemiology as a science, judged which speciality
in medicine deserved the gold medal for being the most evidence-based, he
gave a ‘Bradford’ (a ‘gold medal’ named after epidemiologist Sir Austin
Bradford Hill) to tuberculosis specialists, and he gave obstetrics the wooden
spoon (page 65).1 This witness seminar supports that assessment of
tuberculosis, providing a fascinating account of laboratory research, clinical
trials, and treatment regimens since the MRC randomized controlled trials on
the first antituberculosis drug, streptomycin, led by Bradford Hill, Philip
D’Arcy Hart and Marc Daniels in 1948.2
Standard treatment for pulmonary tuberculosis in the 1960s consisted of
administering streptomycin for three months, and the drugs isoniazid and PAS
(para-aminosalicylic acid) for 18 months to two years. This seemed to work.
Dr Kenneth Citron from the Royal Brompton Hospital, London, who had
been consultant adviser on tuberculosis to the Department of Health, tells us
of a follow-up study in England in 1971 showing that 90 per cent of patients
were treated for the allocated time and that all but 2 per cent became culture-
negative, and on a follow-up for three to seven years none had relapsed (page
67). The drive for a shorter course of treatment came not from Britain, with its
well-staffed tuberculosis clinics and army of tuberculosis health visitors, but
from developing countries with their under-developed health services, where
tuberculosis was rife and which later also had to contend with the HIV/AIDS
epidemic. The two-year course of treatment was not only expensive but there
was also a major problem of patient compliance and supervision. As a result of
various trials, primarily carried out in India and East Africa, by the end of the
1970s the accepted course of treatment had become an eight-month regimen,
consisting of two months of streptomycin/isoniazid/rifampicin/pyrazinamide,
followed by six months of thiacetazone and isoniazid. This was subsequently
reduced to six months, a change embraced wholeheartedly by health workers
in these countries, and endorsed by the International Union against
Tuberculosis and Lung Disease and the World Health Organization.
1 Cochrane (1979): 1–11.
2 Medical Research Council (1948); For details of Bradford Hill’s first attempt to introduce the concept
of randomization in controlled trials, see Wilkinson (1997). See also D’Arcy Hart (1999); Chalmers
(2005): 309–34.
Speakers at the seminar highlighted the important trials which led to the
changes – Professor Wallace Fox’s famous 1959 trial in Madras on sanatorium
versus home treatment, which contributed to the trend of closing of
tuberculosis sanatoria by the end of the 1960s (page 32).3 The East African
study, known affectionately as ‘Study R’, was the first short-course
chemotherapy study, carried out in 42 centres in East Africa and Zambia, and
coordinated by Dr Amina Jindani, one of the seminar’s witnesses. This study
along with one in Hong Kong, brought together the three drugs, isoniazid –
rifampicin and pyrazinamide – for the first time.
Dr David Girling, who was involved with the International Union Against
Tuberculosis and Lung Disease, listed the impressive geographical spread of
trials, including East and Central Africa, Hong Kong, Singapore, Transkei,
Poland, East Germany, Czechoslovakia, Algeria, Finland, Argentina and
Korea, as well as the UK and France. He commented, ‘I think this is probably
one of the largest international combined research enterprises that has been
conducted in the history of medicine’ (page 26), and Ian Campbell noted
significantly that it was not driven by pharmaceutical companies.
For the historian of medicine, the insights into the use of streptomycin are of
particular interest. Streptomycin is always given pride of place in medical
history books as the subject of the first randomized clinical trial. At the seminar
it was pointed out that it was not, as commonly believed, the very first ‘properly
controlled multicentre trial’; that honour goes to the 1944 antibiotic patulin
trial, organized by Philip D’Arcy Hart, who also ran the streptomycin trial
(page 35).4 The absence of D’Arcy Hart at the witness seminar was regretted,
although it was pointed out that his 104th birthday was imminent!
The streptomycin trial was considered by participants to be important for
another reason. Sir John Crofton, Professor of Respiratory Diseases and
Tuberculosis at the University of Edinburgh from 1952 to 1977, explained
that it was the first important new antibiotic after penicillin. Patients on
penicillin did not develop resistance under treatment; patients on
streptomycin did. In Crofton’s view, this was a grim new phenomenon and a
xx
3 Tuberculosis Chemotherapy Centre, Madras (1959).
4 Medical Research Council, Patulin Clinical Trials Committee (1944); Clinical trials ran from
December 1943 to April 1944, supervised by Dr Joan Faulkner. See also D’Arcy Hart (1999);
Chalmers and Clarke (2004); The James Lind Library (www.jameslindlibrary.org) visited
7 June 2005. 
forewarning of things to come. He also commented on the rather negative
initial response to this famous trial, until other drugs came along. Professor
Denis Mitchison, Professor of Bacteriology at the Royal Postgraduate Medical
School at Hammersmith Hospital, also thought streptomycin was ‘not a very
good drug’. Professor Peter Ormerod, another former consultant adviser on
tuberculosis to the Department of Health, provided a more personal touch. He
recalled as a seven-year-old experiencing intramuscular streptomycin: ‘As
someone who had very little buttock at the age of seven, it was not a very
pleasant experience’ – he had to sleep on his front for three months! (Page 31.)
Some ‘streptomycin defenders’, we are told, kept it for ‘fractious patients’, who
received injections to ensure compliance (page 39).
One of the advantages of a witness seminar, not normally captured in the
written record, is the sense of ‘being there’ when important research is being
carried out. Thus you have Dr Joseph Angel’s reference to research worker
Tony Jenkins ‘drowning in sputum’ (page 72), and Dr Jindani’s encounters
with giraffes and elephants in Africa (page 21). Professor Janet Darbyshire,
who coordinated MRC clinical trials in Africa, also described encounters with
elephants and lions, and spending hours and hours in Land Rovers (page 18).
Moreover, the way in which research was conducted in 1950s is often
forgotten in our computer age. Mrs Gaye Fox described research conditions
in Madras in the 1950s – ‘no air conditioning at all for the first two years, no
machines for sorting out statistical cards, hence the cards were sorted by hand,
in their thousands, without even the benefits of a fan to cool the room. Fans
would have blown the cards about!’ (Page 46.)
Drs Daphne Christie and Tilli Tansey are to be congratulated for bringing
together this remarkable group of experts who were involved in major
developments in the treatment of tuberculosis over the second half of the
twentieth century. The transcript will prove an invaluable document for
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Dr David Girling: Perhaps I can express a warm welcome to everybody to this
witness seminar on short-course chemotherapy. It’s good to see the interest that
this topic has attracted. It’s always seemed to me that a uniquely important
feature of the development of short-course treatment has been the enormously
large, worldwide programmes of randomized controlled trials, running in
parallel with essential laboratory research. I think it has been those two
components, complementing each other, that have been particularly
important. Now sadly, of course, a notable absentee is Professor Wallace Fox
(Figure 1),1 although we are delighted that Gaye, his wife, is able to be here
with us . As Director of the [British] Medical Research Council’s Tuberculosis
and Chest Diseases Unit,2 Wallace was responsible for directing the crucial
series of MRC clinical trials3 that led to the development of the now
internationally accepted six-month antituberculosis regimens, and it is indeed
sad that his health no longer allows him to participate in events such as this.
Perhaps we can all convey our affection and our very best wishes to him
through Gaye. Our aim is that the style of this meeting should be informal. We
are certainly invited to discuss and debate, but we are also invited to reminisce,
to say what it was like at the time, and why things happened the way they did,
the constraints that there were on the planning and the conduct of trials, and
the laboratory work. So please remember the historical nature of today’s
seminar. Now is our chance to establish our role in history.4
We come to the first main topic: laboratory research and the integration of
laboratory and clinical research. Denny Mitchison is kindly going to introduce
this topic for us.
Professor Denis Mitchison: Thank you. One can think in terms of how
fundamental the work was in the laboratory, and what was the timescale
involved. If we take the most fundamental point, which is how the
antibacterial drugs that we are concerned with, actually work, one finds that
Short-course Chemotherapy for Tuberculosis
3
1 See biographical note on page 101 and Appendix 1 (page 75).
2 Formerly the Tuberculosis Research Unit, 1946–68, the Tuberculosis and Chest Diseases Unit
(TCDU) continued until the retirement of its director Professor Wallace Fox in 1986. Members
included Tony Miller, Joan Heffernan, Bill Stott, Janet Darbyshire (Africa), David Girling (Hong
Kong and Singapore), Ruth Tall, Peter Fayers and Andrew Nunn (statisticians).
3 See Fox et al. (1999).
4 Dr David Girling wrote: ‘For a history of pulmonary tuberculosis, see Keers (1978). For a comprehensive
review of the [British] Medical Research Council studies, see Fox et al. (1999).’ Letter to Dr Daphne
Christie, 28 July 2004. See also D’Arcy Hart (1946); Tansey and Reynolds (2000); Mitchison (2005).
for rifampicin, its mode of action was known very early on in the 1960s.5 This,
with a little bit of addition, has not changed much since. But take the other
almost as important drug, pyrazinamide. Pyrazinamide was introduced in
1952,6 and it’s only really in the last year or two that we have a clear idea of
how it works. It is completely different from any other drug.7 For that reason,
one sometimes has to take a very long timescale. We used to look at
pyrazinamide and say this is a drug that never behaves the same in two
different experiments. Now the reasons for all that are much clearer.8
Short-course Chemotherapy for Tuberculosis
4
5 Rifampicin facilitates treatment by means of its capacity to kill mycobacteria undergoing
intermittent metabolism, the so-called ‘sterilizing effect’. See note 34. For a reference to its
biochemical mode of action, see Wehrli and Staehelin (1969).
6 See Chorine (1945); McKenzie et al. (1948); See also Mitchison (1985); Fox et al. (1999); Zhang
and Mitchison (2003). 
7 Zhang and Mitchison (2003). See also notes 19 and 22. 
8 Professor Denis Mitchison wrote: ‘We did not understand that the degree of bacterial metabolism
is as important as pyrazinamide concentration and pH in determining the bactericidal action of
pyrazinamide.’ Note on draft transcript, 22 March 2005.
Figure 1: Professor Wallace Fox in 1959 at
the time that he was working in India.
The other aspect of fundamental research is to look at modelling in various
ways. One can do it in terms of in vitro exposure of bacilli to drugs. For this,
I would particularly think of Jean Dickinson’s work on cultures and guinea-
pigs, modelling intermittent administration of drugs, a very important
component of modern treatment.9 Also the immense importance of long-term
mouse experiments, with the most recent ones done by Jacques Grosset in
which the regimens model exactly those used in man.10 Yet it has still to be
proven that the results obtained would exactly simulate those in man. But there
has been a huge change from very early crude tests in mouse experiments, to
very exact simulation. So important is this that any change in regimens or drug
treatment now has to be preceded by these long-term mouse experiments. 
Girling: Denny, a thing I always found enormously helpful was your
hypothesis on the different components of the bacterial population, because
from the point of view of those of us who were actually running the trials, it
has helped us to see how the various drugs of the regimen were active against,
or sometimes had uniquely important actions against, certain components of
the bacterial population.11 Would you like to say a bit more about that?
Mitchison: This was a hypothesis put forward in about 1970. It started with
the observation that if you look at what happens to the count of viable bacilli
in sputum during treatment, you see an early abrupt fall and then it slows
down.12 This is quite different from the effects on a culture, where you get an
exponential fall with a straight-line relationship between log count and time.
This implies, I think, that there are at least two different bacterial populations.
This idea led to the concept of a very early rapid killing of bacilli, mainly in
the first two days of treatment, followed by a much slower killing of persisting
organisms in what we call ‘sterilizing’ action. These two concepts are basic to
an understanding of the action of drugs. If we could improve the speed of
sterilizing by drugs, then we could shorten treatment. These ideas have been
going on for the past 50 years.13 The most recent paper on it, with Amina
Short-course Chemotherapy for Tuberculosis
5
9 Intermittent treatment, that is treatment given twice or thrice weekly rather than daily. For a
summary see Dickinson and Mitchison (1968, 1970); Mitchison and Dickinson (1971). 
10 Nuermberger et al. (2004a).
11 Dr David Girling wrote: ‘For an account of how laboratory and clinical research have
complemented each other, see Girling (1989): 285–323.’ Letter to Dr Daphne Christie, 28 July 2004.
12 Mitchison (1979). 
13 Mitchison and Selkon (1956); Brindle et al. (2001).
Jindani and Caroline Doré, has looked in great detail at what happens during
the first two days and then in the subsequent 12 days, and saw completely
different drug actions during these two times.14 But most important, it is in the
search for new sterilizing drugs that one needs these particularly important
ideas, because one needs methods for measuring sterilizing activity.15 The
bactericidal tests that you do on actively growing cultures are almost
completely irrelevant. You need a completely different type of test to estimate
how good at sterilizing are your drugs.
Sir John Crofton: You talked about new discoveries about just how
pyrazinamide might work. Could you tell us what these are?
Mitchison: We go back to 1952 when pyrazinamide was first introduced, when
you had this remarkable drug active in mice, not active at all in the test-tube,
not active in guinea-pigs either. This drug was taken up rather fortuitously by
Walsh McDermott at Cornell University, who started long-term animal
experiments that showed that it went on killing bacteria when other drugs had
stopped.16 That was the essence of it. It was those experiments that actually led
directly to the start of short-course regimens in man, as the initial clinical trial
was started because of two series of mouse experiments: one at Cornell and the
other at the Pasteur Institute.17 For pyrazinamide the current idea is that it’s a
pro-drug: it gets converted to pyrazinoic acid, the active molecule. Pyrazinoic
acid gets into the bacterial cell better in an acid environment, which is why
pyrazinamide only acts in an acid environment. It then accumulates in the cell,
because it’s only excreted by an inefficient efflux pump and it’s the
accumulation of this acid that causes damage to cell membranes and eventually
kills the cell. It doesn’t have a site of action, as do other drugs, and the result
is that the factors that influence its effect are completely different from other
drugs. For instance, for all other drugs, as you slow down bacterial growth, the
bactericidal effect gets less and less.18 With pyrazinamide, it’s exactly the
opposite. As you slow down growth, so the efflux pump gets less efficient, the
pyrazinoic acid accumulates and you get more bactericidal effect.19
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Crofton: It seems you should not use it for the whole of the treatment, rather
just at the beginning.20
Mitchison: Yes, the answer to that is that probably it has to have a slightly acid
environment to work, and this is probably created by inflammation at the site
of action. That dies down during treatment to leave a neutral environment in
which the drug cannot act.21 That’s my hypothesis, but nobody else has got a
better hypothesis. 
Girling: In the clinical trials, we found that by giving pyrazinamide for the first
two months that was enough, and you added nothing by giving it for longer,
but that was just a pragmatic finding from the clinical side of the study.22
Crofton: Can I ask one other question? You mention about the mouse
experiments for long term being so valuable. Isn’t tuberculosis a bit different in
the mouse – there are more intracellular organisms – and isn’t it rather
surprising that it parallels the human situation?
Mitchison: The most recent molecular studies suggest that both the nitric
oxide expressed by immune cells, and low oxygen tension, which is the other
controlling influence in preventing growth of tubercle bacilli, actually have
similar controlling effects upon tubercle bacilli.23 The changes in controlling
gene expression patterns are closely similar, whether the bacilli are exposed to
low oxygen tension or to nitric oxide. So, it may be that the immune process
in the mouse cells, using nitric oxide, and low oxygen tension around
extracellular bacilli in cavities, are having similar effects on the bacilli. 
Girling: Amina, you were involved in part of the clinical side of this, this
concept of looking at the bactericidal action of individual antituberculosis
drugs. Would you like to tell us a bit about this? Was this in East Africa?
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Dr Amina Jindani: Yes, I was at that time coordinating the first short-course
chemotherapy studies in East Africa, and this hypothesis of separate bacterial
populations, and the drug having different effects on different bacterial
populations, was very much around, and I had seen a publication saying that
ethambutol in large doses, in vitro, increased the bacterial count.24 Now this
suggested to my simple mind that it caused the bacteria to divide and get them
into an actively dividing state. So I had this wacky idea that if I could get the
bacteria in my patients to divide in the lung, I could then zap them with
rifampicin, cure their tuberculosis in two days, and win the Nobel Prize. Alas, we
did a small study, using different doses of ethambutol and doing colony-forming
counts, and that study showed no difference at all between the different doses of
ethambutol. But we were visited at that time by two eminent gentlemen,
Professor Wallace Fox and Professor Denny Mitchison, and because we were an
MRC-collaborating unit they descended upon us from time to time.25 I
mentioned this small study to Denny and far from pouring scorn over it, he
encouraged me to do the same counts on the rest of the drugs (these were in
sputum, that is, counts of viable tubercle bacilli in the sputum). Yes, sputum of
patients with active, newly diagnosed tuberculosis, and he helped me design the
study, carry it through, and even wrote that famous paper that I think many of
you know about.26 But that’s how the early bactericidal activity came into being.
Professor Alan Glynn: Denny, your results were in mice and in people, but of
course mice vary enormously in their response to mycobacteria. Which strains
were used mostly?27
Mitchison: The strain that is used is almost always the H37Rv strain.
Historically that has been the strain most often studied. But there are studies
done, particularly in the USA, with different strains, so it’s not ideal. Now the
point has been raised whether responses in mice are the same as those in man.
In actual fact, most of the antituberculosis drugs penetrate into macrophages,
into immune cells, fairly well. So you do in general tend to get much the same
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response. The only one which is a bit different is pyrazinamide, because
pyrazinamide doesn’t appear to be as bactericidal inside host, macrophage cells as
it is outside, and so pyrazinamide in mouse tuberculosis, which is predominantly
inside macrophages, is a much weaker drug than it seems to be in people.28 But
that doesn’t usually make all that much difference to the experiment. I think it is
quite remarkable how these long-term mouse experiments do correlate very
closely with human disease, and there’s been a very exciting recent study just
published about moxifloxacin, which I think may disturb the whole future of
chemotherapy, but that’s again the present, not history. 29
Girling: Anyone else like to say something on the laboratory side of the
research, ask any further questions, or make comments?
Crofton: A minor one. When rifampicin was first found in Italy, a couple of
people came over to me and said how should we try this out, because it’s very
difficult to feel that they could give it to patients who could have more well-
established treatment, and it had to be given intravenously at that time.30 I
suggested that they gave the drug and did daily bacterial counts of sputum
content for the first week or so, to make a preliminary test for bactericidal
effect. The patients could then be switched to standard treatment. I am not
quite sure whether they followed my advice. Someone else might know.
Dr John Moore-Gillon: Can I ask a very naive question and that is, what led
you to look at these particular molecules? Things were clearly very different
then from the way they are now, where pharmaceutical companies can screen
literally thousands or tens of thousands of molecules to look at potential
activity. What steered you in the direction of the drugs that we now have?
Mitchison: I seem to be asked to answer a lot of these questions. They occurred
very largely by chance – apart from streptomycin, where there was good reason
to look for a soil organism that produced an antibiotic like penicillin.31 That
was a very profitable way of looking for drugs. You had para-aminosalicylic
acid (PAS) where the idea was that salicylic acid stimulated the metabolism of
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tubercle bacilli and hence an antagonist might be effective. But that turned out
to be completely untrue, of course.32 Then there was isoniazid,33 which was a
molecule similar to nicotinamide. Most of the other drugs started with
nicotinamide. Again, nicotinamide acts much more like pyrazinamide, and
completely unlike the action of isoniazid. So, you know, people followed clues,
which were almost always wrong. The discovery of rifampicin, an antibiotic
produced by soil Streptomyces, was a more logical process. You had pots of soil,
hundreds of pots of soil from all over the world, and you looked at the soil
Streptomyces to find your new drug. That worked like anything for a bit.34
Girling: Thank you very much. We can move to our next topic, which is the
poor results of treatment achieved with standard long-term regimens in clinical
practice. John Crofton has kindly agreed to introduce the topic.
Crofton: I am sorry this is going to be very anecdotal, but I think it’s worth
looking back to the beginning. Tuberculosis, before the drugs came in, was a
notoriously relapsing disease. To begin with the aim of the new
chemotherapies was only to try to arrest the disease, and the early MRC studies
showed this very well. We had PAS/isoniazid and streptomycin at that time.
Our group started work in 1952 in Edinburgh, just when isoniazid came in.
We took part in the trials.35 But to prevent relapse nobody knew how long to
continue chemotherapy. We had found earlier on, when we had a couple of
cases of primary PAS resistance who were initially given two drugs, including
PAS, that by the time we had the lab results showing PAS resistance, the
tuberculosis had become resistant to the second drug. We decided it was much
safer to give all three available drugs initially and were surprised to find we
were curing all new cases.36
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But nobody knew how long to go on to prevent relapse. Naturally, some gave
fairly short-term treatment to milder cases and long term to the really severe.
J D (Ian) Ross looked at our relapse rate a year or two later. Paradoxically he
found that it was the mild cases given short-term treatment who relapsed.37 We
had no relapses in those given 18 months or more. 
At the same time we were doing a lot of surgery (lung resection), after
preliminary chemotherapy, to prevent relapse, as was a widespread policy at
that time.38 Two of our research fellows, Derek Turnbull and Sheila Stewart,
both I am afraid now dead, did multiple cultures of the resected specimens.39
Their findings correlated very well with the relapse rates. For instance, in
patients operated after 12–18 months’ chemotherapy the relapse rate proved to
be 1 per cent; cultures were positive in only 2 per cent. None of those who had
had more than 18 months’ treatment either relapsed or had positive cultures.40
These relapse results were later confirmed by an MRC controlled trial of
different lengths of chemotherapy in ‘chronic’ tuberculosis patients.41 So 18
months became the standard duration.
How well this policy was adopted over the country in general, it’s very difficult
to know, because it really took about 20 years before everybody was given good
treatment, so it was very difficult to judge the results. But the MRC did two
studies, one in Scotland, and one in England and Wales, in which they looked
at the total intake for a year and followed them up, but I cannot quite
remember whether that was before or after triple therapy.42 Perhaps somebody
will be able to tell us that. 
If we switch now to overseas, the early work by Denny [Mitchison] and
Wallace Fox in Madras found that relapse rates, usually after a year of two-drug
treatments, were relatively low, and that seemed a great financial advantage for
Third World countries. As a result of this, they went on and did their
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wonderful work in East Africa, producing short-course chemotherapy. I hope
they will be able to tell us what the routine results in those countries were in
their previous studies, and in the general population, and perhaps they can do
that more accurately for Singapore and Hong Kong, both of which had good
services, but I cannot give those figures. My general impression, going round
Third World countries was a 40 per cent cure rate, which most of them were
getting. This seemed to improve dramatically with the short-course
chemotherapy because there were fewer defaulters, but there were no accurate
figures. As WHO showed, five to ten years ago the low cure rates in a number
of countries resulted later in high rates of history of previous treatment in
newly presenting patients, reflecting, of course, high rates of relapse and
consequent drug resistance.43 In contrast, well-supervised and completed
therapy, short-course or long-term, both gave very low relapse rates. 
Perhaps I could add one other thing? Short-course chemotherapy was initiated
at a stage when the relevant drugs were very expensive. Accordingly, the
Britain–Nepal Medical Trust,44 with which I was involved, did a carefully
controlled trial comparing results in two groups of remote hill districts that had
previously had similar success rates using previously standard therapy.45 If I
remember correctly, it was 87 per cent success rate with short-course
chemotherapy and 61 per cent with the other, so confirming the general
impression that patients seemed to have much lower defaulter rate and thus
did better with the short-course chemotherapy.
Professor Andrew Nunn: Just a couple of things. First, in relation to the poor
results with standard chemotherapy. We did a number of surveys; Janet
Darbyshire was more involved in these than I was. In the follow-up of the East
African drug resistance surveys one of the striking things was the remarkable
drop-off in the number of patients coming to collect their drugs. In the 1964
survey only 28 per cent of the patients were recorded as receiving drug supplies
over the whole 12 months.46
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The other thing I wanted to mention was a fascinating study we did in the
Algerian Sahara where we were comparing two regimens: one a standard 12-
month regimen, which was based on isoniazid/streptomycin/ethambutol; the
other was a short-course, six-month rifampicin-based regimen.47 The
population included quite a lot of nomads who picked up their drugs at
convenient places, or took sufficient supplies to get them from one place to
another or to complete their treatment. The results in the short-course regimen
were vastly better than in the standard treatment: 3 per cent compared with 17
per cent failures and relapses at two years. So it made an enormous difference
that patients didn’t actually have to go on taking their treatment for so long.
Professor Janet Darbyshire: Just after that, yes, we did surveys. The first one
was before my time. I am not even sure if Amina [jindani] will remember it,
but 1964, 1974 and 1984 in Kenya, and 1969, 1979, I think, in Tanzania.48
And to me the striking find was the fact that you did quite well up to about
six months, and I often wondered if that’s why Wallace and Denny decided
that the first big step into short-course chemotherapy was six months, because
that’s just about what you could get in people in East Africa.
Girling: Am I right in saying that these regimens included thiacetazone? Of
course, in some communities, there was an enormous problem of thiacetazone
toxicity wasn’t there?
Darbyshire: Yes, thiacetazone is a fascinating drug. It’s cheap, it’s actually easier
to combine with isoniazid and much easier to take than PAS–isoniazid which
was probably the alternative at the time. But it seemed to be, again before my
time, from all the wonderful studies that you did, it showed very interesting
variations in its toxicity by population, which weren’t really explained by
ethnic group, or by anything in particular, but it was very well tolerated in East
Africa. So that really formed the basis of the standard treatment of
streptomycin plus thiacetazone and isoniazid (or thiazina as it was known),
followed by thiacetazone and isoniazid alone.49 But the fascinating thing is that
I remember in the early 1980s, that all of a sudden we started to get quite
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severe Stevens–Johnson reactions to the thiacetazone, which was the serious
skin side-effect.50 We thought that maybe it was the wrong concentration,
maybe there was something wrong with it, but in retrospect it was probably
the very early cases of HIV infection. In people with HIV infection the
incidence of adverse reactions is much higher, and the more severe reactions
are common, hence most countries now are not using thiacetazone if they have
a high incidence of HIV infection. So that’s interesting. These probably were
some of the early HIV infections in Africa.
Mitchison: Could I add a bit of evidence to this? The study reported by Pierce
Kent, Wallace Fox and myself compared the thiacetazone regimens given in
clinical trials with the results obtained in the survey.51 Because what this
showed was that although you could get excellent results with regimens in
clinical trials, unfortunately when you looked at them in use in populations,
the results were very much worse, and this was attributed to failure to take
drugs in the latter months of treatment. 
Dr Peter Davies: I’m really a newcomer to this. It’s really what Sir John was
glossing over, and it’s something that I have had in the back of my mind for
20 years and I have been meaning to ask. There is very good literature on
streptomycin alone and also on streptomycin against streptomycin and PAS,
but I am at a loss to find anything very good on streptomycin and PAS, against
streptomycin and PAS and isoniazid. Were there any randomized controlled
trials done on those two comparisons?
Mitchison: The first trials were with streptomycin and PAS and streptomycin
and isoniazid, weren’t they? 
Davies: No, they did streptomycin/isoniazid versus PAS/isoniazid, but not
streptomycin/PAS, you see that was never included. 
Mitchison: That was a matter of great interest because streptomycin is not a
very good drug, it’s only moderately good, whereas on the whole isoniazid is
an excellent drug, and you see this on the very rare occasions when a
comparison of that sort is made. It was actually made in some of the US
studies, but the method of analysis doesn’t help you very much because it was
never really very clear how well those regimens did. Then there was a very
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small study done in Bulawayo comparing streptomycin/thiacetazone with
thiacetazone/isoniazid, in which the streptomycin/thiacetazone did extremely
badly.52 So I think there is no doubt that streptomycin is not actually the
world’s best drug; nor is PAS, everybody agrees on that. 
Davies: I would like to be absolutely clear about this. So there has been no
study done, as you might have expected, of streptomycin plus PAS, which are
the oldest two, against this newcomer isoniazid, and you might have given
streptomycin and PAS and isoniazid, the old against the new, it’s never 
been done. 
Mitchison: It has in the USA, but the methods of assessment are very different
from those we would use now and so it is actually very difficult to assess the
relative merits of those two. If you like I could try to give you a reference to it.53
Davies: But this seemed to be a big slip up on the part of the MRC who started
well but didn’t continue logically. 
Professor John Grange: Peter has just asked a question that has been
bothering him for 20 years. May I do likewise and ask our experts when, how
and why did isoniazid monotherapy get introduced for treating latent
tuberculosis? The reason I ask is that I have always been puzzled by a paradox,
which nobody has explained: isoniazid, as we know from the work of
Mitchison and others, hits the actively replicating mycobacteria, and yet we
assume that in latent tuberculosis these organisms are dormant. So it seems
illogical. How does it work and why?
Dr Joseph Angel: A brief historical memory. Isoniazid exploded on to the
tuberculosis scene and seeing the excellent results that were produced by using
it alone, there was no question of leaving it out of any clinical trial. 
Grange: I suspect that helps to answer Peter Davies’s question. This was
before there were any ideas of different bacterial populations, and so
presumably drugs, including isoniazid, were classified as either effective or not
effective. Am I right in thinking that isoniazid appeared on the scene fairly
soon after PAS?
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Crofton: In point of fact, PAS was developed before.54 It wasn’t published
before. It was being used in Sweden before. Can I just tell a story about the
early isoniazid? You remember Walsh McDermott was one of the people who
did the first testing of isoniazid and he thought that isoniazid-resistant
organisms didn’t matter.55 When patients produced resistant organisms and
these were injected into guinea-pigs they proved less pathogenic. He sold this
to WHO. Monotherapy with isoniazid was the cheap answer to Third World
tuberculosis. Everybody tries to forget it nowadays. Walsh and I had
tremendous, if good-tempered battles, but for a number of years monotherapy
was used in many countries and caused a great deal of isoniazid resistance,
both primary and secondary.56 Of course monotherapy with isoniazid, as a
preventive for tuberculin-positive individuals without disease, proved very
effective in North America and resulted in little resistance.
Dr Ian Campbell: I came into respiratory medicine in 1970, so I am a
relatively new boy in this audience. But I came in when 18 months’ PAS and
isoniazid with three months’ streptomycin was standard treatment, and used
until 1975 when the British Thoracic Association’s (BTA) trials were
published.57 I have been in respiratory medicine since, and everyone has been
talking about high relapse rates with 18 months’ PAS/isoniazid, three months’
streptomycin, especially overseas. I don’t know about my other colleagues of
similar vintage, of whom there are some about still. Had there been a high
relapse rate in Britain in standard practice? Has Janet [Darbyshire] any data on
this from the survey she did before? Because it seemed to me that it worked in
Britain quite well. Now that’s anecdotal and I didn’t conduct any surveys.
Dr Kenneth Citron: If you cast your mind back to the 1960s and 1970s, we
had many tuberculosis nurses, we had well-staffed clinics, and therefore we
could monitor self-administered drugs extremely efficiently. I ran a large chest
clinic in Wandsworth, south London, in the 1960s and early 1970s. At that
time we were giving isoniazid/PAS for at least 18 months and often for two
years, with streptomycin added in the initial three months. In 1971 we
Short-course Chemotherapy for Tuberculosis
16
54 Lehmann (1946); Dubovsky (1988). 
55 McDermott (1969). 
56 Drug-resistant tuberculosis can be transmitted (primary) or develop during the course of
treatment (secondary). Mitchison et al. (1957); McDermott (1970).
57 British Thoracic and Tuberculosis Association (1975).
published our results.58 In routine treatment, we found that 90 per cent of our
patients had completed the prescribed treatment. Of the 10 per cent that
didn’t, most of them had died, mostly from nontuberculous causes, mostly
elderly men. Among the 90 per cent who completed treatment, all but 2 per
cent became culture negative. We had a post-treatment follow-up for between
three and seven years, and found that none had relapsed. I can tell you that
we were delighted with the results of long-course therapy at that time. But
adequate staffing and meticulous attention to detail were needed to attain
good results.
Moore-Gillon: To put myself in a historical context, I am even younger than
Ian Campbell. I qualified in 1976, so was training as a clinical student in the
mid-1970s, and then in respiratory medicine from 1980 onwards. I want to
come back to the question of isoniazid monotherapy for latent tuberculosis.
For those who were there at the time, how much of it was a pragmatic
decision, in that you had a patient who was clinically well but you were telling
them that they had a potential problem, and when they asked you, ‘What can
you do about it?’, you had to reply, ‘Well, you can have two or three months
of injections, that will make you very dizzy, and some disgusting tasting
granules, or you can take this fairly simple and benign medication.’ In
practical terms, you could persuade people to take isoniazid, whereas you
couldn’t persuade them to take combination therapy for latent tuberculosis.
Was that a factor?
Crofton: In the early stages people with minor lesions were usually very
carefully watched until they broke down. We persuaded our colleagues in
Scotland, with some hesitation I think, to randomize these patients into doing
the normal follow-up or having PAS and isoniazid, and we showed a very
significant difference.59 This was an all-Scottish study. However, that was using
the two drugs. I was always worried about resistance, with the single drug, and
when they did this North American study, they did get a few, but it was only
one or two. It was quite a small resistance risk. 
Mitchison: The study of isoniazid in chemoprophylaxis was done on a massive
scale by the US Public Health Service.60 They went into the question of
whether it caused isoniazid resistance and concluded it did not. You got a little
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selection of those people who started off with isoniazid-resistant strains, because
the chemoprophylaxis wouldn’t work in them, but I think they felt that, as you
needed about 105 sensitive organisms to have one mutant bacillus resistant to
isoniazid, you simply don’t get that number of organisms or anything like it in
dormant disease. Of course it is quite a different matter in treating people with
active disease and you have to screen them very carefully. 
Girling: It seems to me that the message that comes across from this section of
the meeting is that those old long-term regimens were actually quite effective
regimens, and that the main problem in their use in routine clinical conditions
was patient compliance, their actual compliance in treatment. And so there
was great pressure to look for regimens that could be given under full
supervision for a much shorter period of time, maybe with some intermittency,
and not just daily administration. We turn now to the importance of the
combination of isoniazid/rifampicin/pyrazinamide. 
Darbyshire: I will kick off, although I am introducing something that again
started before I joined the MRC Tuberculosis and Chest Diseases Unit in
1974. I think the first step in establishing the importance of rifampicin and
pyrazinamide was ‘Study R’, which was the really quite radical study, that
looked at three drug combination (triple combination therapy) of
streptomycin and isoniazid with rifampicin, with pyrazinamide, and with
thiacetazone, as well as streptomycin and isoniazid alone, all given for six
months, and compared with the standard East African regimen.61 That very
clearly showed that the two drugs that were really potent were rifampicin and
pyrazinamide, in addition to the streptomycin and isoniazid. So that, I think,
was the foundation and I believe it was really Amina Jindani, Pierce Kent and
Joan Heffernan, who were responsible for overseeing that trial. That was really
the beginning. After that, what followed was an unbelievably elegant series of
studies, crossing continents and crossing countries, which showed the important
role of these drugs, both in the initial phase, and all the way through, and I can
never decide whether I drew the short straw or the long straw, because I inherited
East Africa from Joan, which meant I had fantastic elephants and lions, and spent
hours and hours in Land Rovers. David [Girling] actually was very lucky – he got
to go to Hong Kong and Singapore.
It seems to me that in East Africa we had the studies where it was very clear at
that stage, that we couldn’t give rifampicin and pyrazinamide for six months;
they were just too expensive, and actually you couldn’t give streptomycin for 
six months, it was too painful. At that time we were keeping the patients 
in hospital too, which again is not really feasible. So that’s really how we 
moved into the initial intensive phase of four-drug treatment –
streptomycin/isoniazid/pyrazinamide/rifampicin – followed by a cheap
combination phase. All the studies in East Africa were focusing around: firstly
establishing whether pyrazinamide was important in that first two-month phase
– which it clearly was – if we took it away, if we could drop to one month, which
would have been even better, but it wasn’t as good; and secondly, looking at the
combination phase afterwards. But that was paralleled by studies which, as I say,
you, David, were ‘minding’, and Andrew probably knows more about, so that’s
perhaps the next step.
Nunn: I would like to say a little bit more about East Africa before we go on to
Hong Kong. The study, which was affectionately known as Study R, had a
fascinating design, because it answered so many questions and provoked so many
hypotheses. Janet [Darbyshire] mentioned the fact that patients were in hospital for
the full six months, and that was intentional, in order to give the maximum
opportunity to see if these drugs worked and how well they worked. One thing that
should also be said, of course, was the cost of rifampicin in those days. It was
between £100 and £200 for six months, a very expensive drug at that time. Ethically
it would have been very difficult to do a trial like that today. We are seeing
antiretrovirals coming into Africa now for HIV/AIDS, but that’s only because the
drugs have been considerably reduced in cost. Prior to that reduction, many ethicists
would have considered trials of HIV drugs quite inappropriate in such a setting.
I mentioned the cost of rifampicin, which was between four and ten times as
expensive as pyrazinamide, so when the first study was planned in Hong Kong
it was decided not to study rifampicin, but to base the study on pyrazinamide.
Because the results of pyrazinamide were not as good as those of rifampicin, two
durations were compared: six months and nine months. The six-month results
were considerably inferior to results in East Africa. This is something that we
have seen over the years too: the results in East Africa differ from results in Hong
Kong. Certainly you cannot give the same drugs and get the same results
necessarily, unless the regimens are highly effective. So the first study in Hong
Kong investigated only streptomycin, isoniazid and pyrazinamide, looking at
intermittent as well as daily regimens.62
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The second study in Hong Kong actually did include rifampicin and, in fact,
both the second study in East Africa, along with the second study in Hong
Kong, brought together the three drugs, isoniazid, rifampicin and
pyrazinamide for the first time. The striking finding was a dramatic increase in
the culture conversion rates by two months, compared with any other
regimens. From that point onwards those three drugs pretty well stayed
together, although both the second and the third short-course studies in Hong
Kong included a comparison of ethambutol substituted for pyrazinamide;
ethambutol was clearly inferior.63
Darbyshire: Study X (the fourth short-course study in East Africa) was
actually great.64 We wouldn’t be allowed to do it today, but Andrew and I used
to analyse it about once a week, to see how many relapses there were, because
this was the study that actually showed that you don’t need to carry
pyrazinamide all the way through. I think it was this study (Study X in Africa)
and a corresponding study in Singapore that really showed that what is now
virtually a standard regimen – of streptomycin/isoniazid/rifampicin/pyrazinamide,
followed by isoniazid and rifampicin – was just as good as carrying on with the
pyrazinamide all the way through. So I think that was an important study. The
reason we watched it very carefully was that we found out if you dropped to
four months, which is what we hoped we could, you actually have very high
relapse rates. So we learnt a lot about the minimum duration of chemotherapy,
with probably the most potent combination we had at that time, and probably
still have today.
Jindani: I want to tell you about two completely different aspects of study R,
which was the first short-course chemotherapy study that I had the privilege
of coordinating in 42 centres in East Africa and Zambia. The first is this
business about informed consent.65 Of course there were no 20-page consent
forms to be signed, and it would have been difficult to get African patients
with tuberculosis to sign a 20-page form; they might have signed it, but they
might not have understood it. I did it this way: when they came to the
hospital, I would say, ‘Look you have tuberculosis, if I give you treatment for
18 months, and you take it, you will be cured. But we have drugs that we want
Short-course Chemotherapy for Tuberculosis
20
63 Hong Kong Chest Service/[British] Medical Research Council (1979, 1987).
64 East African/[British] Medical Research Council (1978).
65 The process by which a patient can make an informed decision about his/her wish to participate
in a trial.
to test on you, and we think six months of treatment will be enough if we give
you those drugs. But for that you will have to come into hospital and remain
in hospital for six months. Can you do it? Or can’t you do it’? I think that was
a pretty good way of getting informed consent from them, because those who
couldn’t stay, didn’t stay. Now the second point is about the giraffes and the
elephants. No! Tigers. All I remember after a site visit, was the car going off the
road and myself going through the windscreen and ending up at the bottom
of the Rift Valley and having to have my face reconstructed after that, so I
think, Janet [Darbyshire], you were pretty lucky.
Girling: It seems to me that you have brought up an enormously important
issue about informed consent, because it sometimes bothered me whether
these trials could even be conducted today just on that basis. In Hong Kong
and Singapore, Wallace, or Wallace and I, would go over and discuss the plans
for a trial with the Minister of Health, and with the Director of the National
Tuberculosis Service. If they were happy with the trial, and you had to
persuade them, they had to be convinced that this was a trial that was relevant
to their country, and sometimes plans of trials had to be changed on the basis
of what they said. But in a sense that was where the major step of informed
consent occurred. Patients certainly were told that they were in a trial, because
in Hong Kong and Singapore we did occasionally get a patient who decided
not to take part, but they were very few and far between. This does actually
raise quite an important issue: the whole aspect of informed consent, and if
anyone would like to contribute on that, we would be very interested to know.
Mitchison: Before we get on to that, which I think is a side issue for the
moment, let us go back to Study R, because I think it’s important to realize
why Study R was done. I was at the first meeting where the planning of this
study was made, with Andrew, but David, I can’t remember were you there?
[No, I don’t think so.] And Janet certainly was not. We were going there to
plan a new study in East Africa, and they came quite often. Wallace turned up
and he really sprang a bombshell on us, because he said he had been talking to
Georges Canetti,66 who was firmly convinced from the mouse experiments that
he had done that rifampicin was a wonder drug that could be used to shorten
treatment.67 That really was the reason why Study R got started. I added in the
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fact that I had been in contact with Walsh McDermott and his mouse
experiments on pyrazinamide for many years.68 As a result, we also included
pyrazinamide, which nobody else had thought of at all at the time. It was the
mouse work, at Cornell and the Pasteur Institute in Paris, that led to short-
course chemotherapy. 
Having said that, I perhaps should also say that, as I understood it, the
physicians in Hong Kong were at first dead against this dangerous drug,
pyrazinamide, which they associated with liver damage.69 It was only with
some difficulty that the plans for the first study with pyrazinamide and no
rifampicin were put in place, but as soon as the results came through, no
study was complete without pyrazinamide. So I think there was a radical
change of opinion.
Crofton: The reason was that when pyrazinamide was used early on, it was given
in much bigger doses, and that’s when they got this disastrous liver damage.
Campbell: When we were running the second BTA [British Thoracic
Association] trial in the UK, which included pyrazinamide, the fear of the
organizing committee, which included Ken Citron, Joe Angel and Joe Selkon,
was that physicians would not want to put patients in, because physicians in
Britain in the middle 1970s were still scared of pyrazinamide. I think it was to
the credit of the BTA members that they grasped the nettle. Consent by
patients was not as informed as it would be today, because all we did for those
trials was to say to the patients, ‘Look, we are running a study of four different
durations of tuberculosis treatment that you used to have to take for such a long
time, and we are going to try to see if we can shorten it, would you take part?’
And the patients uniformly said, ‘Yes’.
Angel: I would like to go back a little while, just to talk about the genesis of
the BTA trials. My interest was first aroused by going to a BTA meeting in
Cambridge in 1969, when a Belgian physician, Dr Gyselen [André Gyselen],
described the results of a three-month treatment with the three regimens,
which I have given the details of in the sheet you have in front of you (Figure
2).70 Ethambutol plus isoniazid, ethambutol plus rifampicin, and rifampicin
plus isoniazid, and you will see that at the end of the three months of
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Figure 2: Sputum conversion in advanced pulmonary tuberculosis on treatment with
three regimens of chemotherapy.
Dr Joseph Angel wrote: ‘In the long-term chemotherapy study conducted by the MRC
with streptomycin for six weeks/PAS/isoniazid or PAS/isoniazid, culture negativity rates at
three months were 55 and 44 per cent respectively.’ Note on Figure 2, 3 February 2004.
Adapted from Gyselen and Simon-Porthier (1969): 328.




Figure 3: Cumulative percentage of patients culture-negative at each month during
the course of drug treatment.
* Significant reduction in sputum conversion in non-pyrazinamide containing-regimen.
Adapted from British Thoracic Association. (1981) A controlled trial of six months
chemotherapy in pulmonary tuberculosis. First Report: Results during chemotherapy.
British Journal of Diseases of the Chest 75:141–53.
Regimen                                    Number of patients                                      Months
1     2     3     4     5     6
SHRZ (six months) 146 38  77  97   99  100 100
EHRZ (six months) 141 33   77  99 99  100  100
EHR (nine months) 157 29   64*  88* 98  100  100
S=Streptomycin; H=Isoniazid; R=Rifampicin; Z=Pyrazinamide; E=Ethambutol
chemotherapy, the sputum conversion rates were significantly higher with the
two rifampicin-containing regimens, and much higher than with the
PAS–isoniazid regimen, which was standard at that time. 
So I thought about this for a year or two, and by this time I was on the
Research Committee of the BTA, so I put it to the Research Committee that
we might consider doing a trial of reduced durations. Initially, it provoked a
little hesitation, not surprisingly because most of the members of the
committee had spent their professional lives encouraging people to take drugs
for longer and longer periods. It had gone up from six weeks to three months,
to six months, to 18 months, to two years. So there was quite a lively discussion
as to the ethics of this trial, but some of us stood out, in particular Alan
Somner,71 who, I am sorry to see, wasn’t able to come to this meeting. As a
result of his intervention the committee said, ‘OK, those who are enthusiastic
about it, should go away, form a subcommittee and plan the trial.’ And so we
did. We arranged that we were going to put it to the summer meeting of the
BTA in June 1972. It was interesting that at the second meeting of the
Research Committee, when we put forward our protocols, the mood had
changed completely. People who were originally rather sceptical were all for it
and made very positive suggestions. We didn’t know anything about the East
African studies, and we only learnt about them I think, about three weeks
before this June meeting, and you have just heard the results of the East African
study, so that encouraged us enormously. So we set out the protocol at a special
meeting of the clinicians who might be involved where they turned up in
droves and were extremely enthusiastic. They clearly didn’t like the standard
18-month or two-year regimens, and were only too delighted to participate in
a trial of shorter durations, and in fact this was reflected in the large number
of patients submitted for the study, which was 911 in seven months and, as Ian
Campbell probably remembers, taxed us to the utmost. 
This study was funded by two pharmaceutical companies, Ciba-Geigy (Basel)
and Lepetit (Milan), and was launched in October 1972.72 We compared four
durations, six, nine, 12 and 18 months of rifampicin plus isoniazid with the
first two months being allocated at random to either streptomycin or
ethambutol, with follow-up for five years. The results were quite striking. Only
one patient still had positive sputum cultures at the end of chemotherapy. The
relapse rates were 7 per cent for the six-month group, and 1.7 per cent for the
nine-month group, which occurred very late in the follow-up, 1 per cent in the
12-month group and none in the 18-month group. On the strength of these
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72 Dr Joseph Angel wrote: ‘Lepetit Research Laboratories in Milan developed rifampicin and were
extremely helpful in the planning of the first BTA study. They were later absorbed into Dow
Chemicals, which is now, I think, Merrill-Dow. The details of the study are given above.’ Letter to
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results, the BTA recommended a regimen of rifampicin plus isoniazid for nine
months, supplemented by ethambutol, because we had more trouble with
streptomycin toxicity than ethambutol toxicity, in a dose of 25 mg per kg for
the first two months.73
Girling: Thank you very much. There are two points that occurred to me that
come out of this. I think it is important to emphasize the extraordinarily
important international scope of these trials. There were MRC trials, but other
groups were conducting trials as well. I have listed the countries that I thought
were involved, and you can probably think of others. There were those in East
and Central Africa, Hong Kong, Singapore, Transkei, Poland, what was then
East Germany, Czechoslovakia, Algeria, Finland, Argentina, as well as, of
course, the UK and France; and, yes the Korea spinal tuberculosis studies,
that’s right. Also the collaboration of the pharmaceutical industry was essential.
We were hoping to get somebody from the pharmaceutical industry here, but
unfortunately have not been successful.74 It really does emphasize how
important the collaboration of the pharmaceutical industry was in conducting
certainly the MRC programme and evidently other programmes as well.
Sir Iain Chalmers: I have a question about funding of this very impressive
series of controlled trials. It arises from something that I think I understood
Wallace Fox 75 to say at a meeting in 1986 at the London Hospital, which was
convened by the Consumers’ Association to discuss clinical trials in society. My
understanding is that the manufacturers of antituberculosis drugs contributed
to a research fund, which was then administered by the MRC to do whichever
studies seemed to be most important. Have I mis-remembered something that
Wallace said?
Mitchison: The point was that in the early days the drugs were provided free
from the manufacturers and at the time this was the only contribution that
they made. The actual running of the studies and of the units concerned was
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entirely MRC-funded. At a much later stage, there began to be this ancillary
fund which was actually only a quite minor contribution made by drug
companies, and particularly by the manufacturers of rifampicin who provided
a great deal of support.76 This was used for various ancillary purposes,
including often some support of the local tuberculosis programmes in the
countries concerned.
Girling: Perhaps I can finish this discussion by emphasizing again what a huge
achievement was made by this large programme of randomized clinical trials in
the various countries. This programme determined clinically the best drug
combinations to use, the appropriate duration for treatment, both in the daily
initial phase and in the continuation phase. It determined that pyrazinamide
need be given for no more than two months. It determined appropriate drug
dosages in both phases of treatment. It identified regimens that were both highly
active and yet relatively free of adverse effects. It produced regimens that could
be given under full supervision, or with very high levels of supervision, and that
were robust in the face of some lack of compliance. It produced regimens for
which there was minimal risk of the development of acquired resistance during
chemotherapy and failure, and with very low relapse rates after treatment. I
think this is probably one of the largest international combined research
enterprises that have been conducted in the history of medicine.
Campbell: I would like to say that it wasn’t driven by pharmaceutical companies,
which have driven the beta-blockade research, the H2 antagonist research, the
inhaled steroid research and other fields, ever since.77 It came from within the
profession and the research organizations.
Girling: Thank you very much. Shall we now move on to consider the
recommended short-course regimens?78
Darbyshire: A lot of the importance of the programme of research, which was
involving collaborators in so many countries and so many different conditions,
was actually to produce not just one recommended regimen, but regimens that
were widely applicable in many different circumstances. With my East African
hat on, what we wanted was something that was cheap, that didn’t actually
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require patients to be in hospital all the time, and that was relatively nontoxic.
So the regimen that came out of this programme as the recommended regimen
that was widely adopted by the IUATLD (International Union Against
Tuberculosis and Lung Disease)79 and the WHO was an eight-month regimen,
of two months of streptomycin/isoniazid/rifampicin/pyrazinamide, followed
by six months’ thiacetazone and isoniazid. That extra two months was shown
in a study whose name I cannot remember, but I think it was Study U, to really
make a difference compared with just stopping at six months. So that was very
widely introduced. There were quite a lot of debates as to whether the first two
months should be fully supervised and therefore required hospital admission,
and some quite, I won’t say angry debates, but noisy debates, particularly
between Karel Styblo and Wallace occurred. But I think that was the big
contribution that the African studies made, a widely used regimen. The impact
of HIV has meant that a lot of people have switched over from thiacetazone to
ethambutol, although until very recently we never tested that regimen and
Amina might like to say something about that. 
Jindani: As Janet said, the recommended regimen then became
isoniazid/rifampicin/pyrazinamide supplemented by streptomycin in the
initial intensive phase, followed by thiacetazone/isoniazid in the continuation
phase for six months. Now, with the arrival of the HIV pandemic, people did
not want to give streptomycin, so they have replaced streptomycin with
ethambutol.80 The basis of this was the second BTA study, which showed that
when you gave streptomycin and the other three drugs, followed by
isoniazid/rifampicin, the relapse rates were 0.8 per cent. But when you
replaced the streptomycin with ethambutol, the relapse rate was 2.4 per cent,
and that was, I think, accepted as equivalent, although it is three times higher
than when giving streptomycin.
The other assumption that is made by the tuberculosis world, especially by
WHO and the IUATLD, is that thiacetazone could equally be replaced by
Short-course Chemotherapy for Tuberculosis
27
79 The International Union Against Tuberculosis (IUAT) began as the International Conference
for Tuberculosis Doctors in 1867. In 1902 the Central Bureau for the Prevention of Tuberculosis
was housed in Berlin and became Paris based in 1920, as the International Union Against
Tuberculosis. In 1986, a mandate extended its function to include other lung diseases such as
asthma and tobacco complaints. For further details see www.tbrieder.org/ (site visited 19 April
2005). See also Enarson (1995).
80 Dr Amina Jindani wrote: ‘Streptomycin is given by injection and there is a risk of transmission of
HIV if the same needle is used in more than one patient.’ Note on draft transcript, 23 March 2005.
ethambutol in the continuation phase, but this combination, although
recommended, was never tried in a clinical trial. We have recently just
completed such a clinical trial, and the results when compared with the six-
month regimen, rifampicin, in the continuation phase, showed that
ethambutol/isoniazid for eight months was not as good as the rifampicin and
isoniazid.81 So now we are back to another, or several, probably noisy debates,
because the big question now is with the arrival of antiretrovirals in Africa,
should we give rifampicin in the continuation phase, or should we not give
rifampicin in the continuation phase. It will be interesting to hear what
anybody else might have to say on that.
Darbyshire: Just to pick up on that. One of the problems is the interaction
between rifampicin and many of the anti-HIV drugs, which I think has led to
quite a lot of debate as to whether you start the tuberculosis treatment first, or
start the antiretroviral treatment, so I think there are huge numbers of issues
now around the management of what is a major problem, namely coinfection
with HIV and tuberculosis worldwide, but particularly in sub-Saharan Africa. 
Crofton: Can I ask a question? I know the IUATLD was very worried about
using ethambutol or rifampicin in the follow-up phase in developing
countries, because they thought it wouldn’t be taken properly and there would
be much more resistance. Have you any evidence of increased resistance as a
result of either of these two uses, compared with before when they weren’t
being used in the follow-up phase?
Jindani: There is one report from Tanzania about increased resistance to
rifampicin, but really it has never been confirmed.82 The IUATLD is still very
much wedded to thiacetazone, but in sub-Saharan Africa I think that they will
have to change. The latest recommendations still say thiacetazone/isoniazid, but
as I have said the great debate now is whether we should give
rifampicin/isoniazid, because you have a shorter duration of treatment, and you
have a higher cure rate. That debate has only just started. And Andrew reminds
us there is no cost problem. 
Moore-Gillon: One of the things a political historian, if not the medical
historian, might like to pick up on, is the mention of the involvement of East
Germany, Czechoslovakia and Poland. That’s a quite extraordinary thing, it
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seems to me. One can understand how many other parts of the world were
involved. But you are dealing with countries behind the Iron Curtain at that
time. Maybe it was heading up for the Prague spring in Czechoslovakia. How
on earth did you manage it?
Crofton: I went to Poland in about 1956, but their system there was that they
had one major postgraduate training centre for tuberculosis. The head of that
unit, Professor Marion Zierski of Lodz, spent quite a long time with us in
Edinburgh and went back convinced about the ordinary good chemotherapy.
Under the communist regime, all chest physicians had to attend a revision course
in Zierski’s unit every five years. So it was very easy to spread a good
chemotherapy regimen quite quickly. Then they went on to do their own trials.83
Mitchison: Can I make one further comment about this problem of resistance?
What happened in Amina’s study is what you expect. You start with initial
isoniazid resistance and that’s roughly between 8 and 9 per cent or so of many
populations, as in much of East Africa. If you continue such patients with an
ethambutol/isoniazid regimen in the continuation phase, then you get quite a
high percentage of failures occurring. I cannot remember what the figures are,
but I would give it at about 17 per cent or something like that. If you have a
six-month rifampicin/isoniazid continuation, it makes no difference
whatsoever, because isoniazid is not doing anything in the six-month regimen;
we could leave it out perfectly well.
Campbell: I want to pop back to streptomycin versus ethambutol, which was
I think quite a critical comparison. Amina [Jindani] says that ethambutol was
inferior to streptomycin, but in fact, and I will seek Joe’s and Tony’s memories
on this, and Ken’s, in the two BTA trials we showed no difference between the
ethambutol- and the streptomycin-containing initial regimens.84 So in the
British population anyway, there was no difference. But turn it round. We are
all doctors and medically orientated scientists in here. The patients were
delighted to hear and to consider that they didn’t have to have two or three
months of injections, but they could possibly take two or three months of
tablets, and I suspect that if there was any difference in the relapse rate, the
patients would have said, ‘I still want the tablets, I will take my chance’.
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Angel: I have got the paper here [British Thoracic Association (1982)], the
relapses were, two out of 119 (1.7 per cent) with the initial streptomycin, four
out of 127 (3.2 per cent) in the initial ethambutol and there were two out of
127 (1.6 per cent) with the new standard regimen without pyrazinamide in the
second BTA trial (the nine-month regimen).84a
The other point I would like to make about the second BTA trial, is that
although there was, as Ian [Campbell] has said, a fear among some clinicians
about using three potentially hepatotoxic drugs, the actual rates of
hepatotoxicity were 4 per cent in the non-pyrazinamide-containing regimen
and 4 per cent in the pyrazinamide-containing regimens.
Darbyshire: I just thought I should carry on the story a little further, because
that was Africa. But to me, that’s where we should start from, because that’s
where it all started. But I think the story in the UK is that the BTA studies,
together with the Singapore and East African studies, clearly demonstrated
that probably the best regimen was isoniazid–rifampicin for six months with
two months of pyrazinamide and a fourth drug. But I think the great debate
in recent times in the UK is whether you actually need that fourth drug and
here the dilemma is all to do with initial isoniazid resistance. So one of the
questions which I think we have debated a number of times, and we have
written guidelines about, is whether you need that initial fourth drug or not.85
So that’s another quite interesting route that we might like to go down. Then
we could discuss Hong Kong and Singapore, and intermittent chemotherapy,
if you like.
Girling: I think that is a very important point, because the key regimen that
was actually recommended by the International Union Against Tuberculosis
and Lung Disease was a three-drug regimen, rifampicin/isoniazid for six
months with pyrazinamide for the first two, but they point out that that
didn’t have to be given daily, it could be given twice or three times a week; 
and they then went on to suggest some cheaper alternatives for 
developing countries.86
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Darbyshire: So even though we didn’t call it DOTS [directly observed therapy
short-course strategy], we were doing DOTS.87
Girling: Yes, and of course that raises the whole issue of intermittent
administration as well.
Mitchison: That’s not what DOTS is. DOTS is a five-point strategy, and has
nothing to do with directly observed treatment, or with short-course
treatment, either. It’s now a complete misnomer you see, but it’s a five-point
strategy. It includes short-course chemotherapy and supervised treatment, but
also government support, smear examinations for diagnosis, proper follow-ups,
and proper drug supplies. It’s a whole catalogue of things, so let’s not use the
term DOTS here.88
Girling: Thank you very much, Denny, we take your point.
Professor Peter Ormerod: As somebody who was treated with the old-style
regimens in 1957 and has helped bring in newer short-course regimens in
practice, in the streptomycin versus ethambutol debate, there’s no comparison
between my personal experience of three months of intramuscular
streptomycin at the age of seven, and patients’ joy at taking ethambutol, rather
than streptomycin later. As somebody who had very little buttock at the age of
seven, it was not a very pleasant experience, and sleeping on my front for three
months was the result, though I am not deaf. 
Citron: There is a study that we haven’t mentioned, that seems to me is
absolutely fundamental to our routine practice. And that is the 1959 study in
Madras of home versus sanatorium treatment.89 It showed that domiciliary
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89 Tuberculosis Chemotherapy Centre, Madras (1959); Fox (1962a): 413–7, 473–8; Dawson et al. (1966).
chemotherapy was as effective as in the sanatorium and caused no more disease
among household contacts. It had a profound effect on our practice here, so
that by the end of the 1960s most of the tuberculosis sanatoria and hospitals
were either closed or were closing down. It seemed to me that this was
absolutely fundamental. The physicians are now treating tuberculosis in
outpatient departments in this country, and I think we ought to give credit to
that Madras Study for the major effect on our clinical practice.
Dr Geoff Scott: I am quite interested by the transition from the treatment for
18 months to the treatment for six months. Clinical trials were going on and
results were coming up and I was doing some treatment, although I wasn’t
involved in any trials, but gradually treatment courses shortened. I
remembered there was a study that I think the MRC did, which was to ask
people what treatments they did give and the replies weren’t very consistent
with anything which had been recommended. They tended to be longer,
people tended to give more treatment than was necessary. I wondered if those
around the room can tell us a bit about research into practice and how you
made this transition?
Citron: I will deal with that subject in some detail in my talk about how
chemotherapy regimens were introduced into routine clinical practice, because
it’s interesting to see the difference between what people say they do and what
they actually do.
Ormerod: I will wait until Ken [Citron] does that, because last year I
published the latest review of what treatment was actually given in 1998  in
Clinical Medicine.90 We have done follow-up studies, and the MRC in
combination with the British Thoracic Society (BTS),91 followed up what
treatment was given in the surveys in 1983, 1988, 1993 and 1998.92 I know
it’s not quite the past, but it showed what happens, and it does mirror how
short-course chemotherapy was brought in. It was in 1988 that pyrazinamide-
containing regimens were the rule rather than the exception, whereas in 1983
only about 11 per cent of people were on a pyrazinamide-containing regimen. 
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Campbell: Again, going back to the first British Thoracic and Tuberculosis
Association’s (BTTA) trial that started in 1972. What impressed me, as a very
junior research fellow helping to run this trial, was first of all the people of a
very conservative nature, with a little ‘c’, that is the doctors, were going to go
ahead with a new project, testing new ideas, and I think a lot of the credit for
that must come from the earlier MRC study that was done in England and
Wales, and the Scottish studies done by Sir John. The chest physicians, by this
time, were a fairly disciplined bunch, accustomed to being led into doing
studies. What became apparent during the trial, and this might give a context,
was that senior physicians would ring this boy up in Edinburgh and ask him: is
it really safe to stop these drugs now? What do you think I should do? And these
were a number of very senior people ringing up. They had taken part, but their
attitude was still, ‘I am not terribly certain, can I give it for a little bit longer?’
And I would say, ‘No, you are not allowed, it’s a clinical trial.’ It is very salutary
and I think it will have bearing on what Peter and Ken [Citron] are going to say
later on, even after the results of the trial were published, people thinking, ‘I will
give it another two or three months’, superstition influencing science.93
Crofton: Can I comment on what Ken [Citron] was talking about? In the first
Madras study comparing sanatorium and home treatment, the patients at
home in the slums were also intended to be on bed rest. But, of course, as they
improved many of them no longer stayed in bed. Before that trial we had
become so impressed with the success of chemotherapy that we thought that
many of the milder, overtly noninfectious, patients might do adequately if they
received chemotherapy while continuing to lead normal lives. We had a
tremendous business trying to persuade the Scottish physicians that such a
controlled trial was ethical because everybody thought that you needed at least
three months’ bed rest. We ran the study, they had the same chemotherapy,
either for three months in bed, or living normal lives, and of course the ones
living normal lives did just as well.94
Mitchison: Can I add one point to this? The person who started this was Philip
D’Arcy Hart, because he organized the first clinical trial on streptomycin.95 He
had to deal with the fundamental conservatism of physicians. It’s a great pity
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he’s not here, but he’s still alive, and I think one ought to recognize the huge
debt I believe we all owe to him, in getting clinical trials started. [Hear, hear.]
Jindani: Can I just say, in contrast, that my African colleagues, whenever they
were presented with a trial that was going to be innovative, particularly six
months, they were really excited about it, because if these came about, six-
month trials, imagine how it would improve their practice and the possibility
for eradicating tuberculosis. So I never encountered any resistance at all from
my participants out there.
Crofton: I would like to draw attention to the identical problem in Russia,
where they don’t want to give up their old system and use the WHO regimen.96
There’s a very good example of how powerful conservatism can be.
Chalmers: I want to add a further plug for Philip D’Arcy Hart (Figure 4). On
22 June 2004, three days before Philip’s 104th birthday, at the Royal College
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Figure 4: Dr Philip D’Arcy Hart in the 1950s.
of Physicians, there will be a celebration of the sixtieth anniversary of the
patulin trial. This is a much-underrated trial, which was beautifully done by
Philip D’Arcy Hart, with the late Joan Faulkner, as she then was, being the
driving force behind it.97
Campbell: Iain, what was the patulin trial? 
Chalmers: It was the first properly controlled, multicentred trial done under
the aegis of the MRC. Patulin was an antibiotic that Professor Harold
Raistrick, from the London School of Hygiene and Tropical Medicine, felt was
going to be useful in a number of ways. There were some case reports
suggesting that it was good for the common cold and then there were a couple
of small trials, one done in the navy by Surgeon Commander Hopkins, which
suggested that it had an effect, and then other trials done in the army by Dr
Stansfeld, which failed to replicate the findings in naval personnel. A large
multicentred, very well controlled trial was done under the aegis of the MRC.
Philip D’Arcy Hart was the principal driving force, and he was the secretary to
the oversight committee. The assistant secretary was Joan (Faulkner, the late
Lady Doll). It’s a beautifully done trial and the whole paper will be reproduced,
together with some historical papers and commentaries, and published in the
April 2004 issue of the International Journal of Epidemiology to celebrate this
sixtieth anniversary.98
Mitchison: Could I make the point here that the patulin trials didn’t have a
randomized intake? That was the one way in which they weren’t quite the
forerunner of modern clinical trials.
Chalmers: I think it’s quite important to recognize there’s no statistical
advantage to random allocation over strict alternation.99 The key thing is
whether an unbiased allocation schedule is concealed successfully from those
people who are entering patients. What is special about the patulin trial is that
there were two identical drug groups, and two identical placebo groups. It is
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clear from papers at the National Archive as well as from Philip D’Arcy Hart’s
memory, that they used these four groups to muddle people up, to ensure that
it was less likely that they would vitiate the allocation schedule.100 So it was a
key study methodologically. Perhaps the reason that it has not received the
attention that the streptomycin for pulmonary tuberculosis trial has is because
of the magic reference to random sampling numbers in the report of the
streptomycin trial, but not in the patulin trial. I think Philip D’Arcy Hart is
right to say that the patulin trial was the first properly controlled multicentre
trial done under the aegis of the MRC.101
Campbell: David, we are still, I think, on short-course regimens, aren’t we?
Others have voiced their 20-year questions. My 20-year question is directed to
you and to Janet as disciples of Wallace, and to Sir John: we know that twice
weekly therapy for the continuation phase is as efficient as daily,
supplementing the first two months of an intensive phase. Why is that not
recommended therapy in Britain?
Girling: The International Union recommendations did say that treatment
could be given intermittently three times a week, or twice a week. That
brings us on to the whole question of intermittency, which I think is
another one that would be good for us to cover today on the suitability of
some drugs and not others for intermittent use and the effectiveness of
intermittent drug administration and its supervision. Of course, this is
another area where there have been hugely important parallel developments
of the clinical trials and the laboratory work. I think this was largely Jean
Dickinson’s work on the guinea-pig experiments. Perhaps, Denny, you
could start by telling us a bit about these, because these were really quite
important findings, weren’t they? They were, to some extent, quite
unexpected as to what might happen if you gave certain antituberculosis
drugs once a week or every day? She studied different intervals, didn’t she,
between drug administrations?
Mitchison: What she was mainly concerned with, in the in vitro, in the test-
tube experiments, was simply giving the bacilli a pulse of drug lasting various
times from two up to 96 hours. From those it became evident that if you
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pulsed with isoniazid, first of all the pulses were cumulative, a fact of great
importance, because a lot of small pulses add up to give a maximal lag that
lasted about seven to eight days. This agreed well with what happened in
the intermittent isoniazid/streptomycin trials in Madras, where when you
gave the drugs twice weekly, so you got fairly frequent pulses, the slow and
the rapid inactivators behaved the same. But when you got to once weekly
treatment, the small pulse in the rapid inactivators didn’t last until the next
pulse, whereas the big pulse in the slows did. So that was the basis to explain
that particular set of effects. Also it was the opposite of what happened with
rifampicin which has an immediate bactericidal effect, followed by a
gradual recovery with an almost immediate start. Now, this has a bearing on
things happening at the moment, particularly in the use of once weekly
rifapentine in HIV-positive patients, and the emergence of monoresistance
to rifamycins, because there’s a gap in the effect of rifapentine, which there
isn’t in the effect of isoniazid.102 These postantibiotic effects were explored
for the then current drugs, all of which have slightly different
characteristics. That work has not, as far as I know, been extended in any
meaningful way.
Campbell: Was it not the Singapore study, David [Girling], that showed you
could give intensive therapy for two months, and then rifampicin and
isoniazid for four months twice a week and get the same results as daily? [Yes.]
I am intrigued that that has not crept into routine practice, and I am not
talking about supervision now, I am asking why has it not crept in? Why are
we still stuck with daily? How did this not arise as it were, or not happen? 
Girling: I think it is routine practice, as I understand it, in Singapore, and in
Hong Kong now. Well, during the trials in Hong Kong, they got used to the
idea of organizing their entire treatment service on a three-times weekly basis
and patients came Mondays, Wednesdays and Fridays, or Tuesdays, Thursdays,
and Saturdays, and it was so well organized that they were in and out of the
clinic, just like that; their drugs were waiting for them. We talked a little time
ago about the communist regimes. In Prague, for example, in Czechoslovakia,
considerable success was achieved by enabling treatment to be supervised at
various different places. People could have their treatment supervised at their
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place of work, for example.103 So I think in some countries it has caught on,
and not in others. I am not sure about Czechoslovakia now. 
Mitchison: Could I make a point that in the USA if you say that you want
daily continuation therapy, they say it’s impossible, they will only give
intermittent chemotherapy, so quite clearly there are totally different ideas in
different countries?
Darbyshire: I was just going to say that I think one of the issues here is
whether it is supervised or not, because I think the great danger of moving over
into intermittent treatment that’s not supervised, will be that it is much less
likely to be taken properly. I think people find it much harder to take
something twice a week than they do daily, and therefore we in this country
are focused on daily treatment, because we have relatively little supervised
treatment. I think it’s a practical thing.
Citron: Could I ask Peter Ormerod about the surveys that the BTS has done?
In a situation which is predominantly daily, self-administered chemotherapy
regimens, are we getting very good results? I can say that intermittency is used
a fair amount at this time. My own practice with the homeless and alcoholics
and so on, and I think John Moore-Gillon will bear this out, that those people
who are likely to be unreliable need supervised therapy and get twice weekly
or three-times weekly therapy in their own hostels, or in hospitals, or in the
places they go to have meals and so on. It is certainly used selectively.
Ormerod: In the BTS guidance, it is allowed to give intermittent treatment,
in fact thrice weekly is the recommended regimen for people who are thought
likely to be noncompliant, but the drug dosages also include a twice weekly
dosing option. The surveys that we have done following up the 1998 and 1993
surveys show that we are getting reasonably good results with daily treatment,
which is the norm but not the rule: with cure and completion rates of over 80
per cent in those people who return the forms, and it’s as good as any
comparison with cohort studies across Europe. But there isn’t always
compliance monitoring, people are not using the four-drug initial
Short-course Chemotherapy for Tuberculosis
38
103 Dr David Girling wrote: ‘The organization of fully supervised chemotherapy must be efficient
and flexible so that patients can choose to receive their chemotherapy at centres near their home,
near, at, or on the way to their place of work, or at some other place convenient for them. Such
centres can include chest clinics, general practitioners’ surgeries, dispensaries, welfare clinics,
hospitals, factory clinics, rural health units and special treatment stations, such as can be set up on
market days in rural areas. See Fox (1979).’ Letter to Dr Daphne Christie, 8 April 2005.
combination in ethnic groups with isoniazid resistance rates of 7 per cent,
these ethnic groups now making up over 70 per cent of all cases in the UK,
and there is a risk of failure from that. With reference to Denny’s comment
about the availability of anything other than twice weekly continuation
therapy in the USA: in the USA it is mainly three times weekly if given
intermittently. But when you do studies, the Americans say they are giving
DOTS. When they did a national analysis three years ago, only 15 per cent
were actually getting supervised treatment, not anything like the numbers that
they say they are. It should come with a health warning, some of their statistics. 
Girling: Amina, do you have any feel, internationally, of the extent to which
intermittency is being used and, of course, full supervision or not?
Jindani: That was the point I was going to make, that at the moment I am
coordinating international multicentre trials in Latin America, Asia and Africa.
Most of the Latin American and Asian countries give intermittent therapy in
the continuation phase, which they claim is fully supervised, with good results.
Crofton: Can I come in briefly on this? Denny and I were both at the WHO
meeting which made this formal recommendation, but there was a good deal
of discussion as to whether it should be twice a week or three times a week.
The general feeling was that they were nervous about reducing it to twice a
week, and the recommendation was three times a week. The basis of this
decision, I think, depended quite a lot on the Singapore study.
Angel: It has been claimed by some streptomycin defenders, that if you keep
streptomycin for these fractious patients on whom you wish to use twice- or
three-times weekly treatment, this is an advantage. Would anybody like to say
anything about that?
Girling: What, because it encourages compliance; because they need injections,
do you mean?
Campbell: Betraying my ignorance again: Janet [Darbyshire] said that patients
prefer to take tablets daily. I would like to ask Janet, if there is any evidence of that
from studies, even of surveys asking patients which they would prefer, twice weekly
or a daily tablet? I don’t know of any myself, but I am a very ignorant person.
Darbyshire: I think it has been confirmed that people will not remember.
What I was saying was not so much that the patients might prefer it, but the
concern is that it is actually much more difficult to remember to take
something twice a week, so there’s the worry about compliance, not that it’s the
patient that prefers it. I don’t know if any studies have tested that, except that
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at one time we went a long way down planning one – although we actually had
placebo on the other days, because we were very worried that people wouldn’t
take it the other days. So it may be that the book by Sackett,104 which was one
of Wallace’s favourites on compliance, has a study, I know we looked at how to
give intermittent nonsupervised treatment, and as I say we got a long way
down developing a packet that had two days of active within a week of pills
that all looked the same. I will go back and look at Sackett and let you know
if it’s there.
Campbell: It will be very difficult to have a placebo that doesn’t contain
rifampicin – the patients will know which days they are taking their active
treatment, because they would have orange urine.
Darbyshire: That’s maybe why we didn’t do it.
Jindani: On this point about recommended short-course regimens: it’s  become
evident to me that the different countries in the world use different short-
course regimens, and the Republic of Guinea, in spite of their rising prevalence
of HIV, still give streptomycin as an inducement to make the patient come
daily for the first two months of treatment. There are other countries like that. 
Dr Bertie Squire: I am very much a newcomer to the scene, but very
interested in this question of intermittency. Henry Mwandumba from Malawi
and I were interested in whether intermittency was possible from much earlier
in short-course regimens, and are responsible for the Cochrane Systematic
Review, which pulled out evidence for head-to-head comparisons of
intermittency versus daily dosing right from the second week onwards. If we
have got it right, and we did try very hard, there is only one comparison that
is two parts of one of the Hong Kong trials, which actually compares
intermittent dosing from very early on. I just wanted to add that into the
debate, because I think what I have been hearing is a debate about
intermittency during the continuation phase. But it often gets spread into a
question about intermittency from much earlier on, which is of huge
programme importance, if you are trying to organize direct supervision on a
community basis, in African situations.
Davies: I recall being interviewed by Wallace Fox for an MRC job in the
middle of the summer of 1978. It was a fascinating experience. I got more and
more transfixed by the fact that Wallace was never able to take a sip of coffee,
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because he was always asking questions, or listening to answers. But one thing
he asked me, I remember, was what regimen did my bosses use? At that time I
had been working as a senior house officer and registrar in west London, and,
of course, none of my bosses used anything like the regimens that were by then
being recommended at the MRC. It was a source of Wallace’s frustration that
he couldn’t get his message across to the ordinary punter, to the chest physician
in the street, and this led Wallace in the early 1980s to write a couple of papers,
I recall, on the lack of compliance by chest physicians in fulfilling the MRC
criteria that he had worked out so thoroughly.105 Janet [Darbyshire] mentioned
the fact that we give daily therapy, because patients can take it at home. We
observe intermittent regimens because that’s the way that we can make sure
that the patients take the medication. But I would like to throw another
question in here, and that is the one about side-effects. Like Ian Campbell,
who trained me in tuberculosis, to some extent I share his ignorance: I cannot
recall whether adverse effects were an issue in using intermittent as opposed to
daily regimens, but I guess they must have been. 
Girling: We will come to adverse effects after tea.
Mitchison: Can I say something about the history of this? It arose immediately
after the Madras home sanatorium comparison, and it was quite evident to
Wallace, and indeed to all of us, that we had to do something about compliance.
You see we were throwing chemotherapy open to the world, we had to do
something. The first step was to look at supervised intermittent chemotherapy.
Most of the important studies then were done at Madras. So, if one wants to go
back historically, one has to go back to Madras. It was only later that the
possibility of shortened treatment came up as an even more effective way of
ensuring compliance. And toxicity came into it very early on. Wallace’s slides that
he showed always had the statement that intermittent treatment reduces toxicity. 
Moore-Gillon: I was going to ask a question. Coming back to something that
Sir John [Crofton] said about the meeting at the WHO, and then Peter Davies
mentioned the same sort of problem. Presumably the issuing of guidelines is
partly the art of the possible, not just the evidence that you have got in front
of you, because having persuaded one’s colleagues that they didn’t need to treat
for 18 months, but only for a short period of time, that’s quite a big jump to
take on board. To then say, ‘Well, you only need it twice a week as well’, was
an even bigger step to take, but you thought you might be able to swing three
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times a week past them. Was there some judgement made as to what was going
to be possible to persuade people to do in making these recommendations?
Crofton: Denny may remember the discussion, but I cannot remember it very
clearly, but there was obviously nervousness about the twice a week. Do you
remember what the worry was?
Mitchison: The issue was that if you forgot one of your twice weekly doses,
then you would have a once weekly treatment which had been shown not to
work very well. So I think it was the nervousness about what would happen
with the missed doses that pushed people towards three times a week. 
Crofton: I think I ought to point out that one of the reasons why we got such
good results in Edinburgh was that we always tested the urine for drugs at every
attendance so we knew when people weren’t taking their drugs. We always kept
it quiet, and in my entire career I had only two patients who realized what was
happening, that they were being tested, because we never said, ‘Oh your urine
is negative’. We said, ‘I’m not sure things are going so well, you’d better be
admitted for a little bit’. Or, ‘You must be very careful to take all your drugs
every day’ and then bring them back to the clinic shortly to retest their urine, if
necessary readmitting them to ensure they completed treatment.
Girling: Before we break for tea in about eight minutes’ time, we have said nothing
as yet about the management of extrapulmonary tuberculosis.106 The original
International Union Recommendations recommended short-course chemotherapy
for both pulmonary and extrapulmonary disease. So does anyone have anything
they would like to share with us on the management of extrapulmonary disease?
Ian, I think you were involved in the lymph node trials, is that right?
Campbell: Yes, because again when I was a BTTA research fellow on Sir John’s
unit, the Clinical Trials Subcommittee of the Research Committee came up
with a idea of doing short-course chemotherapy in lymph node tuberculosis,
which raised a huge fuss, because everybody thought lymph node tuberculosis
was a grim disease that never really went away and usually came back. When
you look at the literature, as that group did – Elizabeth Hills will remember this
– what had been done previously in lymph node tuberculosis was inadequate or
just anecdotal. When we did that first trial, 18 months was included as a sort of
sop to Reg Bignall: ‘Let’s keep this 18 months in, chaps, and we will go for the
nine as well, and the 12’. That was much more challenging than doing the
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short-course trial for pulmonary. The first short-course trial for lymph node
tuberculosis, done by the BTTA, was the first-ever randomized, controlled
clinical trial of lymph node tuberculosis.107 It also served as the first prospective
survey of that disease under treatment. So it was a very interesting study, but it
raised everybody’s fears because the disease was dreaded so much.
Girling: They weren’t still using the Queen’s touch, I suppose?
Campbell: Yes, perhaps some people were! The present Queen was on the throne
by then, wasn’t she? Yes. But some people not too far away on your right108 still
think that sunlight and vitamin D might help this disease, you know. 
Girling: Would anybody else like to comment on extrapulmonary tuberculosis?
Glynn: These are two completely anecdotal, probably not very useful, but
rather amusing, stories. First from St Mary’s: in the 1950s, there was a trial on
treatment of tuberculous meningitis. I went there just after that trial had
finished, so I was never involved in it, but we still used to get patients with
tuberculous meningitis referred. They were treated with streptomycin, among
other things, sometimes intrathecally.109 At some stage one of them developed
a block and it became impossible to give him streptomycin by lumbar
puncture. We thought we might have some burr holes [little holes in the skull,
made by a burr drill] and he was referred to Mr Dickson-Wright,110 who said,
‘Rubbish, get on with it’. He was referred again with some pressure by
Professor Neuberger, and I came in one morning at about 9.00am and was told
to go to Dickson-Wright in theatre immediately. I was then the senior registrar.
I got there and Dickie was doing some major operation, I don’t know what,
with his mask hanging well below his nose, and he said, ‘Well, this is how you
need to give this, by cisternal puncture, this is how you would do it,’ and
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explained how to do a cisternal puncture in about two minutes flat, and said,
‘Go away and do it’. So I did. Much to my surprise, the patient survived and
actually got better. I was terrified at one end of the needle, I don’t think he [the
patient] was surprised at the other, because he didn’t know what was happening. 
The other story was at St Mary’s too. At that time there was a relic of a so-
called boils clinic among other things. One day a lady of about 50 or so came
up, a school teacher, who many years before had tuberculosis glands in the
neck, for which she had been treated by the people there at that time with
injections of something called ‘tubercle powder’. I looked at the notes, which
were really a history of injections, week after week, or month after month, and
that was all. The nurse, or the amateur nurse actually, I think, she was, gave
me a bottle of tubercle powder, it said on the label it was that, and said you
give her this. I thought, no way can I give her this. This bottle is ancient, the
rubber top was so dry it was cracked and there was a sort of nasty stuff inside.111
So I tried to persuade her not to have it, that she was better now, but she said
no I must have it. So I gave her an injection of saline. She never came back; I
don’t know whether she died.
Girling: Thank you for those historical insights.
Darbyshire: I thought I should mention what took up quite a lot of my life at
one time, namely the tuberculosis spine studies, which again were a series of
studies, the first set used standard treatment and looked at different ways of
managing the disease, and which showed that bed rest was of no benefit,
plaster jackets were of no benefit and debridement was of no benefit.112 This
was a programme in Korea, Hong Kong, Bulawayo and South Africa. But the
second set of studies did look at short-course chemotherapy, again in Hong
Kong and Korea, and also in Madras this time, and showed that just six
months of rifampicin plus isoniazid – I don’t know quite why we didn’t put
pyrazinamide in, but maybe Denny [Mitchison] will tell me why we didn’t –
was actually very highly effective. The only benefit was from this radical
surgery in Hong Kong where they developed the technique, but the benefits
were really quite small. So I think those series of studies really defined the
management of spinal tuberculosis and the role of short-course chemotherapy. 
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Sir Christopher Booth: Can we go back to tuberculous meningitis? Because
that was an appalling condition, and treating small children with intrathecal
injections was a disastrous experience for all doctors who had to deal with it.
My understanding is that there were some very good trials in South Africa and
elsewhere in Africa that produced regimens there. Could somebody comment
on what those regimens were and how it happened?
Girling: I have to say I am not familiar with those trials. Does anyone else
know about them?
Mitchison: I do know a little bit about them, but they have been mainly done
by Peter Donald at the University of Stellenbosch, near Cape Town, because
he is very much a paediatric specialist, although he’s done a lot with adult
tuberculosis. I have been on his ward rounds where half of his patients tend to
have miliary or tuberculous meningitis. It’s quite phenomenal how much there
is. He’s done a long series [of studies] treated with six months of isoniazid and
rifampicin.113 What I think is quite evident about tuberculous meningitis, and
about bone and joint tuberculosis, is that you don’t have the same problem
about drug resistance, because your bacterial populations are much smaller, so
you are concerned with just killing the bugs, not with preventing drug
resistance. As rifampicin is the most important drug for shortening treatment,
it’s a key drug in this combination. But, of course, isoniazid penetrates very
well into the lesions.
Ormerod: I will expand on what Ian Campbell said. The BTS have done a
further study, which he chaired, looking at six months versus nine months, so
we have actually shown with six months’ regimens that they are just as effective
for lymph node tuberculosis. 
One final comment about South Africa. I think they use ethionamide there
sometimes as a fourth drug, rather than ethambutol, because of better
penetration of the CSF [cerebro-spinal fluid].
Citron: I don’t think we ought to forget the studies done by Sister Mary
Aquinas and Sister M Gabriel in Hong Kong on tuberculous meningitis.114
Again, they confirmed the value of ethionamide and pyrazinamide, which I
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believe penetrates very well into the CSF, and of course rifampicin and
isoniazid. She did a series of studies over almost a decade with extremely good
results, except in the advanced cases.115 Essentially, the prognosis depends on
the stage at which the patients present with this disease. In stages 1 and 2 she
got extremely good results.
Crofton: Perhaps after tea somebody could say something about using steroids
in these diseases like meningitis.
Girling: Gaye Fox is now going to say a few words about her experiences in
Madras, I think, with Wallace.
Mrs Gaye Fox: I am very pleased to attend the seminar, but I am awfully sad
that Wallace cannot be here himself.116 Wallace went to Madras, as you
probably all know, in 1956, when he embarked on his famous studies, which
led to short-course chemotherapy. I remember him telling me one day that
somebody’s got to do a study on home versus sanatorium, so I am sticking my
neck out! From that study came the contact study, and I think, Janet
[Darbyshire], from that there was a compliance study. From that followed the
shorter and shorter courses of chemotherapy, and I really wonder if there were
ever any more important studies than those undertaken in the Madras centre.
These were done in very difficult conditions. It was said that the Indians might
not be cooperative, but with a dedicated team the patients were persuaded to
cooperate and the studies had very few absconders. The climate was also
notoriously hostile, and yet many of the staff worked long hours, and Wallace
usually worked an 18-hour day, often bringing colleagues back to chew over
the problems in the evening. There was no air conditioning at all for the first
two years, no machines for sorting out statistical cards, hence the statistical
cards were sorted out by hand, in their thousands without even the benefits of
a fan to cool the room. Fans would have blown the cards about! 
Wallace also had something to contend with that I think you would have all
dreaded, he had to answer to four separate bodies: the Madras Government,
the Indian Government, the WHO and the MRC. How many of you would
enjoy that prospect! Sometimes they didn’t always understand the problems in
the field. 
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When he finally returned to the UK he was occupied with studies all over the
world, and where he used his usual creative ability, designing studies to suit all
the varied conditions. For example, the Bedouins in Algeria, overcrowding in
Hong Kong, communist Czechoslovakia; each one was designed to make the
best use of the best way to look after the patients to ensure they took their
drugs. And just to sum up, because Wallace cannot talk for himself, I hope that
you, his colleagues and friends, will strive to ensure that the work he pioneered
in Madras and later, that was undertaken all over the world is not forgotten
and his name is not buried in history.
Girling: Thank you very much indeed. Now we are going to have a session on
the role of steroids in the management of tuberculosis. Now John, you brought
this up. Do you want to say a few words to introduce it?
Crofton: We did a study in Scotland on pulmonary tuberculosis and  it was
a controlled trial, and they were randomized, all having standard
chemotherapy and in one group, 20 mg prednisolone a day, if I remember,
for three months, and the other no steroids. They were assessed at the end,
and the initial results were quite dramatic. The patients’ X-rays cleared more
quickly, they felt much better more quickly, and they gained weight more
quickly. No effect on sputum at all. We then did a follow-up a year later to
try to compare the two groups, because we thought that the prednisone
might have decreased fibrosis in the lungs. So we did blind readings of the
X-rays and we couldn’t find any fibrosis that had not already been present at
the beginning, as far as you could judge from the X-ray. So, it made no
difference long term, but there was some immediate effect.117 One of the
reasons we did this was that there had been a lot of controversy in the
medical press. Some doctors had given corticosteroids to counter allergic
reactions to the drugs and had been impressed by dramatic improvement
both subjectively and radiologically. Then other places said they had used it,
and it was absolutely disastrous. Reading the literature rather carefully, I
thought the ones that had gone wrong were those who were giving bad
chemotherapy and getting resistance. So we thought that it was justifiable to
do a trial of this kind. The BTTA did a later trial, but unfortunately they
didn’t do a year’s assessment; they found the same things in the early stages,
but they didn’t do a blind reading after a year to see whether it affected the
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X-ray. Then, of course, other people tried it. I don’t think the MRC did a
trial in meningitis, but they did one in pericarditis in South Africa.118
There’s been a lot of controversy over the years about how useful steroids
would be in meningitis, but there was a controlled trial done in India, actually
on pleural effusion, which was a reasonably good one and it did show the
effect. I don’t know of any controlled trial on meningitis. For years we have
had so little. But the conclusion seemed to be in recent years, when we were
doing our book, that it seemed to be established that it was useful, but
somebody here can perhaps tell us about it more scientifically. 
Mitchison: I think I should add that there was a very big and rather important
study in pulmonary tuberculosis, well controlled with follow-ups that showed
no effect of steroids at all.119 Now, I have heard from Guy Thwaites who claims
to have got a very definite answer from a very big study of tuberculous
meningitis in Vietnam. This is quite recently, and he says that he has
incontrovertible evidence that it does have a positive beneficial effect. But this
is not yet published as far as I know. It was used at the beginning of treatment
of pulmonary tuberculosis in Madras, in high dosage. It was randomized. It
was a factorial study with two treatments.120
Crofton: Were you looking at X-rays and patients and weights and things?
Mitchison: The whole lot, probably even more than in Edinburgh, because it
was done at a rather later date. 
Crofton: Yes, but ours wasn’t an Edinburgh study, it was a Scottish study.
Mitchison: Oh, Scottish study, I beg your pardon. But I think this issue has
been settled with regard to pulmonary tuberculosis, both in a non-short-course
trial, which is yours, and in a short-course trial, which is the Madras one.
Crofton: Yes, I don’t think there’s any particular point in patients who are not
very ill, but I was fairly convinced to begin with that we had several patients
who came in moribund, and these would often die and they often had
electrolyte upsets. We felt that by giving steroids they improved fairly quickly
and we kept them alive for the chemotherapy to take effect.
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Mitchison: I remember that effect in your report, but it didn’t turn up again in
the Madras study I am pretty sure, because we were well aware of that report,
you see, at the time and I think there was a completely negative result in Madras.
Crofton: I wonder why?
Angel: I did a study of adrenocorticotropic hormone (ACTH) rather than
prednisone when I was in the USA. I corroborate what Professor Crofton says
about moribund patients, they certainly were saved. The other point was that
the X-ray changes were quite remarkable, that somebody with very extensive
tuberculosis radiographically cleared up within a couple of months. We gave the
ACTH for three months and then withdrew it gradually and, of course, you got
a rebound on the X-ray, it sort of clouded up again. Unfortunately at that time
we didn’t, I didn’t, appreciate the absolute importance of bacteriology, and the
follow-up was rather short, because I came back to the UK.
Mitchison: Was this a comparative trial?
Angel: Yes it was streptomycin, PAS and isoniazid for six months, with or
without ACTH.
Nunn: I thought I would say a few words about the pericarditis study in
Transkei in South Africa. It was a remarkable study in several respects. First of
all when George Strang came to the MRC’s Tuberculosis and Chest Diseases
Unit and told us about these cases of tuberculous pericarditis, nobody believed
the extent of the problem. In fact, over 350 patients were enrolled in that study
from one hospital in the Transkei – a study funded by the Wellcome Trust,
incidentally. Patients were randomized to prednisolone or placebo for three
weeks, in addition to the standard short-course chemotherapy. The results
were impressive in terms of reducing the need for further pericardiocentesis, or
pericardiectomy, and survival rates improved. We have recently been writing
up the ten-year follow-up for that study, over 95 per cent of patients were
followed and there’s a significant benefit in terms of mortality to those who
were on the steroids compared with the placebo group.121
Citron: A question to Sir John. I think that Norman Horne produced some
evidence that steroids were useful in renal tuberculosis, in preventing stricture
of the ureter, so I would like to know what the evidence for that was?122 May I
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say that Sister Mary Aquinas, with her vast experience of tuberculous
meningitis, was convinced that steroids should be given in stage 3 and in stage
2, and were particularly valuable for preventing CSF block. But I don’t think
she did a randomized study. 
Mitchison: Can I make the point that the possibility of steroids making a
difference to the results of chemotherapy, that is to say on the bacterial
population, was investigated pretty thoroughly, both at Cornell by Walsh
McDermott’s group, and also by John Batten when he came back from New
York. These experiments as well as his own showed quite clearly that steroid
administration to murine tuberculosis makes absolutely no difference to the
killing action of drugs.123 But, of course, the thing that they could, and
probably do, make a difference to is inflammation. I think one has to separate
these two components.
Dr Freda Festenstein: I certainly recall in our clinical practice that in cases of
severe drug reactions we used prednisolone and it was very effective indeed. 
Crofton: As far as I can remember, Norman really did this by looking at what
had happened in the people who were treated. I don’t think there was a
controlled trial; I don’t think we had enough patients.
Dr Adrian Martineau: Just a comment. Is it possible that steroids are effective
in very severe tuberculosis because these patients are Addisonian – they have
adrenal tuberculosis? 
Angel: If they were Addisonian they wouldn’t respond to ACTH, would they?
My study was with ACTH.
Dr Jeanette Meadway: I am very interested in all the discussion that I am
listening to, because I am thinking how this points to the future, with more
and more tuberculosis going to be something that’s associated with HIV, more
and more we will be thinking of treatment of the two conditions together. One
thing that’s very striking about patients with HIV who get tuberculosis is the
proportion who have it with almost no localizing reaction, and you get
something like a positive blood culture for Mycobacterium tuberculosis or a
positive stool culture for Mycobacterium tuberculosis as the main sign, apart
from the patient being nonspecifically unwell, maybe to the point of dying of
the disease. But there’s no localization. If patients start on antiretrovirals for
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their HIV, they then raise their CD4 count and start to get localizing
symptoms, and this can be very severe. They get immune reconstitution
syndrome (IRS) where they actually have a systemic upset that can be quite
striking, or the localization can produce local symptoms which are major, such
as a tuberculoma, which can suddenly precipitate raised intracranial pressure.
The treatment for IRS is steroids. So maybe, if we look to the future – patients
with HIV and tuberculosis – an extra question as well as which do you start
first out of tuberculosis drugs and antiretrovirals, which antiretrovirals? Which
tuberculosis drugs? There’s another question there, which is whether you
actually give steroids, thinking about the possibility of IRS?
Nunn: Just one quick comment. In a study, which was reported last year from
Uganda, Alison Elliot assessed the role of prednisolone on HIV-infected
patients with tuberculous pleural effusion, and found no benefit.
Girling: There was a Zimbabwe study wasn’t there? Was that the one you were
talking about?
Nunn: No, these were pleural effusions.
Girling: Yes, the Zimbabwe study was in pericarditis. But all their patients were
HIV positive and they also found the benefit of steroids.124 I think we probably
ought to move on. The next topic is directly observed therapy. I think we have
probably covered most of that unless anyone else has still got something that
they are burning to say about supervision, or about directly observed therapy.
How about you, Knut, have you got anything you would like to add on that
to supervision of chemotherapy or directly observed therapy?
Dr Knut Øvreberg: As a matter of fact, directly observed therapy is the
headline of the programme that is implemented by WHO and the IUATLD.
But if you look at the results of therapy itself, there is good directly observed
therapy, and there is directly observed therapy that is not so good. When I go,
for example, to Nepal and observe the way the type of treatment is given,
some patients come and take the drugs, but are not observed while they are
taking the drugs, and therefore it is quite easy for patients to come, appear,
take the drugs and throw them away. So directly observed therapy has to be
really directly observed. If it’s not directly observed, then it means that it
doesn’t comply with the principles that we know we are looking at.
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Davies: The point that needs to be made at the beginning of directly observed
therapy is that it is only a means to an end, it is not an end in itself. The end
in itself is twofold: one, if you are a public health doctor, to prevent the
emergence of drug resistance; and two, if you are a clinician, to cure your
patient. If you have in a community, in a service, cure rates of 85 per cent or
better, and no emergence of drug resistance, then whatever method you are
using, that’s appropriate. But if you are not achieving that, then DOT is what
you should be considering.
Moore-Gillon: This Witness Seminar is covering a period when people could
be more creative in their choice of titles for their scientific journal papers,
because there’s a paper in the Journal of the American Medical Association from
the 1960s entitled ‘It’s the skid row hotel manager who sees that Ernie takes
his tuberculosis drugs’ – that’s the title of the paper.125
Jindani: I keep hearing that directly observed therapy was the invention of the
WHO and the IUATLD, and I would like to correct that. There are two
people we miss here greatly, one of course is Wallace Fox, and the other is Dr
Pierce Kent, who was the Director of the East African Tuberculosis
Investigation Centre in Nairobi,126 and I had the great privilege of working for
him. He invented directly observed therapy, particularly for patients with
drug-resistant tuberculosis, on the basis that we had very few second-line
drugs, and this constituted their last chance for survival. So that was an
invention of Pierce Kent.
Darbyshire: I would just like to add a Pierce Kent story. One of the things I
remember when I was very young is Pierce saying that he could solve
tuberculosis if he had a blood test that you could use with a thumb prick, and
an injection that you could give a month’s treatment in people’s bottoms.
Girling: Shall we move on to adverse effects of short-course regimens?127 Now
I think it’s worth emphasizing yet again the importance of randomized clinical
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trials, and also indeed of the complementary laboratory research, because in
this whole programme of trials there were large numbers of patients being
studied in reliable, concurrent comparisons. Their treatment was being fully
supervised, and so it’s most unlikely that adverse effects were going to be
missed. This programme also meant that we knew exactly how much of their
drug patients had taken, how much they had actually received. It also enabled
us to assemble data from many types of patient being studied in a large number
of trials, and to study both single drugs and drug combinations. Reliable
information was therefore obtained on the clinical characteristics of the adverse
effects, their severity, their frequency, the effects of dose size and of the interval
between doses and also on ways of managing them. Complementary
laboratory research was invaluable in showing the mechanisms of some of these
adverse effects, and also suggesting ways not only of treating them, but also of
preventing them. 
So I thought I would give one example to set us off on this session of adverse
effects, and that’s the example of the flu syndrome, an adverse effect of
rifampicin when given intermittently.128 A lot of information from the MRC
trials showed that it occurred during intermittent [treatment], but very, very
rarely during daily, administration. The clinical symptoms were fever, chills,
malaise and headache. They appeared about three months after the start of
treatment, and they started about one or two hours after a dose, and lasted for
about eight hours. And of particular interest, their frequency varied with the
dose, and also with the interval between doses of rifampicin, being more
common with larger doses and, interestingly enough, with longer intervals
between doses. So as you moved from twice weekly to once weekly, you got an
increase in the incidence of the flu syndrome. It therefore became possible with
this information to study, and indeed determine, drug doses of intermittently
administered rifampicin that were both highly effective and associated with
very low risk of reaction. In fact, episodes of the flu syndrome are now very
rarely seen, or so I have been told, with the current intermittent doses
recommended by the International Union.129 Interestingly enough, episodes of
the flu syndrome could be stopped by giving rifampicin daily instead of
intermittently, even though the total dose was larger. Complementary
laboratory research showed that it was associated with circulating rifampicin-
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dependent antibodies; strongly suggesting it had an immunological nature.
Indeed, research by Sister Gabriel in Hong Kong showed that the
concentration of antibodies fell during an episode.130 So it seems that
rifampicin–antibody complexes were being formed, and the activation of
complement was suggested as a possible mechanism. That’s all I am going to
say by way of introduction, but if people want to ask questions, or make other
comments on adverse effects to the drugs, particularly those used in modern
short-course chemotherapy, but not necessarily limited to those, please feel free
to do so.
Citron: This information is, of course, very important to clinicians who are
using daily rifampicin, because from time to time you see flu syndrome or,
even worse, renal complications, in a patient who is supposed to be taking
their rifampicin daily, but in fact is only taking it once or twice a week, or just
when they turn up for the clinic. So it’s very important to know about that.
Crofton: This is just a rather comic interlude. When isoniazid came in people
were terribly impressed with what it did to the patients, they felt absolutely
marvellous and it was thought that it might have a major metabolic effect on
people, and some people said they felt wonderful. We did a controlled trial on
ourselves, we did a double-blind switchover trial, and we were weighed every
day with our backs to the scales, so that we couldn’t see what was happening,
and we recorded bad dreams and that sort of thing.131 And of course it showed
that nothing happened at all. But it was quite amusing the sort of symptoms
that some people reported when they were on placebo: ‘Never felt so
wonderful’, ‘glorious dreams’, and so on.
Girling: Somebody ought to do a study of the adverse effects of placebo. 
Mitchison: Pyrazinamide, now here is a clear reason why one should be giving
pyrazinamide intermittently. The point is that pyrazinamide blocks the
excretion of uric acid. If you give it three times a week, there is a sufficiently
long period between the doses for the excess uric acid to be excreted, and if I
were having modern chemotherapy, I would want my pyrazinamide to be
given intermittently, even if the other drugs were being given daily. In fact, in
the Hong Kong study in which pyrazinamide was being given daily, three
times a week, or twice a week, the incidence of arthralgia was 1 per cent when
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it was being given twice a week, 3 per cent when it was being given three times
a week, and 7 per cent when it was being given daily. So the laboratory results
correlated very nicely with the clinical studies.
Jindani: Just to give you the scale of the problem: in Study A we randomized
1355 patients to three short-course regimens, and in only 27 did we have to
stop or change treatment because of adverse effects. Most of these were
jaundice, but there were four cases of ocular side-effects due to ethambutol and
the ethambutol had to be stopped. There was one case of thrombocytopaenic
purpura and one patient had an isoniazid psychosis, but that was all.
Ormerod: People were concerned about giving three hepatotoxic drugs
together, but in some of the US PHS (Public Health Service) studies of isoniazid
prophylaxis, there was actually a placebo arm, and hepatitis occurred in 0.7 per
cent of the placebo group, so in certain parts of the world with poorer sanitation
we have to remember some of the so-called drug hepatitis may just be hepatitis A,
hepatitis B, or hepatitis C, and that the placebo had a hepatitis rate.
Girling: I think one of the best studies of isoniazid versus placebo as
chemoprophylaxis was the one from Finland, wasn’t it, with Riska? He had well
over 30 000 subjects randomized to isoniazid or placebo, and showed that the
added risk of hepatitis from isoniazid was only 5.2 per 1000 subjects per year.132
So that was isoniazid on its own. Then, of course, there was a great worry, as
you say, when you add rifampicin and pyrazinamide. I think there are quite
good reasons for thinking that rifampicin might not be hepatotoxic. Certainly,
in our trial in Hong Kong, in which silicotic patients were given prophylaxis
with isoniazid or rifampicin or isoniazid plus rifampicin or placebo, there was
virtually no hepatotoxicity with rifampicin alone. There was a little with
isoniazid, and with isoniazid and rifampicin.
Angel: I think one of the reasons that it got its reputation was because
originally it was used very much as a second- or even third-line drug, and it was
used on patients who were in pretty bad condition, a lot of them heavy
drinkers. So there was quite a lot of underlying liver disease, I think, in the
patients who were given rifampicin.
Girling: Of course, it was given in high dosages too.
Crofton: One of the peculiar things about this is that you can then go back
and give the drug again afterwards, and that seems rather surprising. I don’t
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know whether any expert toxicologists can explain this. Is it just that the liver
is not very sensitive? It doesn’t occur if you give the drug again.
Girling: Can anyone help us on that? It’s certainly been our experience in trials
that you can use the same regimen again, and, of course, what did, I think,
confuse some people was that it’s quite usual to get an increase in serum
transaminase concentrations during the early weeks of antituberculosis
chemotherapy anyway, and that these just come down again.
Angel: Sometimes you will see transaminase zoom up before you start treatment.
Davies: The Americans have invented their own weapon of mass destruction
called pyrazinamide and rifampicin alone for people who are fit and well, but
just happen to have a positive skin test. I have just been asked to review a paper
that shows that RZ (rifampin and pyrazinamide) has a greater hepatotoxicity
than HRZ (isoniazid, rifampin and pyrazinamide).133
Mitchison: Can I explain how that regimen got into being, because it’s actually
quite interesting? It was because of some mouse experiments done by Jacques
Grosset, who is normally one of the most careful, thorough people, but he
never looked at blood levels of drugs in his mice, and we showed a little bit
later that unlike in man, you get interference in absorption of drugs, and that
some of the effects that he thought were drug–drug interaction, were in fact
due to differences in drug absorption.134 He found the regimen that was best
was this RZ regimen, but it was because of a drug absorption problem, and
didn’t therefore really apply in man. Rick O’Brien, who was in charge then of
starting preventive chemotherapy studies,135 took up this wonderful new
regimen with great enthusiasm and despite adverse comments [verbal] from
Wallace Fox and myself.136 I remember very clearly the meeting at which it
happened – this RZ regimen was promulgated in the USA, and it has done a
great deal of damage in my view. But this is just a very sad example of failure
at the more fundamental level in the mouse work leading to a bad mistake at
the clinical level.
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Ormerod: The hepatitis rate with that combination is 6.5 per cent, because I
have had to review it for something I am doing for the Joint Tuberculosis
Committee at the moment, with a high fatality rate as well. On this side of the
Atlantic, we were getting our guidelines together at much the same time. We
said we would not use it because it was going to be more toxic, it was no more
effective than 3RH and there wasn’t a combination tablet available for RZ,
whereas there is for RH, so you still wouldn’t guarantee people weren’t taking
monotherapy. I am afraid we were proved right on this side of the pond. But
we are not having an inquiry about it.
Girling: Any more points about drug toxicity? Those of you in clinical practice
have on the whole, I assume, found the modern short-course chemotherapy to
be very acceptable to patients and not unduly toxic, which is what we certainly
found in our trials.
Campbell: David, there’s one theoretical thing that strikes me that’s different
over the last ten to 15 years, compared with 20 to 30 years ago. Many patients
are on many different drugs by the time they get to 55, and we did the same
trials, you did and the BTA did, in populations that were not very likely to be
taking other drugs. Now in this country, I don’t know about Scandinavia and
Europe and the USA, practically everybody is on treatment for hypertension;
they are taking their thiazide, they may be taking an ACE [angiotensin-
converting enzyme] inhibitor. I think it’s well worth ongoing surveillance,
looking at side-effects, because of the poly-pharmacy that exists today.
Ormerod: Just to reply to that. That is getting less and less of a problem in the
UK, nearly 70 per cent of patients are now non-white, and the median age of
those patients is 29. The white population’s median age is 55 so it is only a
minority of the white population with tuberculosis who tend to be below 50. So
that’s 15 per cent of the cohort are likely to be on aspirin, statins, ACE inhibitors,
the super pill that was talked about. The majority of people with tuberculosis are
not on things for the other chronic diseases in the UK at the moment.
Meadway: But it’s very different in Africa, where a large proportion of patients
with tuberculosis will have HIV. In KwaZulu–Natal the incidence of HIV
positivity is 26 per cent, I think, in adults. It will be higher in tuberculosis
patients – 80 per cent.137 So you are really dealing with a population who, if they
are being treated appropriately, will by definition be on something else and will
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need the something else to recover fully from their tuberculosis and to prevent
relapse. So when we are looking at the evidence that people have gathered
through the years about the different toxicities of the different drugs, that’s
something that we are going to need to draw on when looking to the future for
planning the appropriate treatment for those patients. It’s very interesting, it
seems to be rifampicin which showed up as less hepatotoxic than some of the
others, because often rifampicin is the very one that interacts and cannot be
used with antiretrovirals. That’s the opposite of what one would have wanted.
Looking back at the research that’s been done, not in HIV patients, and not in
patients with poly-pharmacy, that’s going to be the pointer for the future, isn’t
it, to work out where to go next with these very difficult situations. 
Dr Elizabeth Hills: With regard to toxicity. There was a problem with isoniazid
in Tanzania, because they use the tablets that are 150 mg of rifampicin with 100
mg of isoniazid, and so if people need 600 mg of rifampicin they are getting
400 mg of isoniazid, and there were quite a lot of problems with peripheral
neuropathy. Admittedly, some of them may have got HIV as well, that may
contribute to it, I don’t know. But also a problem in that you couldn’t
necessarily get the pyridoxine to treat them, so that was a problem. As I listen
to this, and thinking about it, I think that there are more side-effects in a place
like Tanzania, than possibly have been reported in the trials, because in many
cases the drugs are being administered by people with rather minimal medical
training. Sometimes they were rural medical aides in the past, they are gradually
being upgraded over the years, but people who are just not aware of what the
side-effects are. If you have got a fever you have got malaria, or if you have got
a bit of jaundice, you have probably got malaria. People would be allowed to
get extremely ataxic with their streptomycin without anybody doing anything
about it. So I think we don’t really know the incidence of side-effects in East
Africa perhaps.
Darbyshire: It’s actually true, we used to do some comparisons, David [Girling]
and I, of the side-effects between the African trials, and the Hong Kong and
Singapore trials. There were definitely much lower reported rates of toxicity in the
African trials.138
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Mitchison: Perhaps I should say something here about the isoniazid toxicity
studies that were done in Madras, because they are actually a beautiful example
of a highly investigated problem, with very clearcut answers. What happened
was that there was a big study in Madras with isoniazid alone, at different dose
sizes, largely because WHO wanted to know what would happen with
treatment with isoniazid.139 Then following that, there were some further
studies of high-dosage isoniazid in which glutamic acid, B group vitamins and
so on, were added. These showed quite conclusively that it was vitamin B6 that
was necessary both to stop and to some extent to cure peripheral neuropathy.
And they also showed that there was a marked dosage effect.140 Now from these
studies we showed that the incidence of peripheral neuropathy is determined
by the area under the curve (total exposure) of isoniazid, whereas the efficacy
of isoniazid is determined by the peak isoniazid concentration, due to the
selection of resistant mutants.141 That was a beautiful set of results, I think
probably one of the best pharmacological and clinical investigations ever done.
At the end, 2 mg of vitamin B6 prevented peripheral neuropathy, so it
shouldn’t be very expensive. 
Crofton: How much was the incidence related to malnutrition? I mean, poor
slum dwellers in Madras and a lot of Africans are very malnourished. Did you
get a higher amount of neuropathy in the malnourished than the others, or did
you make any studies of that?
Mitchison: Wallace did a study on the food intake of the patients, but I don’t
think it established a relationship with neuropathy. I think all that it really did
was to establish that the Madras population had a vitamin B-deficient diet, and
therefore at the 300 mg isoniazid dose level, you probably were wise to give a
small B6 supplement.142 If you were using higher dosages, it was really very
necessary. So there was a look at dietary factors, it was quite a thorough
investigation done with the ICMR (Indian Council of Medical Research)
nutritional unit.143 Anyway it didn’t actually correlate peripheral neuropathy
with diet.
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Crofton: It’s rather a subsidiary aspect of this, but I know that in the current
National Tuberculosis Programmes of India and Malawi, they have been rather
concerned with the number of deaths in sputum-negative patients with
tuberculosis, and there’s been a lot of discussion as to whether this may be due
to malnutrition, because they are often very malnourished. But it’s extremely
difficult to work out an ethical controlled trial, keeping some people
malnourished and doing things to others, and you might do it by giving
specific vitamins, but perhaps people who are engaged in these researches now
might comment on that.
Ormerod: I am not involved in research there, but a very high proportion of
these people are likely to be HIV-positive and I think that’s the explanation.
Hills: And also as they are sputum-negative, and in these countries you have
not got any very accurate diagnostic methods, they have often got some other
pulmonary disease. In many countries I think they are beginning to realize
now, but they had been saying they didn’t see pneumocystis. There are other
conditions and it may not have been tuberculosis.
Girling: Shall we move on to preventing drug resistance, and I think Peter
Davies is going to introduce this topic for us.
Davies: Thank you, David. I think in the UK we have actually been very good,
by and large, at preventing the emergence of drug resistance. Certainly, as I was
a senior house officer, registrar and a consultant through to about 1990, it
really didn’t impinge on my practice. There are papers published by the MRC,
which show drug resistance varying between 4 and 7 per cent for isoniazid
alone, but certainly MDR (multidrug-resistant) tuberculosis wasn’t very much
of a problem until about 1993.144 I will come to that in a second, but I think
there are three ways in the UK in which we have been able to ensure that drug
resistance has been a minor or a lesser problem. 
First of all, by ensuring compliance. We have done this, again, in three ways.
Tuberculosis health visitors have been mentioned already. Ken [Citron]
brought them up in the 1960s and these have formed a vital link between the
hospital, the clinician and the patient, and I think if we didn’t have tuberculosis
health visitors we would have a big drug resistance problem. Countries that do
not have had drug resistance problems, and areas of this country that have not
had them, have had drug resistance problems. In Liverpool by fighting and
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fighting and fighting, we’ve got our allocation of tuberculosis health visitors,
one to 40 and we have got our clerical support, but dotted all around, satellites
to Liverpool, are places which do not have tuberculosis health visitors and they
are a right pain, they really are. Unless we get our health visitors, tuberculosis
visitors, right the way round, doing their work in adequate numbers, we are
going to have this potential for drug resistance. But I think tuberculosis health
visitors have formed the mainstay in preventing drug resistance over the last 40
years in the UK. 
Secondly, selective DOTS has been very important. Those patients that really do
not comply at home taking their own medication have had to go on DOTS. We
have been using that selectively in the UK, I would say with pretty good effect. 
Thirdly, physician control. It is important that there is a chest physician who
is in command of an area and has overall control to make sure that health
visitors do their stuff, and that the patients are therefore seen to be doing their
stuff. So that’s three subheadings under the heading ensuring compliance:
tuberculosis visitors, selective DOTS and physician control. 
The second important ingredient for preventing the emergence of drug
resistance, I believe, is fixed-dose combination (FDC) chemotherapy, which
we have used traditionally in this country ever since I started, that’s 30 years. I
did a study once comparing the use of FDCs in the UK with the USA. This is
going back ten years. In 1993 75 per cent of all rifampicin prescribed in this
country was attached to isoniazid, or isoniazid and pyrazinamide, 75 per cent
of all rifampicin was in FDCs, and this must have included rifampicin given
in preventive therapy as well. So that’s good. My colleague in the USA couldn’t
find accurate figures, but it was certainly no better than 20 per cent and was
probably about 11 per cent. They have had big problems with emergent MDR
in the USA. If you look at the figures on the website for HPA (Health
Protection Agency) you will find that MDR began to emerge as a problem in
the UK in about 1993. It was 0.6 per cent then and that was the first year that
I had my MDR patients. It then climbed to 1.7 per cent in 1996, it has gone
down a little, and it’s gone up a little. My feeling is that what we are getting
now is basically imported. What we had in 1993 was largely self-inflicted. 
There’s one further area that I would like to bring up as a controversial point
here, and that is the introduction of HRZ as opposed to HRE or HRZE as a
possible potential for creating drug resistance, in that Z is less good at
preventing the emergence of drug resistance compared with E. So bringing in
Z as the third drug on its own might possibly have been a contributing factor.
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There’s absolutely no proof, it’s very hypothetical, but it does seem to be a
relatively interesting coincidence in terms of time and the development of
the relatively few MDR cases we have had. So that’s what I want to say
about preventing the emergence of drug resistance, finishing up on a
controversial note. 
Meadway: I agree totally with what you say, but I would love to pick up on
two things. One was that the thing that helped prevent drug resistance
emerging was a combination tablet of two effective antituberculosis drugs, and
the other was that in the UK we do have a certain amount of resistance already
and much of our tuberculosis is imported. Take those two together and you
have a significant proportion of people with tuberculosis who have isoniazid
resistance before you start. You tend to find that out at the end of a couple of
months of treatment, by which time the patient has been taking a combination
of rifampicin and isoniazid, which acts as one drug because isoniazid their
tuberculosis is resistant to, and two other drugs that are also separate tablets
quite often, and they sometimes pick and choose. I had a patient who picked
and chose.146 She had HIV but she had tuberculosis. Her initial culture was
isoniazid resistant, which we didn’t know, of course, at the onset. She picked
and chose which of her drugs she took and took them rather intermittently,
and by the time she had treatment failure and pyrexia, and wasn’t responding,
her cultures showed multidrug-resistant, rifampicin-resistant tuberculosis. So
my question is why are we being so slow about asking and pressing for a
combination tablet of something other than rifampicin and isoniazid, because
isn’t that what we need in isoniazid resistance?
Davies: The answer is, yes we do. We have Rifater, rifampicin/isoniazid/
pyrazinamide and we have a potential of licensing of a four-drug combination
called ‘Rimcure’, but unfortunately, that has yet to be licensed. That’s the four
drugs in one tablet, and they have certainly got that in many other countries.
I cannot help the name, I didn’t invent that. 
Ormerod: Are you talking about the continuation phase? What we need is Bac
Tec rapid culture methods everywhere, or access to them, so that by the time
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that you get to two months, you have got the organism and you have got the
sensitivity data. Then you can have a proper continuation phase, and if
somebody has got drug resistance it can be monitored. The problem is with
only 6 per cent isoniazid monoresistance in the UK you are not going to get
somebody who will make you a combination of rifampicin/ethambutol, but
the key to preventing it is giving a four-drug initial combination, because of
the populations that we have. We are not alone. The American Thoracic
Society (ATS) says with 4 per cent isoniazid resistance you should use a four-
drug combination, the European Respiratory Society (ERS) says 2 per cent.
But the answer is getting your bacteriological confirmation, which needs
people to send the samples, plus faster culture and faster susceptibility data. 
Meadway: I agree 100 per cent with everything you said. The point about it is
that Rifater, when you look at what the patients have got to swallow, having
those big tablets  is difficult, and the number that they have to take, and to try
to persuade an HIV patient on loads of other medication to take Rifater is
much more difficult than to persuade them to take Rifinah equivalent plus the
pyrazinamide separately. Plus they can jiggle around the times of rifampicin
and pyrazinamide to be different and therefore easier to take if they are in
separate medications. So the very patient, who isn’t likely to cooperate by
adhering to their medication, is the very one who is going to object to taking
a handful of Rifater. So I don’t think the triple and quadruple combinations in
the induction phase will solve the problem with that type of patient who had
poor adherence to medication because they find them difficult to take.
Moore-Gillon: If I can step back to the period being covered by the seminar,
and it’s something which Peter [Davies] talked about, which was physician
compliance with these recommended regimens, and I wonder if I can ask the
people who were around at the time about the role of the BTA and the
Thoracic Society, and crucially about the enmity which I am told existed
between the BTA and the Thoracic Society. Did this really happen, or is this a
figment of my boss’s imagination when I was a junior doctor?
Citron: Can I reserve that for my contribution?
Crofton: Just one slight historical point. Knut Øvreberg and I were at, I think,
the second meeting of WHO when they took on tuberculosis in a big way in
the early 1990s and there was a long discussion as to what should be done
widely. In that discussion, the whole day, there wasn’t a word about resistance,
so we wrote a joint memorandum and said they really must pay attention to
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this, they must get some idea of how severe a problem this was internationally.147
Of course, they have done very good surveys since. 
Can I make one other clinical point? There’s a general feeling in the world that
the word of God comes out of laboratories, and it’s only clinicians who make
mistakes. In many countries I have been asked to see a patient, ‘We have just
had results showing drug resistance, and what are we going to do?’. You go
through the story of this patient; he’s responded perfectly well to
chemotherapy, they’ve just got a report from the lab. They never think of
asking the bacteriologist down to discuss it. So do remember that mistakes
occur in laboratories too. 
Citron: Referring back to this isoniazid-resistant HIV-positive patient. I think
there’s evidence that HIV-positive patients, at least in this country, have more
pretreatment isoniazid resistance than HIV-negative patients. Remember that
you can request a gene probe for rifampicin resistance, and you will get the
answer back in 48 hours. Now something like over 90 per cent of pretreatment
rifampicin-resistant organisms are also isoniazid resistant too, so I think that
you can select patients for this gene probe, which can be done in the central
laboratory and you will get your answer within 48 hours.
Chalmers: I want to ask a question and then place something on the record. I
think John Crofton will probably be able to answer the question best. The
MRC trial of streptomycin for pulmonary tuberculosis is justifiably celebrated
as a methodological landmark in research.148 One of the things that people say,
is that it was important because it revealed the development of resistance, and
indeed documented the eighth nerve damage that you can get with
streptomycin. So my question is, to what extent is that trial seen in that light
as a particularly important contribution? 
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The other thing that I wanted to mention, and to place on the record, relates
to the reputation of the tuberculosis specialists in respect of the very systematic
way that they have used randomized controlled trials to assess treatments.
When Archie Cochrane judged which speciality in medicine deserved the gold
medal for being the most evidence-based, he gave a ‘Bradford’ (a ‘gold medal’
named for Bradford Hill) to the tuberculosis specialists, and he gave my
background speciality, obstetrics, the wooden spoon!149
This view is not universal in respect to the tuberculosis specialists, however.
About four years ago I met Christopher Murray, a very senior member of
Bruntland’s150 [Gro Harlem Bruntland, Director-General] cabinet at WHO. I
was trying to persuade him that WHO ought to take a more systematic
approach to controlled randomized studies. On the basis of his belief that the
Madras sanatorium study had actually resulted in the antibiotic resistance that
people were now facing, he appeared to believe that all randomized controlled
trials were deeply misleading. So it’s an interesting contrast between the way
that Archie Cochrane regarded your speciality, and the way that a senior
member of WHO staff seems prepared to jettison everything about what you
have done that I regard as important. 
Mitchison: Can I make two methodological points about this whole
programme? One of them is that no patient was excluded for initial drug
resistance. This has been of tremendous value, because it is the only way that
one can really assess the contribution made by a drug and, of course, how
important it is to be able to measure drug resistance. I mean, here we have been
talking about rapid diagnosis, and yet for most treatments isoniazid resistance
has no effect at all on the prognosis of modern chemotherapy, whereas
resistance to rifampicin does. One wouldn’t know that sort of thing if one
hadn’t had that methodological decision. This was not available from any of
the American studies; they always exclude everybody with resistance and so
they are almost valueless for looking at the effects of individual drugs. 
The second thing, just a minor comment really, and that was that there are
much quicker and cheaper methods available now for getting very rapid
sensitivity tests. Particularly the phage methods, which have been developed in
various ways, are much quicker and much cheaper. The real problem you will
Short-course Chemotherapy for Tuberculosis
65
149 Cochrane (1979): 1–11.
150 Dr Christopher Murray was appointed Executive Director, Evidence and Information for Policy
Cluster of the World Health Organization in May 2001.
have with a quick sensitivity test is that they tend to be based on expensive
packaging in which some people are making a packet.
Girling: I think that’s a very important point. I was looking back at the old
results in Hong Kong; this was on the use of isoniazid and PAS for 18 months
with streptomycin for the first two. There’s quite a high level of drug resistance
in Hong Kong, and even in patients with initial resistance to all three drugs,
the treatment was successful in about 40 per cent, and that’s even with the old
regimen. Results in patients with initial isoniazid resistance were almost as
good as in patients who were subsequently found to have fully susceptible
strains. So resistance is a relative thing.
Mitchison: Very recent work, actually looking at the distribution of drug
resistance inside the lungs, shows that what you actually see in the sputum can
be completely different from the foci, bacillary foci, in the lungs, which often
show very diverse patterns.151 So the fact that we actually see resistant tubercle
bacilli in the sputum does not necessarily imply that the same resistance
patterns are present all through the lungs. It just means that sputum
bacteriology is only a relative help, not an absolute help.
Crofton: I think it probably depends at what stage the resistance is developing.
We found the same thing in the early days. But Iain Chalmers was asking about
the first streptomycin trial. It’s quite interesting, I recently looked back again at
that report and Denny and I worked together at the Brompton, because I was
coordinating the Brompton part of the trial, and of course it was streptomycin
alone, and the original intention of the MRC was to treat the patients for six
months, but because so much drug resistance occurred152 and many of these
patients relapsed when resistance did occur, the conclusion at the end of that
was that chemotherapy could only be an accessory treatment, but then, of
course, fortunately, the other drugs came on. It’s quite interesting that the initial
response to this famous trial was rather negative, until we got the other drugs. 
Davies: To go back to what Iain [Chalmers] was saying about Chris Murray, I
think he deserves three or four marks out of ten. The lesson of Madras was that
patients under close supervision, being treated at home, did just as well as
those in sanatoria.153 The word there is close supervision. Now what’s
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happened as a result is people say patients do just as well at home as they do
in sanatoria so send them home with the drugs and they will do fine. And of
course that is not learning the lesson of Madras. The lesson of Madras is close
supervision. So in a sense, Madras has given people the wrong, well they have
taken the wrong message out of Madras, and that could well be contributing
to drug resistance. So I think Chris Murray deserves three out of ten. But he’s
a young lad, he’s done a lot and he deserves to be re-educated, and I would
welcome him back. 
Angel: Apropos of Denny’s last remarks, in the chronic trial, the chronic MRC
trial,154 where we took patients with quite big cavities and treated them for one
year, two years, or three years, we did get a group with what was labelled
isolated positive cultures, and quite often these were resistant, but then you
carried on the treatment and you had no further trouble. So this may have
been the sort of sample of stuff from the cavity wall.
Girling: Our last topic is implementing short-course therapy in routine clinical
practice, and I think Ken is going to start us off on this, and then I think
Amina [Jindani] might perhaps chip in with something on developing
countries, if we are still allowed to call them that.
Citron: Thank you, David. What I want to do is to try to give an overall
impression of the way that short-course chemotherapy was introduced into
routine clinical practice in England and Wales. I want to start in the 1960s,
and early 1970s when, as I said, we were using isoniazid and PAS for 18
months to two years, with streptomycin initially. This was routine practice, in
hospitals and in chest clinics, and I have already mentioned that we published
our follow-up in 1971 and we were delighted because 90 per cent of patients
were treated for the allocated time and all but 2 per cent became culture-
negative, and on a follow-up for three to seven years none of those actually
relapsed. So we were happy. Now there were a lot of other physicians who were
also very happy, because physicians on the whole tend to be rather
conservative, with a little ‘c’, and they tend to persist in using regimens with
which they are familiar. Of course, not all these physicians ever counted their
failures, and this was a problem that they got the impression that they were
doing very well, but they hadn’t actually had a prolonged follow-up. 
The other point I think was that they weren’t going to change to new-fangled
regimens which they had read about and had been studied in Africa and in
155 See Benedek (2004).
156 See note 91.
157 Dr Ian Sutherland was Director of the Medical Research Council’s Statistical Research and
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Hong Kong and so on, they wanted to have something for British patients,
English and Welsh patients living here, which they regarded probably as very
different. I am talking about England and Wales. I am not talking about
Scotland, which was managed by John Crofton. Remember, and we must
keep on stressing this, that we had a very adequate number of tuberculosis
nurses, so that we had the ability for close supervision at that time. I think
that there was a general feeling, especially among the old chest physicians,
who had seen tuberculosis patients lying about in sanatoria for years, to
regard tuberculosis as something that needed very prolonged treatment.
They had seen a number of apparently wonderful breakthroughs like gold
therapy155 and they had seen all that fail, so there was a great deal of
scepticism, at that time. I have no doubt that the studies that were done by
the BTTA, as it was then called, were a very important factor in convincing
physicians to adopt these short-course regimens.156 Now, as Joe [Angel]  has
said, the first BTA study was started in 1972. It was run by a committee and
the coordinators were Joe Angel and Alan Somner, and at various times, Ian
Campbell and Tony Dyson. I was chairing the committee. The statistics were
done by Ian Sutherland,157 and I am very sorry that Ian isn’t well enough to
be here this afternoon. The mycobacteriology was done by Joe Selkon.158 I
won’t go over the details, but will just remind you this was a big study. We
had over 900 patients admitted to the study.159 They were divided into eight
regimens, and these were rifampicin and isoniazid for six months, nine
months, 12 months, or 18 months, and allocated to either streptomycin or
ethambutol for two months initially.
In 1976 we published the results with a two-year post-treatment follow-up,
which showed 100 per cent conversion and no relapse in the nine-month
regimen.160 Because ethambutol was easier to take than streptomycin, the BTTA
recommended that EHR [ethambutol, isoniazid, rifampicin] for nine months
was the optimal treatment. 
161 Medical Research Council Tuberculosis and Chest Diseases Unit (1985).
162 British Thoracic Association (1982).
163 British Thoracic Society (1984).
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At that time I had the great pleasure of associating with Wallace Fox. He was
the most practical clinician you could meet and he was very concerned with
what was actually happening in practice in England and Wales, and he talked
about, as I think has been mentioned, physician compliance, or lack of
physician compliance with recommended regimens. With his MRC study
team, he looked at the epidemiology of tuberculosis throughout the UK. That
study was done in 1978–9, two or three years after the official BTTA
pronouncement of optimal therapy. He studied the treatment that was actually
given rather than what physicians said they gave. In fact, what was found was
that only one-third of patients were having anything like the BTTA
recommended regimen and most patients, at least half, were having very long
periods of treatment. So physicians were really very reluctant to reduce
treatment duration to nine months.161
You have already heard about the strong prejudice against pyrazinamide there
was at that time, because many physicians had seen toxicity in drug-resistant
cases given high doses of pyrazinamide for a prolonged period of time. It was
regarded as a dangerous drug. The BTTA did a national study of pyrazinamide
given for the first two months with either ethambutol or streptomycin. The
regimens were rifampicin and isoniazid for six months with pyrazinamide for
the first two months, with either streptomycin or ethambutol. I have to say,
and Joe Angel will remember this, that there were a few very eminent
physicians who said they wouldn’t cooperate because we were using this
dangerous drug, pyrazinamide. It was a very closely supervised study, we were
doing routine liver function tests frequently throughout. We found that there
was no difference in the incidence of hepatitis or the results of liver function
tests between the pyrazinamide regimens and the non-pyrazinamide-containing
control regimen, so that we were able to reassure physicians that it was safe given
in this dose for this period of time. In 1982 we published a two-year post-
treatment follow-up, which showed that the six-month regimen was as good as
the nine-month.162 The regimen of six months’ rifampicin and isoniazid with
initial pyrazinamide and ethambutol was recommended by the British Thoracic
Society for use in Britain in 1984.163 The MRC published the Singapore results
in 1981, and the East and Central African study was in 1983, so we published,
as it were, in the middle of these two very important MRC papers. 
I am quite sure that these multicentre studies were the thing that gave our
physicians’ confidence in and experience of using short-course chemotherapy,
and I think that these BTTA studies transformed clinical research into
practical benefits for patients. Unfortunately, I cannot tell you how quickly the
six-month recommendation was taken up, because, very sadly, the MRC
Tuberculosis and Chest Diseases Unit was shut down in 1986 when Wallace
retired and it wasn’t possible to do that study. But I am sure we have data now
to show how this has become the standard treatment.164
Dr Tony Jenkins: I would have to correct Ken [Citron] slightly.165 Joe Selkon
provided bacteriological advice to the committee, but it was my laboratory
that did all the bacteriology for both studies, and that brings me to another
point. The volume of work, particularly at the intake period, was enormous.
Specimens were flooding into the laboratory in great numbers. As one of the
staff so eloquently put it, ‘We are drowning in a sea of spit’. Fortunately we
had the capacity to absorb that amount of work, but the staff were working
their socks off to do it. The second study also involved routine urine testing
for isoniazid metabolites. My point is that to get that sort of study done today,
from the laboratory point of view, I don’t think you could do it in the UK, I
don’t think there is a laboratory that could handle that volume of primary
work, and I don’t think the accountants would let us do it. Somebody would
have to pay, and that work didn’t cost the BTTA, it cost the PHLS [Public
Health Laboratory Service] in one way, but it was absorbed totally through the
PHLS budget, but today it would be quite a different ball game.
Girling: Amina, do you want to add anything on implementing short-course
chemotherapy in developing countries, particularly in African countries?
Jindani: Yes, I want to repeat that our experiences – and I think Andrew, Janet,
Denny will confirm this – in Africa and other countries where we did trials,
things were quite different to your experiences in that our colleagues
wholeheartedly embraced short-course chemotherapy. Imagine 18 months to
six months, wow! They wholeheartedly embraced it. They have a great deal of
confidence and will accept almost anything. This can be a disadvantage,
because in a country like Nepal for instance, there are about 3000 NGOs, local
and overseas, operating in Nepal, not all in tuberculosis, but this is the extent
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of interference if you like. So we have the Japanese in the east saying use this
regimen, the Germans in the middle saying use this, and the Brits in the west.
Everybody’s getting a mixed message and so there is no standard chemotherapy
– and this is not just Nepal, this is in many other countries – so on the one
hand, while this is an advantage to have such cooperating, collaborating
compliant colleagues, on the other hand it can be a disadvantage. 
Booth: First, I have to confess I was chairman of the MRC Tropical Medicine
Research Board that, in fact, made the decision that Wallace Fox should not
be replaced when he retired. That’s simply a confession. Second point, having
listened with such interest to Ken Citron’s presentation, what does that mean
in terms of health service provision now in 2004? Who treats tuberculosis, is
it chest physicians, is it infectious diseases doctors? Do cardiologists treat
tuberculous pericarditis, do gastroenterologists treat tuberculosis of the gut?
What is the answer to that? My third question is that after 50 years having
been through so many different studies – and we have heard a lot about very
many of them today – does the National Institute for Clinical Excellence now
give advice to the health service on precisely what they should do with patients
with tuberculosis?
Ormerod: I will answer. I will follow on Ken’s comments about who treats
what and how quickly it came in, and I will answer a number of those
questions following it. When the MRC Tuberculosis Unit stopped being a
tuberculosis unit, it became briefly the Cardiothoracic Epidemiology Group,
which together with the BTS looked at the outcome of the 1988 survey, and
subsequently we have looked at it. So 11 per cent of people got short-course
chemotherapy of six months in 1983, and it was up to over 80 per cent by
1988, and now it’s very exceptional if people don’t get that. But what people
give is often longer than seven months, because we allow five to seven months
as a wide range, and people are still being treated for too long, not everybody
gets fixed-dose combinations, and in the last survey in 1998, we could only
demonstrate that about 60 per cent had actually got proper compliance
monitoring. So that’s to say what’s happening. Chest physicians treat 85 per
cent of tuberculosis in this country for pulmonary and nonpulmonary;
infectious disease physicians treat 4 per cent; cardiologists I hope treat
nothing, because they know nothing about tuberculosis, and chest physicians
statistically are better at sticking to recommendations than all other groups,
including infectious disease physicians. B category data were published in the
Royal College of Physicians Journal following the 1993 survey, we also showed
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it after the 1998 survey, but we couldn’t include it in the paper because I think
it had been refereed by an infectious disease physician.166
Girling: So it was a matter of the BTS rather than NICE?
Ormerod: No, the BTS last produced guidelines on chemotherapy and
management in 1998, and on contact tracing, control and prevention in
2000.167 These are currently being looked at by NICE; the Royal College of
Physicians’ Clinical Effectiveness Unit is handling this and I am the clinical
adviser, along with other members in this room, to that process, which started on
17December and will go through for about 18 months before gestation occurs.
Darbyshire: I just wanted to follow on from Tony Jenkins’ comment about
sputum, because the thing I remember about the studies in East Africa and Hong
Kong is jumbo jets full of sputum flying in from Hong Kong and I think that it’s
important that we acknowledge Bryan Allen, who actually masterminded that
whole venture, and Terry Morris, who made sure that they arrived off the airplane
and got to the Hammersmith in time. Because it was again another difference
between Hong Kong in that we had technicians, I think, seconded from your unit,
Denny, into Kenya, Tanzania and Zambia, with Eric, John and Aidan. When I
took over, when the Unit did close, and I remember that day very well, I was taken
to Heathrow through all the back roads and shown where the specimens arrived,
because if there was a crisis, I was going to be called to sort it out.
Angel: I would like to come to the defence of British clinicians, because when
we proposed the first study, there was enormous enthusiasm among the
clinicians who attended the BTTA summer meeting, and over the next seven
months we had 911 patients and that was partly the reason for Tony Jenkins
drowning in sputum. Similarly, with the second study, although there were
some physicians who expressed grave doubts about the toxicity, hepatotoxicity,
nevertheless we had 593 patients within a period of 18 months, so it was
obviously slower than the first one, but still quite useful.
Crofton: Can I just say something about another form of conservatism
internationally? In 1983 the IUATLD and WHO had a symposium in
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Zimbabwe to try to have all the southern African countries there and to make
recommendations about treatment. I was asked to chair the symposium and,
with Karel Styblo, to write the report and recommendations. It was regarded
as urgent. The symposium recommended that the countries should switch to
short-course chemotherapy. Karel and I worked almost nonstop for 48 hours
because of the alleged urgency, but then its publication and distribution were
delayed for months and months by WHO because WHO thought that short-
course drugs were too expensive for poor countries.168 Later, when we
introduced short-course chemotherapy through the Britain–Nepal Medical
Trust with a trial comparing similar districts still using previous long-term
treatment, we did a cost–benefit analysis. Rifampicin was still very expensive.
But when we looked at the cost per cured patient, it was just the same as
standard chemotherapy.169
Chalmers: In the 1970s and early 1980s how much tuberculosis research and
tuberculosis programme delivery was funded by private donations, rich ex-
patients or business corporations and charities? 
Mitchison: Could I say something just on that one point about funding? You
see, as far as the MRC funding was going, there was core funding for Wallace’s
unit, my unit, and this amounted at that time to about £1 million per annum,
which of course would be quite a lot more now, but it still seemed quite small
because it covered not just one study, but several studies going on
simultaneously. There was also money coming in from what was then the
Overseas Development Agency, which provided a special block of money
allocated for this work. It was mainly used to promote the African studies.
There was probably a bit of private donation money in the Hong Kong studies,
because private money was used, for instance, to fund the laboratory building
in Hong Kong. On the whole, the contribution in Britain was really very small
from private funds. 
Now the other point. I went over to the USA in about I suppose 1973 to
present for the first time the results of short-course studies to the American
Thoracic Society at their annual meeting. This was very interesting. I wasn’t
used to talking to large American meetings. It was at the end of a four-day
conference, when you normally didn’t have many people coming, but a big
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ballroom entirely packed with very hostile people – that’s what it was. I had to
get up and put over these early clinical trials, and I was attacked right, left and
centre. How could you do these unethical studies? How could you treat your
patients for such a short time? One could answer back saying, ‘Well, it’s
unethical to treat them for longer, you see.’ But it was really quite unlike the
situation in Africa unfortunately. You were met with terrible hostility because
it came essentially from something outside their country. And, of course,
coming from the old colonial master, which makes it even worse.
Girling: I think we have had an enormously enjoyable meeting, and I think we
are now to be subjected to some fully supervised alcohol, with, we hope, not
too many adverse effects. 
Dr Daphne Christie: On behalf of the History of Twentieth Century
Medicine Group, I would like to thank you for participating in today’s seminar
and to add our particular thanks to Dr David Girling for his excellent chairing
of the meeting this afternoon.
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Domiciliary chemotherapy and fully supervised intermittent regimens are the
main pillars of today’s global tuberculosis programme. Both these
revolutionary concepts originated over four decades ago at the MRC
Tuberculosis Chemotherapy Centre in Madras, during the stewardship of
Wallace Fox. While this fact is fairly well known, the trying circumstances
under which a randomized controlled trial of home and sanatorium treatment
was undertaken are not documented. At the time, the prophets of doom were
many, some saying that randomization was an alien concept in a developing
country such as India, while others predicted that no patient could be confined
to sanatorium for a year or expected to self-administer drugs at home daily for
long periods. To persuade sanatorium patients to stay put, Fox visited them
every week and discussed with his clinic staff the next morning any domestic
problems arising from their hospitalization. To monitor compliance of patients
treated at home, he introduced pill counts at periodic intervals and surprise
urine tests to check on drug ingestion; also, home visits were made to retrieve
defaulters, initially by health visitors/social workers and clinic doctors, and
eventually by Fox himself! However, he was quick to realize that such heroic
measures would be impracticable under routine programme conditions, and
that alternative approaches were therefore necessary.
Fox’s understanding of the problem of patient compliance was profound, as
can be gleaned from his remarkable review in 1961 at the Amsterdam
International Tuberculosis conference.171 When he noticed that some patients
on daily chemotherapy responded well despite minor degrees of irregularity, he
wondered if less frequent chemotherapy but fully supervised, might not be
equally effective, a concept suggested by studies of serial serum isoniazid
concentrations in patients on daily chemotherapy. This was the rationale of the
randomized control trial of fully supervised twice weekly treatment and self-
administered daily treatment, and the successful outcome of this study, both
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short-term and long-term, that was to become the genesis for the present day
global DOTS strategy.
After five years at Madras, Fox returned to London in 1961. He could well
have proclaimed then, like Julius Caesar did in 47 BC after vanquishing King
Pontus in Asia Minor, ‘Veni, Vidi, Vici’ (I came, I saw, I conquered). There is
no doubt that Fox put Madras on the tuberculosis map, but it is perhaps
equally true that the Madras experience prepared him for stiffer challenges.
Over the next three decades, even in the midst of his infinite commitments in
East Africa, Hong Kong, Singapore, Czechoslovakia and the UK, he kept very
close contact with the Madras Centre in all its research studies, notably of
short-course regimens, through meticulous correspondence and annual
consultant visits. Equally significant were his efforts in installing a serious
research culture among national staff in Madras, and the building of a first rate
infrastructure for tuberculosis research that will be celebrating its golden
jubilee next year.
Thus, the facets of Fox’s contributions to tuberculosis are many – pure science,
infrastructure development and propagation of a good research culture in
developing countries.
Dr S Radhakrishna, 2005
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On his return in 1961 from secondment to India to establish and direct the
Tuberculosis Chemotherapy Centre in Madras, Wallace rejoined the MRC
Tuberculosis and Chest Diseases Unit at the Brompton Hospital, London, and
was its director from 1965 until his retirement in 1986.  
Under his inspired leadership, this unit conducted a hugely productive
programme of randomized clinical trials and other epidemiological research in
many countries, including the UK, Czechoslovakia, central and eastern Africa,
Algeria, Hong Kong, Singapore, South Korea and Transkei. Moreover,
collaborative research with the Tuberculosis Chemotherapy Centre, Madras,
continued, and useful contributions were made to clinical trials methodology.
This programme of research identified highly effective treatment regimens for
the successful management of smear-positive and smear-negative pulmonary
tuberculosis, spinal tuberculosis, silicotuberculosis and tuberculous pericarditis.
The problems of managing patients with initially drug-resistant disease and
with acquired resistance were also addressed. Practical ways of supervising
regimens, whether given daily or intermittently, were also developed. Wallace
had a special interest in studying methods of supervising chemotherapy in a
wide variety of local situations and so of maximizing patients’ compliance in
their treatment. Such patient populations included drug addicts and prisoners
in Hong Kong, and Bedouin nomads in North Africa.
An important component of Wallace’s research programme was studying
adverse reactions to drug regimens and how best to prevent and treat them. His
programme also led to the crucial demonstration of the high effectiveness of
the combination of isoniazid, rifampicin and pyrazinamide, and so to the
development of modern short-course (six-month) chemotherapy now
universally accepted throughout the world. Few programmes of clinical
research have had such an enormously beneficial impact on public health
throughout the world; Wallace’s contributions are universally acknowledged
and appreciated.
Dr David Girling, 2004
Short-course Chemotherapy for Tuberculosis – Appendix 1 
77

Short-course Chemotherapy for Tuberculosis – References
79
Adegbola R A, Hill P, Baldeh I, Otu J, Sarr R, Sillah J, Lienhardt C, Corrah T,
Manneh K, Drobniewski F, McAdam K P. (2003) Surveillance of drug-
resistant Mycobacterium tuberculosis in The Gambia. International Journal of
Tuberculosis and Lung Disease 7: 390–3.
Algerian Working Group/[British] Medical Research Council Cooperative
Study. (1984) Controlled clinical trial comparing a 6-month and a 12-
month regimen in the treatment of pulmonary tuberculosis in the Algerian
Sahara. American Review of Respiratory Disease 129: 921–8.
American Thoracic Society/Centers for Disease Control and Prevention/
Infectious Diseases Society of America. (2003) Treatment of tuberculosis.
American Journal of Respiratory and Critical Care Medicine 167: 603–62.
Angel J H, Citron K, Campbell I A, Somner A R. (1976) Short-course
chemotherapy in pulmonary tuberculosis. Bulletin of the International Union
Against Tuberculosis 51: 57–60.
Anon. (1952) Notes and News: Isonicotinic acid derivatives in tuberculosis.
Lancet i: 571.
Anon. (1977) Results at 5 years of a controlled comparison of a 6-month and
a standard 18-month regimen of chemotherapy for pulmonary tuberculosis.
American Review of Respiratory Disease 116: 3–8.
Aquinas M. (1974) Observations on tuberculosis meningitis. Bulletin of the
International Union Against Tuberculosis 49: 74–7.
Aronson J. (1999) When I use a word...That’s show business. British Medical
Journal 319: 972.
Baker I A. (1975) The Britain–Nepal Medical Trust. Annals of the Royal College
of Surgeons of England 57: 48–9. 
Barber M, Garrod L P. (eds) (1963) Streptomycin. Toxicity and side effects.
Antibiotic and Chemotherapy. Chapter VI. Edinburgh: E & S Livingstone
Ltd, 98–101.
References
Batten J. (1968) Experimental chemotherapy of tuberculosis. British Medical
Journal 3: 75–82. 
Bayer R, Wilkinson D. (1995) Directly observed therapy for tuberculosis:
History of an idea. Lancet ii: 1545–8. 
Benedek T G. (2004) The history of gold therapy for tuberculosis. Journal of
the History of Medicine and Allied Sciences 59: 50–89.
Briggs I L, Rochester W R, Shennan D H. (1968) Streptomycin plus
thiacetazone (Thioacetazone) compared with streptomycin plus PAS and
with isoniazid plus thiacetazone in the treatment of pulmonary tuberculosis
in Rhodesia. Tubercle 49: 48–69.
Brindle R, Odhiambo J, Mitchison D. (2001) Serial counts of Mycobacterium
tuberculosis in sputum as surrogate markers of the sterilising activity 
of rifampicin and pyrazinamide in treating pulmonary tuberculosis. 
BMC Pulmonary Medicine (electronic resource). 1: 2.
(www.biomedcentral.com/1471-2466/1/2) visited 28 June 2005.
British Thoracic Association. (1982) A controlled trial of 6 months
chemotherapy in pulmonary tuberculosis. Second report: Results during the
24 months after the end of chemotherapy. American Review of Respiratory
Disease 126: 460–2.
British Thoracic Society. (1984) A controlled trial of 6 months’ chemotherapy in
pulmonary tuberculosis. Final report: Results during the 36 months after the end
of chemotherapy and beyond. British Journal of Diseases of the Chest 78: 330–6.
British Thoracic and Tuberculosis Association. (1975) Short-course
chemotherapy in pulmonary tuberculosis. Lancet i: 119–24.
British Thoracic and Tuberculosis Association (1976) Short Course
chemotherapy in pulmonary Tuberculosis. Lancet ii: 1102–4.
Brown I N, Glynn A A. (1987) The Ity/Lsh/Bcg gene significantly affects
mouse resistance to Mycobacterium lepraemurium. Immunology 64: 587–91.
Cairns H, Duthie E S, Smith H V. (1946) Intrathecal streptomycin in
meningitis: Clinical trial in tuberculous, coliform and other infections.
Lancet ii: 153–5.
Short-course Chemotherapy for Tuberculosis – References
80
Campbell I A, Dyson A J. (1977) Lymph node tuberculosis: A comparison of
various methods of treatment. Tubercle 58: 171–9.
Chalmers I. (2005) Statistical theory was not the reason that randomisation
was used in the British Medical Research Council’s clinical trial of
streptomycin for pulmonary tuberculosis, in Weisz G, Jorland G, Opinerl A.
(eds) Quantification in the Medical and Health Sciences in Historical and
Sociological Perspective. Montreal: McGill-Queens University Press, 309–34.
Chalmers I, Clarke M. (2004) Commentary: The 1944 patulin trial: The first
properly controlled multicentre trial conducted under the aegis of the British
Medical Research Council. International Journal of Epidemiology 32: 253–60.
Chonde T M. (1980) The role of bacteriological services in the National
Tuberculosis and Leprosy Programme in Tanzania. Bulletin of the
International Union Against Tuberculosis and Lung Disease 64: 37–9.
Chorine V. (1945) Action de l’amide nicotinique sur les bacilles du genre
Mycobacterium. Comptes Rendus de l’Academie des Sciences (Paris) 220: 150–1.
Christie D A, Tansey E M. (eds) (2002) Peptic ulcer: Rise and fall. Wellcome
Witnesses to Twentieth Century Medicine. Volume 14. London: The Wellcome
Trust Centre for the History of Medicine at UCL. Freely available online
under publications at www.ucl.ac.uk/histmed
Citron K M. (1972) Tuberculosis – chemotherapy. British Medical Journal i: 426.
Citron K M. (1988) Control and prevention of tuberculosis in Britain. British
Medical Bulletin 44: 704–16.
Citron K M, de Silva D J. (1971) The results of tuberculosis chemotherapy in
chest clinic practice. Tubercle 52: 31–6. 
Cochrane A L. (1979) 1931–1971: A critical review, with particular reference
to the medical profession, in Teeling-Smith G, Wells N. (eds) Medicines for
the Year 2000. London: Office of Health Economics, 1–11.
Crofton J. (1954) Chemotherapy in pulmonary tuberculosis. Edinburgh
Medical Journal 61: 155–69.
Short-course Chemotherapy for Tuberculosis – References
81
Crofton J. (1960) Tuberculosis undefeated. British Medical Journal ii: 679–87. 
Crofton J. (1991) Karel Styblo: A personal tribute. Bulletin of the International
Union Against Tuberculosis and Lung Disease 66: 211–3. 
Crofton J, Mitchison D A. (1948) Streptomycin resistance in pulmonary
tuberculosis. British Medical Journal ii: 1–18.
Crofton J, Øvreberg K. (1992) Drug resistance and National Tuberculosis
Control Programmes (NTP). Unpublished Memorandum in WHO.
Dawson J J Y, Devadatta S, Fox W, Radhakrishna S, Ramakrishnan C V,
Somasundaram P R, Stott H, Tripathy S P, Velu S. (1966) A 5-year study of
patients with pulmonary tuberculosis in a concurrent comparison of home
and sanatorium treatment for one year with isoniazid plus PAS. Bulletin of
the World Health Organization 34: 533–51.
Dickinson J M, Mitchison D A. (1968) In vitro and in vivo studies to assess
the suitability of antituberculous drugs for use in intermittent chemotherapy
regimens. Tubercle 49: 66–70. 
Dickinson J M, Mitchison D A. (1970) Observation in vitro on the suitability of
pyrazinamide for intermittent chemotherapy of tuberculosis. Tubercle 51: 389–96.
Dickinson J M, Mitchison D A. (1981) Experimental models to explain the
high sterilizing activity of rifampin in the chemotherapy of tuberculosis.
American Review of Respiratory Disease 123: 367–71.
Dickinson J M, Mitchison D A. (1987) In vitro properties of rifapentine
(MDL473) relevant to its use in intermittent chemotherapy of tuberculosis.
Tubercle 68: 113–8.
Doll R. (1994) Austin Bradford Hill. Biographical Memoirs of Fellows of the
Royal Society 40: 128–40.
Dickinson J, Guy A, Mitchison D A. (1992) Bioavailability of rifampicin in
experimental murine tuberculosis. Antimicrobial Agents and Chemotherapy
36: 2066–7.
Short-course Chemotherapy for Tuberculosis – References
82
Donald P R, Schoeman J F, Van Zyl L E, De Villiers J N, Pretorius M, Springer P.
(1998) Intensive short course chemotherapy in the management of tuberculous
meningitis. International Journal of Tuberculosis and Lung Disease 2: 704–11.
Donald P R, Sirgel F A, Venter A, Smit E, Parkin D P, Van de Wal B W, Doré
C J, Mitchison D A. (2002) The early bactericidal activity of streptomycin.
International Journal of Tuberculosis and Lung Disease 6: 693–8.
Dubovsky H. (1988) The history of para-aminosalicylic acid (PAS), the first
tuberculosis anti-microbial agent, and streptomycin (sm): A comparative
study. Adler Museum Bulletin 14: 7–11. 
East African/[British] Medical Research Council Kenya Tuberculosis Follow-
Up. (1970) Tuberculosis in Kenya: A follow-up of a national sampling
survey of drug resistance and other factors. Tubercle 51: 1–23.
East African/[British] Medical Research Council. (1960) Comparative trial of
isoniazid in combination with thiacetazone or a substituted
diphenylthiourea (SU 1906) or PAS in the treatment of acute pulmonary
tuberculosis in East Africans. Tubercle 41: 399–423.
East African/[British] Medical Research Council. (1963) Isoniazid with
thiacetazone in the treatment of pulmonary tuberculosis in East Africa –
second  investigation. Tubercle 44: 301–33.
East African/[British] Medical Research Council. (1970) Isoniazid with
thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in
East Africa – fifth investigation. A co-operative study in East African
hospitals, clinics and laboratories with the collaboration of the East African
and British Medical Research Councils. Tubercle 51: 123–51.
East African/[British] Medical Research Council. (1977) Tuberculosis in
Tanzania: A follow-up of a national sampling survey of drug resistance and
other factors. Tubercle 58: 55–78. 
East African/[British] Medical Research Council. (1978) Controlled clinical
trial of five short-course (4-month) chemotherapy regimens in pulmonary
tuberculosis. First report of 4th study. Lancet ii: 334–8.
Short-course Chemotherapy for Tuberculosis – References
83
East African/[British] Medical Research Council. (1979) Tuberculosis in
Kenya: Follow-up of the second (1974) national sampling survey and a
comparison with the follow-up data from the first (1964) national sampling
survey. An East African and British Medical Research Council co-operative
investigation. Tubercle 60: 125–49. 
Enarson D A. (1995) The International Union Against Tuberculosis and Lung
Disease model national tuberculosis programmes. Tubercle and Lung Disease
76: 95–9.
Erdei A (with comment by W E Snell). (1948) Pulmonary tuberculosis treated
with para-aminosalicylic acid: Early results in six cases. Lancet i: 791–3. 
Fagerhaugh S, Frankel M. (1970) Behind the scene – it’s the skid row hotel
manager who sees that Ernie takes his TB drugs. Bulletin – National
Tuberculosis and Respiratory Disease Association 56: 12–4.
Ferebee S H. (1970) Controlled chemoprophylaxis trials in tuberculosis. A
general review. Bibliotheca Tuberculosea (Advances in Tuberculosis Research)
26: 28–106.
Ferguson G C, Nunn A J, Fox W, Miller A B, Robinson D K, Tall R. (1971)
A second international co-operative investigation into thiacetazone side-
effects. Rashes on two thiacetazone containing regimens. Tubercle 52:
166–81.
Fox H H. (1953) The chemical attack on tuberculosis. Transactions of the New
York Academy of Sciences 15: 234–42.
Fox W. (1962a) The chemotherapy and epidemiology of tuberculosis. Some
findings of general applicability from the Tuberculosis Chemotherapy
Centre, Madras. Lancet ii: 413–7, 473–8. 
Fox W. (1962b) Self-administration of medicaments. A review of published
work and a study of the problems, in Proceedings of the XVIth International
Tuberculosis Conference, 1961. Excerpta Medica, International Congress
Series 44: 1, 307, Amsterdam.
Fox W. (1979) The chemotherapy of pulmonary tuberculosis: A review. Chest
76S: 785–96.
Short-course Chemotherapy for Tuberculosis – References
84
Fox W. (1983a) Compliance of patients and physicians: Experience and lessons
from tuberculosis – I. British Medical Journal (Clinical Research Edn) 287: 33–5. 
Fox W. (1983b) Compliance of patients and physicians: Experience and
lessons from tuberculosis – II. British Medical Journal (Clinical Research Edn)
287: 101–5.
Fox W, Ellard G A, Mitchison D A. (1999) Studies of the treatment of
tuberculosis undertaken by the British Medical Research Council
Tuberculosis Units, 1946–86, with relevant subsequent publications.
International Journal of Tuberculosis and Lung Disease 3: S231–79.
Garrod L P, Lambert H P, O’Grady F. (eds) (1973) Various anti-bacterial
antibiotics. Antibiotic and Chemotherapy. Chapter 12. 4th edn. Edinburgh:
Churchill Livingstone, 220, 446. 
Girling D J. (1977) Adverse reactions to rifampicin in antituberculosis
regimens. Journal of Antimicrobial Chemotherapy 3: 115–32.
Girling D J. (1978) The hepatic toxicity of antituberculosis regimens
containing isoniazid, rifampicin and pyrazinamide. Tubercle 59: 13–32. 
Girling D J. (1982) Adverse effects of antituberculosis drugs. Drugs 23: 54–74,
also published in Bulletin of the International Union Against Tuberculosis
1984; 59: 152–62. 
Girling D J. (1984) The role of pyrazinamide in primary chemotherapy for
pulmonary tuberculosis. Tubercle 65: 1–4.
Girling D J. (1989) The chemotherapy of tuberculosis, in Ratledge C,
Stanford J, Grange J M. (eds) The Biology of the Mycobacteria. Volume 3:
Clinical Aspects of Mycobacterial Disease. London: Academic Press, 285–323.
Girling D J, Darbyshire J H, Humphries M J, O’Mahoney Sister Gabriel.
(1988) Extra-pulmonary tuberculosis. British Medical Bulletin 44: 738–56.
Grosset J. (1971) Georges Canetti (1911–71). Bulletin of the International
Union Against Tuberculosis 46: 7–8.
Grosset J. (1978) The sterilizing value of rifampicin and pyrazinamide in
experimental short-course chemotherapy. Tubercle 59: 287–97.
Short-course Chemotherapy for Tuberculosis – References
85
Grumbach F, Canetti G, Le Lirzin M. (1969) Rifampicin in daily and
intermittent treatment of experimental murine tuberculosis, with emphasis
on late results. Tubercle 50: 280–93.
Gyselen A. (1994) Tuberculosis in Belgium: Past, present and future. Acta
Clinica Belgica 49: 125–31.
Gyselen A, Simon-Porthier F. (1969) Clinical results in first treatment and
retreatment of advanced pulmonary tuberculosis with rifampicin. Tubercle
50: 328–9.
Hakim J G, Ternouth I, Mushangi E, Siziya S, Robertson V, Malin A. (2000)
Double blind randomised placebo controlled trial of adjunctive
prednisolone in the treatment of effusive tuberculous pericarditis in HIV
seropositive patients. Heart 84: 183–8.
Harland R D. (1962) Stevens–Johnson syndrome with unusual skin features
occurring in two patients undergoing treatment for pulmonary tuberculosis
with thiacetazone. Tubercle 43: 189–91.
Hart P D. (1946) Chemotherapy of tuberculosis – research during the past
100 years. British Medical Journal ii: 805, 849.
Hart P D. (1999) A change in scientific approach: From alternation to
randomized allocation in clinical trials in the 1940s. British Medical Journal
319: 572–3. 
Herxheimer A, Zentler-Munro P, Winn D. (1986) Therapeutic Trials and
Society: Making the best use of resources. A discussion paper. London:
Consumers’ Association.
Hobby G L. (1982) In memoriam: Walsh McDermott, MD, 1909–81.
American Review of Respiratory Disease 125: 141–3.
Hong Kong Antituberculosis Association and Government Tuberculosis
Association/[British] Medical Research Council (1968).  A controlled
comparison of thiacetazone (thio-acetazone) plus isoniazid with PAS plus
isoniazid in Hong Kong. Tubercle 49: 243–80.
Short-course Chemotherapy for Tuberculosis – References
86
Hong Kong Chest Service/[British] Medical Research Council. (1977)
Controlled trial of 6-month and 9-month regimens of daily and intermittent
streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in
Hong Kong. The results up to 30 months. American Review of Respiratory
Disease 115: 727–35.
Hong Kong Chest Service/[British] Medical Research Council. (1979)
Controlled trial of 6-month and 8-month regimens in the treatment of
pulmonary tuberculosis: The results up to 24 months. Tubercle 60: 201–10. 
Hong Kong Chest Service/[British] Medical Research Council. (1987) Five-year
follow-up of a controlled trial of five 6-month regimens of chemotherapy for
pulmonary tuberculosis. American Review of Respiratory Disease 136: 1339–42.
Hong Kong Tuberculosis Treatment Services/[British] Medical Research
Council. (1976) Adverse reactions to short-course regimens containing
streptomycin, isoniazid, pyrazinamide and rifampicin in Hong Kong.
Tubercle 57: 81–95.
Hønneland G, Rowe L. (2004) Health as International Politics. Combating
communicable diseases in the Baltic Sea region. Aldershot: Ashgate
Publishing Limited.
Horne N W. (1960) Prednisolone in treatment of pulmonary tuberculosis. A
controlled trial. Final report to the Research Committee of the Tuberculosis
Society of Scotland. British Medical Journal ii: 1751–6.
Horne N W, Tulloch W S. (1975) Conservative management of renal
tuberculosis. British Journal of Urology 47: 481–7.
Horsfall P A L. (1973) Chemotherapy in the seventies. Bulletin of the Hong
Kong Medical Association 25: 23–32.
Humphries M J, Teoh R, Lau J, Gabriel M. (1990) Factors of prognostic
significance in Chinese children with tuberculous meningitis. Tubercle 71:
161–8.
Hussain S A, Saksena H C, Kothari R P. (1973) Stevens–Johnson syndrome
due to thiacetazone. Journal of the Indian Medical Association 60: 57–9.
Short-course Chemotherapy for Tuberculosis – References
87
International Union Against Tuberculosis. (1964) An international
investigation of the efficacy of chemotherapy in previously untreated
patients with pulmonary tuberculosis. Bulletin of the International Union
Against Tuberculosis 34: 80–191.
International Union Against Tuberculosis and Lung Disease. (1988)
Antituberculosis regimens of chemotherapy: Recommendations from the
Committee on Treatment of the International Union Against Tuberculosis
and Lung Disease. Bulletin of the International Union Against Tuberculosis
and Lung Disease 63: 60–4.
Ipuge Y A, Rieder H L, Enarson D A. (1995) Adverse cutaneous reactions to
thiacetazone for tuberculosis treatment in Tanzania. Lancet ii: 657–60.
Iseman M D. (2002) Tuberculosis therapy: Past, present and future. European
Respiratory Journal 20: 87S–94S. 
Jawahar M S. (2004) Current trends in chemotherapy of tuberculosis. Indian
Journal of Medical Research 120: 398–417. 
Jindani A. (1976) Short-course (6-month) treatment of pulmonary tuberculosis
(Second East African/[British] Medical Research Council Study). Bulletin of
the International Union Against Tuberculosis and Lung Disease 51: 53–6.
Jindani A, Aber V R, Edwards E A, Mitchison D A. (1980) The early
bactericidal activity of drugs in patients with pulmonary tuberculosis.
American Review of Respiratory Disease 121: 939–49.
Jindani A, Doré C J, Mitchison D A. (2003) Bactericidal and sterilizing
activities of antituberculosis drugs during the first 14 days. American Journal
of Respiratory and Critical Care Medicine 167: 1348–54.
Jindani A, Nunn A J, Enarson D E. (2004) Two 8-month regimens of
chemotherapy for treatment of newly diagnosed pulmonary tuberculosis:
International multicentred randomized trial. Lancet 364: 1244–51.
Jochem K, Fryatt R J, Harper I, White A, Luitel H, Dahal R. (1997)
Tuberculosis control in remote districts of Nepal comparing patient-
responsible short-course chemotherapy with long-course treatment.
International Journal of Tuberculosis and Lung Disease 1: 502–8.
Short-course Chemotherapy for Tuberculosis – References
88
Joint Tuberculosis Committee of the British Thoracic Society. (1990)
Chemotherapy and management of tuberculosis in the United Kingdom:
Recommendations of the Joint Tuberculosis Committee of the British
Thoracic Society. Thorax 45: 403–40. 
Joint Tuberculosis Committee of the British Thoracic Society. (1994) Control
and prevention of tuberculosis in the United Kingdom: Code of practice
1994. Thorax 49: 1193–1200.
Joint Tuberculosis Committee of the British Thoracic Society. (1998)
Chemotherapy and management of tuberculosis in the United Kingdom:
Recommendations 1998. Thorax 53: 536–48. 
Joint Tuberculosis Committee of the British Thoracic Society. (2000) Control
and prevention of tuberculosis in the United Kingdom: Code of Practice
2000. Thorax 55: 887–901.
Kahana L M. (1996) The problem of drug resistance in tuberculosis. Editorial.
Chest 110: 8–9.
Kaplan G, Post F A, Moreira A L, Wainwright H, Kreiswirth B N, Tanverdi
M, Mathema B, Ramaswamy S V, Walther G, Steyn L M, Barry C E, Bekker
L G. (2003) Mycobacterium tuberculosis growth at the cavity surface: A
microenvironment with failed immunity. Infection and Immunity 71:
7099–108. 
Keers R Y. (1978) Pulmonary Tuberculosis: A journey down the centuries.
London: Ballière Tindall. 
Kent P W, Fox W, Miller A B, Nunn A J, Tall R, Mitchison D A. (1970) The
therapy of pulmonary tuberculosis in Kenya: A comparison of the results
achieved in controlled clinical trials with those achieved by the routine
treatment services. Tubercle 51: 24–38.
Kenyan/[British] Medical Research Council. (1989) Tuberculosis in Kenya
1984: A third national survey and a comparison with earlier surveys in 1964
and 1974. A Kenyan/[British] Medical Research Council Co-operative
Investigation. Tubercle 70: 5–20. 
Short-course Chemotherapy for Tuberculosis – References
89
Kradolfer F. (1968a) On a new class of bactericidal antibiotics with special
reference to rifampicin. [German] Schweizerische Medizinische Wochenschrift
98: 622–7.
Kradolfer F. (1968b) Rifampicin in experimental tuberculosis.  [German]
Schweizerische Medizinische Wochenschrift 98: 1363.
Kritski A L, Rodrigues de Jesus L S, Andrade M K, Werneck-Barroso E, Vieira
M A M S, Haffner A, Riley L W. (1997) Editorial. Retreatment tuberculosis
cases. Factors associated with drug resistance and adverse outcomes. Chest
111: 1162–7.
Landsborough T A. (1975) Half a Century of Medical Research. Volume 1.
London: HMSO, 238–9.
Lehmann J. (1946) Para-aminosalicylic acid in the treatment of tuberculosis.
Lancet i: 15–16. 
MacGregor A R, Stewart S M, Turnbull F W. (1956) The influence of
chemotherapy on the bacterial content of tuberculous pulmonary lesions.
Tubercle 37: 388–403. 
McCune R M, Feldmann F M, Lambert H P, McDermott W. (1966)
Microbial persistence. I. The capacity of tubercle bacilli to survive
sterilization in mouse tissues. Journal of Experimental Medicine 123: 445–68.
McDermott W. (1952) Isonicotinic acid derivatives in tuberculosis treatment:
History of the development of the drugs. Transactions of the Annual Meeting.
National Tuberculosis Association 48: 421–4.
McDermott W. (1969) The story of INH. Journal of Infectious Diseases 119: 678–83. 
McDermott W. (1970) The John Barnwell lecture: Microbial drug resistance.
American Review of Respiratory Disease 102: 857–76.
McDermott W, Ormond L, Muschenheim C, Deuschle K, McCune R M Jr,
Tompsett R. (1954) Pyrazinamide–isoniazid in tuberculosis. American
Review of Tuberculosis 69: 319–33. 
Short-course Chemotherapy for Tuberculosis – References
90
McKenzie D, Malone L, Kuschner S, Oleson J J, Subbarow Y. (1948) The
effect of nicotinic acid amide on experimental tuberculosis of white mice.
Journal of Laboratory and Clinical Medicine 33: 1249–53.
Medical Research Council, Patulin Clinical Trials Committee. (1944) Clinical
trials of patulin in the common cold. Lancet ii: 373–5. 
Medical Research Council. (1948) Streptomycin treatment of pulmonary
tuberculosis: A Medical Research Council investigation. British Medical
Journal ii: 769–82.
Medical Research Council. (1955) Various combinations of isoniazid with
streptomycin or with PAS in the treatment of pulmonary tuberculosis.
British Medical Journal i: 435–45.
Medical Research Council/Tuberculosis Chemotherapy Trials Committee.
(1962) Long-term chemotherapy in the treatment of chronic pulmonary
tuberculosis with cavitation. Tubercle 43: 201–67.
Medical Research Council Tuberculosis and Chest Diseases Unit. (1985)
Treatment of pulmonary tuberculosis in patients notified in England and
Wales in 1978–9; chemotherapy and hospital admission. Thorax 40: 113–20.
Medical Research Council Working Party on Tuberculosis of the Spine. (1976)
A five-year assessment of controlled trials of in-patient and out-patient
treatment and of plaster-of-Paris jackets for tuberculosis of the spine in
children on standard chemotherapy. Studies in Masan and Pusan, Korea. Fifth
report. Journal of Bone and Joint Surgery. 58-B: 399–411.
Medical Research Council Working Party on Tuberculosis of the Spine. (1978)
Five-year assessments of controlled trials of ambulatory treatment,
debridement and anterior spinal fusion in the management of tuberculosis
of the spine. Studies in Bulawayo (Rhodesia) and in Hong Kong. Sixth
report. Journal of Bone and Joint Surgery. 60-B: 163–77.
Medical Research Council Working Party on Tuberculosis of the Spine. (1999)
Five-year assessment of controlled trials of short-course chemotherapy
regimens of 6, 9 or 18 months’ duration for spinal tuberculosis in patients
ambulatory from the start or undergoing radical surgery. Fourteenth report.
International Orthopaedics 23: 73–81.
Short-course Chemotherapy for Tuberculosis – References
91
Miller A B, Nunn A J, Robinson D K, Fox W, Somasundaram P R, Tall R.
(1972) A second international co-operative investigation into thiacetazone
side-effects 2. Frequency and geographical distribution of side-effects.
Bulletin of the World Health Organization 47: 211–27.
Mitchison D A. (1973) Plasma concentrations of isoniazid in the treatment of
tuberculosis, in Davies D S, Pritchard B N C. (eds) Biological Effects of Drugs
in Relation to Their Plasma Concentrations. London: Macmillan: 171–82. 
Mitchison D A. (1979) Basic mechanisms of chemotherapy. Chest 76S: 771–81S.
Mitchison D A. (1985) The action of antituberculosis drugs in short course
chemotherapy. Tubercle 66: 219–25.
Mitchison D A. (1990) Pyrazinamide in the chemoprophylaxis of
tuberculosis. American Review of Respiratory Disease 142: 1467. 
Mitchison D A. (1998) How drug resistance emerges as a result of poor
compliance during short course chemotherapy for tuberculosis.
International Journal of Tuberculosis and Lung Disease 2: 10–15.
Mitchison D A. (2004) The search for new sterilizing anti-tuberculosis drugs.
Frontiers in Bioscience 9: 1059–72.
Mitchison D A. (2005) The diagnosis and therapy of tuberculosis 
during the past 100 years. American Journal of Respiratory and Critical 
Care Medicine 171: 699–706. E-pub 11 February 2005. See
www.ajrccm.atsjournals.org/cgi/content/abstract/171/7/699 (visited 6
July 2005).
Mitchison D A, Selkon J B. (1956) The bactericidal activities of
antituberculous drugs. American Review of Respiratory Disease 74S: 109–16.
Mitchison D A, Dickinson J M. (1971) Laboratory aspects of intermittent
therapy. Postgraduate Medical Journal 47: 737–41.
Mitchison D A, Selkon J B, Weiner A. (1957) A case of pulmonary
tuberculosis due to isoniazid-resistant, guinea-pig attenuated,
Mycobacterium tuberculosis. Tubercle 38: 382–6. 
Short-course Chemotherapy for Tuberculosis – References
92
Mitchison D A, Ellard G A, Grosset J. (1988) New antibacterial drugs for the
treatment of mycobacterial disease in man. British Medical Bulletin 44: 757–74. 
Monie R D, Hunter A M, Rocchiccioli K, White J, Campbell I A, Kilpatrick
G S. (1982) Survey of pulmonary tuberculosis in south and west Wales
(1976–8). British Medical Journal 284: 571–3.
Mudie I S, Horne N W, Crofton J W. (1954) Isoniazid and weight gain. British
Medical Journal i: 1304–5. 
Murray C J, Styblo K, Rouillon A. (1990) Tuberculosis in developing
countries: Burden, intervention and cost. Bulletin of the International Union
Against Tuberculosis and Lung Disease 65: 6–24.
Murray C J, DeJonghe E, Chum H J, Nyangulu D S, Salomao A, Styblo K.
(1991) Cost effectiveness of chemotherapy for pulmonary tuberculosis in
three sub-Saharan African countries. Lancet 338: 1305–8.
Ntsekhe M, Wiysonge C, Volmink J A, Commerford P J, Mayosi B M. (2003)
Adjuvant corticosteroids for tuberculous pericarditis: Promising, but not
proven. Quarterly Journal of Medicine 96: 593–9.
Nuermberger E L, Yoshimatsu T, Tyagi S, O’Brien R J, Vernon A N, Chaisson
R E, Bishai W R, Grosset J H. (2004a) Moxifloxacin-containing regimen
greatly reduces time to culture conversion in murine tuberculosis. American
Journal of Respiratory and Critical Care Medicine 169: 421–6.
Nuermberger E L, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, O’Brien 
R J, Vernon A A, Chaisson R E, Bishai W R, Grosset J H. (2004b)
Moxifloxacin-containing regimens of reduced duration produce a stable cure
in murine tuberculosis. American Journal of Respiratory and Critical Care
Medicine 170: 1131–4. 
O’Brien R J. (1989) Present chemotherapy of tuberculosis. Seminars in
Respiratory Infections 4: 216–24. 
O’Mahoney G, Wing-kar C. (1973) Relationship between rifampicin-
dependent antibody scores, serum rifampicin concentrations and symptoms
in patients with adverse reactions to intermittent rifampicin treatment.
Clinical Allergy 3: 353–62. 
Short-course Chemotherapy for Tuberculosis – References
93
Ormerod L P. (2001) The clinical management of the drug-resistant patient.
Annals of the New York Academy of Sciences 953: 185–91.
Ormerod L P, Prescott R T. (2003) The management of pulmonary and lymph
node tuberculosis notified in England and Wales in 1998. Clinical Medicine
3: 57–61.
Pomerantz M, Brown J M. (1997) Surgery in the treatment of multidrug-
resistant tuberculosis. Clinics in Chest Medicine 18: 123–30.
Ramakrishnan C V, Rajendran K, Mohan K, Fox W, Radhakrishna S. (1966)
The diet, physical activity and accommodation of patients with quiescent
pulmonary tuberculosis in a poor South Indian community. Bulletin of the
World Health Organization 34: 553–71.
Reynolds L A, Tansey E M. (eds) (2001) Childhood asthma and beyond.
Wellcome Witnesses to Twentieth Century Medicine. Volume 11. London: The
Wellcome Trust Centre for the History of Medicine at UCL. Freely available
online under publications at www.ucl.ac.uk/histmed
Riska N. (1976) Hepatitis cases in isoniazid treated groups and in a control
group. Bulletin of the International Union Against Tuberculosis 51: 203–8.
Ross J D, Horne N W, Grant I W B, Crofton J W. (1958) Hospital treatment
of pulmonary tuberculosis: a follow-up study of patients admitted to
Edinburgh hospitals in 1953. British Medical Journal i: 237–42.
Sackett D L, Snow J C. (1979). The magnitude of compliance and non-
compliance, in Haynes R B, Taylor D W, Sackett D L. (eds) Compliance in
Health Care. Baltimore: Johns Hopkins University Press, 11–22. 
Saerens E J. (1972) Rifampicin: A first line tuberculostatic drug. A critical
review and appraisal. Acta Tuberculosea et Pneumologica Belgica 63: 516–28. 
Schatz A, Bugie E, Waksman S A. (1944) Streptomycin, a substance exhibiting
antibiotic activity against gram-positive and gram-negative bacteria.
Proceedings of the Society for Experimental Biology and Medicine 55: 66–9.
Schurr E, Buschman E, Malo D, Gros P, Skamene E. (1990) Immunogenetics
of mycobacterial infections: Mouse–human homologies. Journal of Infectious
Diseases 161: 634–9.
Short-course Chemotherapy for Tuberculosis – References
94
Scottish Thoracic Society. (1963) A controlled trial of chemotherapy in pulmonary
tuberculosis of doubtful activity, 5-year follow-up. Tubercle 44: 39–46.
Sensi P. (1983) History of the development of rifampin. Reviews of Infectious
Diseases 5: S402–6.
Sirgel F A, Fourie P B, Donald P R, Padayatchi N, Rustomjee R, Levin J,
Roscigno G, Norman J, McIlleron H, Mitchison D A. (2005) The early
bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis.
American Journal of Respiratory and Critical Care Medicine (E-pub ahead of print
1 April 2005). See www.ajrccm.atsjournals.org/cgi/content/abstract/172/1/128
(visited 6 July 2005).
Snell W E. (1978) The British Thoracic Association: The first fifty years. London:
British Thoracic Association.
Snider D E Jr, Zierski M, Graczyk J, Bek E, Farer L S. (1986) Short-course
tuberculosis chemotherapy studies conducted in Poland during the past
decade. European Journal of Respiratory Diseases 68: 12–18.
Somner A R. (1975) Proceedings: Short course chemotherapy in pulmonary
tuberculosis: A controlled trial by the British Thoracic and Tuberculosis
Association. (A report from one of the three clinical co-ordinators.)
Tubercle 56: 165.
Spinaci S. (1990) Tuberculosis in the 90s – a world challenge in the WHO
perspective with special reference to the Eastern IUATLD region, in Short-
course Chemotherapy for National Tuberculosis Control Programmes in
Developing Countries. Proceeding of a symposium held in Beijing Republic
of China. Oxford: Medical Publishing Foundation, 7–14.
Strang J I G, Gibson D G, Nunn A J, Kakaza H H S, Girling D J, Fox W.
(1987) Controlled trial of prednisolone as adjuvant in treatment of
tuberculous constrictive pericarditis in Transkei. Lancet ii: 1418–22. 
Strang J I G, Kakaza H H S, Gibson D G, Allen B W, Mitchison D A, Evans
D J, Girling D J, Nunn A J, Fox W. (1988) Controlled clinical trial of
complete open surgical drainage and of prednisolone in treatment of
tuberculous pericardial effusion in Transkei. Lancet ii: 759–64. 
Short-course Chemotherapy for Tuberculosis – References
95
Strang J I G, Nunn A J, Johnson D A, Casbard A, Gibson D G, Girling D J.
(2004) Management of tuberculous constrictive pericarditis and tuberculous
pericardial effusion in Transkei: Results at ten years follow-up. Quarterly
Journal of Medicine 97: 525–35. 
Sutherland I. (1998) Medical Research Council Streptomycin Trial, in
Armitage P, Colton T. (eds) Encyclopaedia of Biostatistics. Chichester: John
Wiley and Sons 3: 2554–62.
Tansey E M. (2004) Philip Montagu D’Arcy Hart. The James Lind Library
(www.jameslindlibrary.org) visited 1 June 2005.
Tansey E M, Reynolds L A. (2000) Post penicillin antibiotics: From acceptance
to resistance? Wellcome Witnesses to Twentieth Century Medicine. Volume 6.
London: The Wellcome Trust Centre for the History of Medicine at UCL.
Freely available online under publications at www.ucl.ac.uk/histmed
Tanzanian/[British] Medical Research Council. (1985) Tuberculosis in
Tanzania – a national survey of newly notified cases. Tanzanian/British
Medical Research Council Collaborative Study. Tubercle 66: 161–78.
Thwaites G E, Nguyen D B, Nguyen H D, Hoang T Q, Do T T, Nguyen 
T C, Nguyen Q H, Nguyen T T, Nguyen N H, Nguyen T N, Nguyen N
L, Nguyen H D, Vu N T, Cao H H, Tran T H, Pham P M, Nguyen T D,
Stepniewska K, White N J, Tran T H, Farrar J J. (2004) Dexamethasone for
the treatment of tuberculous meningitis in adolescents and adults. New
England Journal of Medicine 351: 1741–51.
Tuberculosis Chemotherapy Centre, Madras. (1959) A concurrent
comparison of home and sanatorium treatment of pulmonary tuberculosis
in South India. Bulletin of the World Health Organization 21: 51–144.
Tuberculosis Chemotherapy Centre, Madras. (1960) A concurrent
comparison of isoniazid plus PAS with three regimens of isoniazid alone in
the domiciliary treatment of pulmonary tuberculosis in South India.
Bulletin of the World Health Organization 23: 535–85.
Tuberculosis Chemotherapy Centre, Madras. (1963a) The prevention and
treatment of isoniazid toxicity in the therapy of pulmonary tuberculosis 
1. An assessment of two vitamin B preparations and glutamic acid. Bulletin
of the World Health Organization 28: 455–75.
Short-course Chemotherapy for Tuberculosis – References
96
Tuberculosis Chemotherapy Centre, Madras. (1963b) The prevention and
treatment of isoniazid toxicity in the therapy of pulmonary tuberculosis 
2. An assessment of the prophylactic effect of pyridoxine in low dosage.
Bulletin of the World Health Organization 29: 457–81.
Tuberculosis Chemotherapy Trials Committee. (1952) The treatment of
pulmonary tuberculosis with isoniazid. British Medical Journal ii: 735–46.
Tuberculosis Research Centre, Madras. (1983) Study of chemotherapy
regimens of 5 and 7 months’ duration and the role of corticosteroids in the
treatment of sputum-positive patients with pulmonary tuberculosis in South
India. Tubercle 64: 73–91.
Tuberculosis Society of Scotland. (1960) The treatment of pulmonary
tuberculosis at work: A controlled trial. Tubercle 41: 161–70.
Tucker W B. (1955) Comparative efficacy of the streptomycin and para-
aminosalicylic acid regimens of prolonged duration in patients with
previously untreated pulmonary tuberculosis. American Review of
Tuberculosis 72: 733–55.
Voskuil M I, Schnappinger D, Visconti K C, Harrell M I, Dolganov G M,
Sherman D R, Schoolnik G K. (2003) Inhibition of respiration by nitric
oxide induces a Mycobacterium tuberculosis dormancy program. Journal of
Experimental Medicine 198: 705–13.
Waksman S A, Woodruff H B. (1940) The soil as a source of microorganisms
antagonistic to disease producing bacteria. Journal of Bacteriology 40: 581–600. 
Wallace A T, Stewart S M, Turnbull F A, Crofton J W. (1954) Isoniazid
resistance in patients with pulmonary tuberculosis treated on isoniazid
alone. Tubercle 35: 164–70.
Wehrli W, Staehelin M. (1969) The rifamycins – relation of chemical structure
and action on RNA polymerase. Biochimica et Biophysica Acta 182: 24–9.
Wilkinson D, Moore D A. (1996) HIV-related tuberculosis in South Africa –
clinical features and outcome. South African Medical Journal 86: 64–7.
Short-course Chemotherapy for Tuberculosis – References
97
Wilkinson L. (1997) Sir Austin Bradford Hill: Medical statistics and the
quantitative approach to prevention of disease. Addiction 92: 657–66. 
World Health Organization. (1994) WHO Tuberculosis Programme:
Framework for effective tuberculosis control. WHO/TB 94: 179.
World Health Organization. (1999) What is DOTS? A guide to
understanding the WHO-recommended TB control strategy known as
DOTS. WHO/CDS/CPC/TB/ 99: 270. Geneva, Switzerland: World Health
Organization; see also www.who.int/gtb/dots (visited 28 June 2005).
Worlledge S. (1973a) The detection of rifampicin-dependent antibodies.
Scandinavian Journal of Respiratory Disease 84 (supplement): 60–63. 
Worlledge S. (1973b) Correlation between the presence of rifampicin-
dependent antibodies and the clinical data. Scandinavian Journal of
Respiratory Disease 84 (supplement): 125–8.
Yoshioka A. (1998) Use of randomisation in the Medical Research Council’s
clinical trial of streptomycin in pulmonary tuberculosis in the 1940s. British
Medical Journal ii: 1220–3.
Zhang Y, Mitchison D. (2003) The curious characteristics of pyrazinamide: 
A review. International Journal of Tuberculosis and Lung Disease 7: 6–21.
Short-course Chemotherapy for Tuberculosis – References
98
Dr Joseph Angel
(b. 1923) was coordinator of the
British Thoracic Association’s trial 
of short-course chemotherapy in
tuberculosis from 1972 to 1984. 
He had previously conducted 
clinical trials in tuberculosis at 
the State University of New York
(1957–8) and as Medical Officer at
the joint WHO/MRC Tuberculosis
Chemotherapy Centre in Madras,
South India, under the direction or
Dr Wallace Fox (1959–60). From
1964 to 1989 he was Consultant
Physician to Watford General and
Harefield Hospitals (Middlesex).
Sir Christopher Booth 
Kt FRCP (b. 1924) trained as a
gastroenterologist and was the first
Convenor of the Wellcome Trust’s
History of Twentieth Century
Medicine Group, from 1990 to
1996, and Harveian Librarian at the
Royal College of Physicians from
1989 to 1997. He was Professor of
Medicine at the Royal Postgraduate
Medical School, Hammersmith
Hospital, London, from 1966 to
1977 and Director of the Medical
Research Council’s Clinical Research
Centre, Northwick Park Hospital,
Harrow, from 1978 to 1988. 
Sir Austin Bradford Hill 
Kt CBE FRS (1897–1991) was
Professor of Medical Statistics at 
the London School of Hygiene and
Tropical Medicine from 1945 until
1961. See Doll (1994). 
Dr Ian Campbell
FRCP (b. 1944), a chest physician
in Cardiff, was one of the
coordinators of the first British
trial of short-course chemotherapy
and coordinated the first
randomized trial of chemotherapy
for lymph node tuberculosis. 
He has retained his interest in
tuberculosis, has been Honorary
Secretary, and currently is
Chairman of the Joint Tuberculosis
Committee of the British Thoracic
Society. He was President of the
Society in 2003. 
Sir Iain Chalmers 
Kt FRCPE FFPHM FMedSci 
(b. 1943) is editor of the James Lind
Library (www.jameslindlibrary.org),
a web-based resource containing
material about the history of the
development of methods to test the
effects of medical treatments. He
was Director of the UK Cochrane
Centre, Oxford, between 1992 and
Short-course Chemotherapy for Tuberculosis – Biographical notes
99
Biographical notes*
*Contributors are asked to supply details; other entries are compiled from conventional 
biographical sources.
2002, and Director of the National
Perinatal Epidemiology Unit,
Oxford, from 1978 to 1992. 
Dr Kenneth Citron 
FRCP (b. 1925) was Consultant
Physician in Respiratory Medicine
at the Royal Brompton Hospital
London, from 1959 to 1990,
President of the British Thoracic
Society (1986–8) and Chairman 
of its Tuberculosis Clinical Trials
Committee and Joint Tuberculosis
Committee (1971–88). He was 
also Consultant Adviser on
Tuberculosis to the Department 
of Health (1976–87). 
Sir John Crofton
Kt FRCP (b. 1912) was Professor
of Respiratory Diseases and
Tuberculosis at the University 
of Edinburgh from 1952 until his
retirement in 1977. From 1947 to
1950, he worked part-time at the
MRC Tuberculosis Unit at the
Brompton Hospital, London, and
as Lecturer, later Senior Lecturer, 
at the Royal Postgraduate Medical
School, Hammersmith Hospital,
London, from 1947 to 1951. 
He was a member of the MRC
Tuberculosis Chemotherapy Trials
Committee from 1952 to 1963.
Professor Janet Darbyshire
OBE FRCP FMedSci (b. 1947)
joined the MRC Tuberculosis and
Chest Diseases Unit in 1974,
where she coordinated clinical
trials and epidemiological studies
in Africa and the UK until 1989.
Subsequently she has been
responsible for a programme 
of clinical trials in HIV infection
and now, as Director of the MRC
Clinical Trials Unit, also in cancer
and other disease areas.
Dr Peter Davies
(b. 1949) has been Consultant
Chest Physician and Director 
of the Tuberculosis Research and
Resource Unit, Cardiothoracic
Centre and Aintree University
Hospital, Liverpool, since 1988,
and Honorary Professor, University
of Liverpool, since May 2004. 
He completed his DM thesis on 
the epidemiology of tuberculosis 
in England and Wales while
working as a Clinical Scientific
Officer at the MRC Tuberculosis
and CDU (1978–80). He is editor
of Clinical Tuberculosis, 3rd edn.
London: Hodder Arnold, 2003.
Mrs Caroline Doré
(b. 1949) graduated in statistics
from University College London.
She was a consultant statistician 
for the MRC Environmental
Physiology Research Unit, MRC
Clinical Research Centre, Royal
Postgraduate Medical School,
London, and became Head of the
Statistical Consultancy Service for
Imperial College School of
Short-course Chemotherapy for Tuberculosis – Biographical notes
100
Medicine. Since 2001 she has been
the Senior Statistician for the
Arthritis Research Campaign
Clinical Trials Collaboration, based
at the MRC Clinical Trials Unit.
Dr Freda Festenstein
(b. 1927) was assistant chest
physician at the London Chest
Hospital from 1963 to 1989 and
full-time Consultant Physician
with a special interest in
tuberculosis, its epidemiology 
and control, and honorary senior
lecturer in the National Heart 
and Lung Institute, London 
Chest Hospital from 1989 to
1992. Following her retirement 
in September 1992 she became
honorary senior lecturer attached
to the Department of
Microbiology with Dr John
Grange in 1993, in the Royal
Brompton National Heart and
Lung Institute. She has since
maintained an active interest in
the International Union Against
Tuberculosis and Lung Disease.
Professor Wallace Fox 
CMG FRCP FFCM (b. 1920) 
was Professor of Community
Therapeutics at the Brompton
Hospital, London, from 1979 to
1986, and Director of the MRC
Tuberculosis and Chest Diseases
Unit from 1965 to 1986. He has
been WHO Consultant from 1961
and was seconded to WHO to
establish and direct the
Tuberculosis Chemotherapy
Centre, Madras, from 1956 
to 1961 (see Appendix 1).
Dr David Girling
FRCP (b. 1937), following
appointments in chest medicine
and neonatal research, joined the
MRC Tuberculosis and Chest
Diseases Unit in 1971 and
coordinated tuberculosis trials 
in Hong Kong, Singapore,
Czechoslovakia and Transkei. 
He served on the Committee on
Treatment of the International
Union Against Tuberculosis and
Lung Disease, drafting this
committee’s recommendations on
antituberculosis chemotherapy. 
He took a particular interest in
adverse effects of antituberculosis
drugs. At the MRC Clinical 
Trials Unit, he coordinated the
programmes of lung cancer and
upper gastrointestinal tract cancer
trials and currently chairs a Data
Monitoring and Ethics Committee
for the Christie Hospital,
Manchester.
Professor Alan Glynn 
FRCP FRCPath (b. 1923) qualified
at University College Hospital,
London. He trained in clinical
medicine but after two years as a
senior registrar at St Mary’s Hospital,
London, he converted to
bacteriology becoming Professor
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there in 1971 and Head of the
Department of Bacteriology in 1974.
In 1980 he became Director of the
Central Public Health Laboratory at
Colindale, London until his
retirement in 1988.
Professor John Grange
(b. 1943) was Reader in Clinical
Microbiology at the National Heart
and Lung Institute, Imperial
College, London, from 1976 to
2000, and is currently a Visiting
Professor at the Centre for
Infectious Diseases and International
Health, Royal Free and University
College Medical School, London.
Dr Jacques Grosset
(b. 1929) was Professor of
Bacteriology, Virology, and
Hygiene, at the Faculty of
Medicine Pitié-Salpêtrière, Paris,
France (1970–99), Emeritus
Professor of Bacteriology, Virology
and Hygiene (1999–present) and
has been Visiting Professor, Center
for Tuberculosis Research, Johns
Hopkins School of Medicine,
Maryland, since 2001.
Dr Philip D’Arcy Hart
CBE FRCP Hon FMedSci 
(b. 1900) trained in medicine at
University College London, where
he became a Consultant Physician.
He was Director of the MRC
Tuberculosis Research Unit from
1948 until his retirement in 1965.
See Tansey (2004).
Dr Elizabeth Hills
MBE FRCP (b. 1935) was
Consultant Physician in Aylesbury
(1969–79) and has worked in the
Mukeza District Designated
Hospital, Tanzania, from 1980–91,
and 1994–2001, being Medical
Superintendent there from 1982.
From 1970 to 1979 she was a
member of the BTA/BTS Research
Committee.
Dr Peter Anthony (Tony) Jenkins
(b. 1936) graduated from
University College Cardiff and
from 1960–5 was Assistant
Lecturer, MRC Clinical
Immunology Research Group,
Institute of Diseases of the Chest,
Brompton Hospital, London. He
obtained his PhD from the
University of London in 1964 for
‘Immunological Studies in Farmer’s
Lung’. From 1965 to 1977 he was
Principal Scientific Officer, at the
Tuberculosis Reference Laboratory
(PHLS), Cardiff, and from 1977 to
1995, Head of the Mycobacterium
Reference Unit (PHLS), Cardiff.
Dr Amina Jindani
FRCP (b. 1936) has held various
posts as coordinator of clinical
trials at the MRC’s Tuberculosis
and Chest Diseases Unit, London,
the East African Tuberculosis
Investigation Centre (1967–77), at
the Department of Preventive
Medicine and Biostatistics of the
University of Toronto (1977–80)
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and at the International Union
Against Tuberculosis and Lung
Disease, Paris (1997–2004). She is
currently Honorary Senior Lecturer
in the Department of Cellular and
Molecular Medicine at St George’s
Hospital Medical School, London,




OBE (b. 1914) was Director of 
the East Africa Tuberculosis
Investigations Centre, Nairobi.
This was an East African
Community Research Centre that
carried out prevalence surveys as
well as clinical trials in tuberculosis
in Kenya, Uganda and Tanzania.
Dr Adrian Martineau
(b. 1971) is a clinical research
fellow at the Wellcome Centre 




(1909–81)  was Professor of Public
Health and Medicine at the
Cornell University Medical
College, New York, and Chairman
of the Department of Public
Health (1955–72). He helped
develop antimicrobial drugs for 
the treatment of tuberculosis and
in 1955 received the Albert Lasker
Award for development of the
antituberculosis drug isoniazid.
See Hobby (1982); New York Times
19 October, 1981.
Dr Jeanette Meadway
(b. 1947) was registrar and senior
registrar in respiratory medicine,
Aylesbury and St Mary’s Hospital,
London, between 1972 and 1980.
In 1981 she became consultant
physician in Newham, London.
From 1985 she worked increasingly
with tuberculosis and HIV,
becoming lead clinician in infection
and immunity in 1996. Since 1997
she has been consultant physician 
at Mildmay Mission Hospital,
London, an HIV rehabilitation 
and palliative care unit.
Professor Denis (Denny)
Mitchison
CMG FRCP FRCPath (b. 1919)
was Professor of Bacteriology at 
the Royal Postgraduate Medical
School, Hammersmith Hospital,
London, from 1971 until his
retirement in 1985 (Emeritus
Professor until 1993) and Emeritus
Professor at St George’s Hospital
Medical School, London, since
1993. He was Director of the
MRC’s Unit for Laboratory Studies
of Tuberculosis from 1956 until
1984, and collaborated with the
MRC Tuberculosis Research Unit
(from 1968 the Tuberculosis and
Chest Diseases Unit) in developing
effective chemotherapy for
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tuberculosis and research
laboratories in East Africa, 
Madras, Hong Kong, Singapore
and Prague. He performed the
laboratory tests for the 1948
Tuberculosis Chemotherapy
Committee Report and was a
member of the 1952 Committee.
Dr John Moore-Gillon
FRCP (b. 1953) is a Consultant
Physician at St Bartholomew’s 
and The Royal London Hospitals,
London. He is lead clinician for
tuberculosis for the London
Borough of Tower Hamlets,
formerly Honorary Secretary 
and now Chairman of the Joint
Tuberculosis Committee, and
formerly Chairman and now
President of the British Lung
Foundation.
Professor Andrew Nunn
(b. 1943) was the senior statistician
in the MRC Tuberculosis and
Chest Diseases Unit, from 1972 to
1986. Following the closure of the
Unit he worked in Uganda for six
years on the MRC AIDS
Programme; in 1998 he became
Head of the Division Without
Portfolio, MRC Clinical Trials
Unit, with responsibility for
developing trials in neglected areas.
Professor Lawrence (Peter)
Ormerod 
FRCP (b. 1950) was appointed
Chest Physician in Blackburn, a
high Tuberculosis District in 1980.
He was awarded his MD (1986)
and DSc (2000) for tuberculosis
clinical and operational research. 
He has been a member of the Joint
Tuberculosis Committee since 1987
(Chair from 1995 to 2000) and a
Consultant Adviser on Tuberculosis
to the Department of Health,
1997–2003. He has written 
widely on tuberculosis with over 
70 peer-reviewed papers.
Dr Knut Øvreberg
(b. 1928) was Head of the Troms
County Chest Clinic in Harstad,
Norway,  (1968–93), when he
retired. He worked with Dr Karel
Styblo in Paris and in Mozambique
from 1982 until 1992. He has
been a member of the Tuberculosis
Committee of the Britain–Nepal
Medical Trust and during the first
years with Dr Wallace Fox and Sir
John Crofton. 
Dr Geoff Scott
(b. 1948) has been Consultant
Clinical Microbiologist at
University College London
Hospitals  since 1984. He manages
patients with tuberculosis.
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Dr Joe Selkon
FRCPath (b. 1928) was a
microbiologist on the staff of the
Medical Research Council Unit 
for research into drug sensitivity in
tuberculosis, and subsequently in
charge of the microbiology
laboratory of the World Health
Organization, Tuberculosis
Chemotherapy Centre, Madras,
India. He was Consultant
Microbiologist and Director of 
the Oxford Regional Public 
Health Laboratory; Honorary
Clinical Lecturer, University of
Oxford; Chairman of the Research
Committee of the British
Tuberculosis and Thoracic
Association from 1973 to 1976;
and President of the British
Thoracic Society from 1988 to
1993. He was awarded the
Dorothy Temple Cross Fellowship
for research in tuberculosis in 1958.
Dr Alan Somner
FRCPEd (b. 1923) qualified in
Edinburgh in 1946, trained at 
the Edinburgh Respiratory
Diseases Unit and was Consultant
Physician in Respiratory Medicine,
North Tyneside, from 1960 to
1984. He coordinated several
national clinical trials in Britain 
on tuberculosis among immigrants
and chemotherapy for tuberculosis
on behalf of the British Thoracic
Association, and was their
President from 1981 to 1982.
Dr Bertie Squire
FRCP (b. 1960) trained in
infectious diseases and tropical
medicine. He was Head of the
Medical Department, Kanuzu
Central Hospital, Lilongwe,
Malawi, between 1992 and 1995.
Since 1995 he has been Senior
Lecturer in Clinical Tropical
Medicine at the Liverpool School
of Tropical Medicine. He manages
a research programme on
tuberculosis, which is funded by
the UK’s Department for
International Development.
Dr Karel Styblo
(1922–98) was scientific director 
of the International Union Against
Tuberculosis and Lung Disease
(IUATLD) in Paris (1979–91) and
developed the tuberculosis control
strategy known as DOTS. See
Crofton (1991).




The use of a chemotherapeutic
agent as a means of preventing
development of a specific disease.
Culture
A laboratory test in which tubercle
bacilli present in biological
specimens such as sputum are
grown on a suitable culture
medium. The susceptibility of the
cultured bacilli to various
antituberculosis drugs can then be
assessed. Culture incubation can
take four or more weeks.
Extrapulmonary tuberculosis 
Tuberculous disease in any part 
of the body other than the lungs
(for example, the kidney or 
lymph nodes).
Fully supervised chemotherapy
Every single dose of a regimen is
given under the direct supervision
of tuberculosis service staff, orally
administered drugs being seen to be
swallowed and the patient’s mouth
shown to be empty afterwards.
Mycobacterium
A genus of bacteria of the family
Mycobacteriaceae, order Actinomy-
cetales, occurring as Gram-positive,
aerobic and mostly slow-growing.
The most characteristic feature of
cultures of mycobacteria is that
they are acid fast.
Pro-drug
A drug that enters cells more easily
and only there gets converted to
the wanted active molecule.
Stevens–Johnson syndrome
(Erythema multiforme)
Severe red and blistering eruptions
of skin and mucous membranes,
accompanied by high fever. An
important and often fatal reaction,








A disease caused by the bacterium
Mycobacterium tuberculosis (tubercle
bacillus) which most commonly
affects the lungs (pulmonary 
tuberculosis) but can also affect 
the central nervous system
(meninges; brain and spinal cord),
lymphatic system, genitourinary
system, bones, joints and other
organs/tissues. Miliary tuberculosis
is widespread dissemination of the
bacilli in the body.
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Abbreviations
ACE =  Angiotensin-converting enzyme
ACTH = Adrenocorticotrophic hormone
ATS = American Thoracic Society
BTA = British Thoracic Association
BTS = British Thoracic Society
BTTA = British Thoracic and Tuberculosis Association
DOT = Directly observed therapy
DOTS = Directly observed therapy, short-course strategy
E = Ethambutol
EHR = Ethambutol, isoniazid and rifampicin 
ERS = European Respiratory Society
FDC = Fixed-dose combination
H = Isoniazid
HPA = Health Protection Agency
HRE = Isoniazid, rifampicin and ethambutol
HRZ = Isoniazid, rifampicin and pyrazinamide
HRZE = Isoniazid, rifampicin, pyrazinamide and ethambutol
ICMR = Indian Council of Medical Research
INAH = Isoniazid
IRS = Immune reconstitution syndrome
IUATLD = International Union Against Tuberculosis and Lung Disease 
MDR = Multidrug-resistant
MRC = Medical Research Council
NICE = National Institute for Clinical Excellence
PAS = Para-aminosalicylic acid
PHLS = Public Health Laboratory Service
PHS = Public Health Service
R = Rifampicin
3RH = Three months of daily rifampicin and isoniazid
RZ = Rifampicin and pyrazinamide
S = Streptomycin
TB = Tuberculosis
TCDU = Tuberculosis and Chest Diseases Unit
WHO = World Health Organization
Z = Pyrazinamide
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absorption, drug, 56









adverse drug reactions, 52–60, 77
HIV infection and, 57–8, 60
intermittent therapy and, 41, 53–5
prednisolone for, 50
see also hepatotoxicity; individual drugs
Africa, 30, 34, 39, 77
adverse drug reactions, 57–8, 59–60
extrapulmonary tuberculosis, 44, 45
implementing short-course therapy, 70
recommended short-course
regimens, 27, 28, 40, 73
research funding, 73
see also Central Africa; East Africa
AIDS see HIV/AIDS
air conditioning, xxi, 46
alcoholic patients, 38, 55
Algeria, xx, 13, 25, 47, 77






antibiotic sensitivity tests, 62–3, 65–6
antibodies, rifampicin-dependent, 54
antiretroviral drugs, 19, 28, 50, 58
antituberculosis drugs
adverse reactions see adverse drug 
reactions
bactericidal action, 5–6, 7–8
discovery, 9–10
intermittent therapy see intermittent
chemotherapy




resistance see drug resistance
short-course regimens see
short-course chemotherapy





ATS see American Thoracic Society
Bac Tec rapid culture methods, 62–3






Bedouin nomads, Algeria, 13, 47, 77
beta-blockers, 26
bone tuberculosis, 45
Britain see United Kingdom
Britain–Nepal Medical Trust, 12, 73
British Thoracic and Tuberculosis
Association (BTTA) see British 
Thoracic Society
British Thoracic Association (BTA) see
British Thoracic Society
British Thoracic Society (BTS) 
(formerly British Thoracic 
Association, BTA, and British 
Thoracic and Tuberculosis 
Association, BTTA), 16, 63
Index: Subject
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Cambridge meeting (1969), 22–3
lymph node tuberculosis trials, 
42–3, 45
name changes, 32
recommended regimens, 38, 68–69,
70, 72
Research Committee, 23–4, 42
short-course trials, 22–5, 27, 
29–30, 33, 68, 69–70
steroid trial, 47
summer meeting (June 1972), 24, 72
surveys of clinical practice, 32, 38, 
69, 71
Brompton Hospital see Royal
Brompton Hospital
BTA see British Thoracic Society
BTS see British Thoracic Society
BTTA see British Thoracic Society






Central Africa, xx, 25, 69
Central Bureau for the Prevention of
Tuberculosis (later IUATLD), 27
Central Research Institute, Prague, 29
chemoprophylaxis (latent 
tuberculosis), 107




chest physicians, 33, 41, 61, 68, 71–2
children, 45




implementing short-course therapy, 
32, 67–74
results of long-course therapy, 
10–18, 67
results of short-course therapy, 38–9
clinical trials
funding, 24, 25–6, 73
initial drug resistance, 65, 66
short-course chemotherapy, xx, 12, 
13–14, 18–26
see also randomized controlled trials;
specific trials
Cochrane Systematic Review, 40
communist countries, 29
compliance, 14, 18
in drug resistance prevention, 60–61
efficacy of short-course therapy and, 26
fixed dose combinations and, 62, 63
intermittent therapy, 38–40, 42
monitoring, 42, 71, 75
of physicians, recommended 
regimens, 41, 63, 69–70, 71–2
short- vs long-course chemotherapy,
12–13
consent, informed, 20–21, 22




drug resistance, 28, 29
fixed dose combination therapy, 62–3
intermittent chemotherapy, 38, 39, 40
introduction, 19
recommended regimens, 27, 28




cultures, 5, 6, 11, 107
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Czechoslovakia, xx, 25, 28–9, 37–8,
47, 76, 77
deafness (eighth nerve damage), 31, 64
Department for International
Development see Overseas 
Development Agency
Department of Health, xix
developing countries
implementing short-course therapy, 
67, 70–71




directly observed therapy (DOT), 51–2
see also supervised chemotherapy
directly observed therapy, short-course
strategy (DOTS), 31, 39, 75
selective, 61
doctors see physicians
domiciliary chemotherapy see home
treatment
DOT see directly observed therapy
DOTS see directly observed therapy,
short-course strategy
Dow Chemicals (later Merrill-Dow), 24
drug addicts, 77
drug resistance, 29, 60–67, 77
agents used in follow-up phase, 28
directly observed therapy, 52
extrapulmonary tuberculosis, 45




East Africa, xix, 25, 72, 76, 77
adverse drug reactions, 58





short course trials, 12, 13–14, 
18–22, 24, 30
East African Tuberculosis Investigation
Centre, Nairobi, Kenya, 8, 52
East and Central African study, 69
East Germany, xx, 25, 28




eighth nerve damage (deafness), 31, 64
England and Wales, 11, 33, 67–70









short-course trials, 22–3, 24–5, 68, 69
in tuberculous meningitis, 45
vs pyrazinamide, 20
vs streptomycin, 27, 29–30
ethical issues, 19, 20–21, 22
ethionamide, 45–6
ethnic groups, 39, 57
European Respiratory Society (ERS), 63
extrapulmonary tuberculosis, 42–6, 107
FDC chemotherapy see fixed-dose
combination chemotherapy
fibrosis, pulmonary, 47
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follow-up phase see continuation phase
France, xx, 25




short-course trials, 24, 25–6, 73
see also Ciba-Geigy; Lepetit  
gene probe, rifampicin resistance, 64
gold therapy, 68
Guinea, Republic of, 40
guinea-pigs, 5, 6, 16, 36–7
H see isoniazid
H2 antagonists, 26
Hammersmith Hospital, London, xxi,
72
Health Protection Agency (HPA), US,
61
health visitors, tuberculosis, 60–61
hepatitis, 55
hepatotoxicity, 30, 55–7, 72
chemoprophylaxis regimens, 56–7
pyrazinamide, 22, 30, 54–5, 56, 69
HIV/AIDS, xix
adverse drug reactions, 57–8, 60
compliance problems, 62, 63
ethics of drug trials, 19
isoniazid resistance, 62, 64
recommended short-course
regimens, 27, 28, 40
streptomycin therapy and, 27, 40
thiacetazone and, 14, 27
tuberculosis coinfection, 28, 50–51,
57–8
home treatment, Madras trial, xx,
31–2, 33, 46, 65, 66–7, 75
see also Madras, home vs sanatorium  
home visits, 75
homeless patients, 38
Hong Kong, xx, 12, 18, 25, 76, 77




intermittent chemotherapy, 37, 40
pyrazinamide toxicity, 54–5
research funding, 73
short-course trials, 19–20, 21, 47, 72
hospital-based treatment, 19, 21, 27, 42
HPA (Health Protection Agency), US, 61
HRE regimen, 61, 108
HRZ regimen, 56, 61, 108
HRZE regimen, 61, 108
human immunodeficiency virus see
HIV/AIDS
hypertension, 57





India, xix, 48, 59–60
see also Madras
Indian Council of Medical Research
(ICMR), 59
infectious disease physicians, 71–2
informed consent, 20–21, 22
intermittent chemotherapy, 30, 
36–42, 75
compliance, 38–40, 42
early trials, 19, 75
laboratory studies, 5, 36–7
toxicity and, 41, 53–5
International Conference for
Tuberculosis Doctors (later 
IUATLD), 27
International Journal of Epidemiology, 35
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International Union against
Tuberculosis (IUAT) (later 
IUATLD), 27
International Union against
Tuberculosis and Lung Disease 
(IUATLD), xx, 27, 72–3
directly observed therapy, 51, 52
extrapulmonary tuberculosis, 42
intermittent chemotherapy, 36, 53
recommended regimens, xix, 27, 
28, 30




adverse effects, 55, 58, 59–60
chemoprophylaxis, 15–16, 17–18, 
55, 56
discovery, 10
in extrapulmonary tuberculosis, 44, 
45, 46
fixed dose combinations, 61, 62, 63
intermittent therapy, 37, 75




regimens, 27, 28, 30, 69
resistance, 16, 17–18, 64
clinical significance, 65, 66
fixed dose combinations and, 62–63
rates, 29, 39, 60, 63
short-course regimens, xix, 13, 77
short-course trials, xx, 18–26, 68, 69
subjective effects, 54
urine testing for metabolites, 70
vs streptomycin, 14–15
isonicotinic acid hydrazide (INAH) see
isoniazid
IUAT see International Union Against
Tuberculosis
IUATLD see International Union




Joint Tuberculosis Committee, 57
Journal of the American Medical
Association, 52
Kenya, 13, 52, 72
Korea, xx, 25, 44, 77




volume of work, 70, 72
Latin America, 39
Lepetit Research Laboratories, Milan,
Italy, 24
liver function tests, 69
liver toxicity see hepatotoxicity
Liverpool, 60–61
London Hospital, 25




results in clinical practice, 10–18, 67
lungs
distribution of drug resistance, 66, 67
resection surgery, 11
lymph node tuberculosis, 42–3, 44, 45
macrophages, 8–9
Madras, India, 11, 44, 46–7, 75–6
adverse drug reactions, 59–60
home vs sanatorium trial, xx, 31–2, 
33, 41, 46, 65, 66–7, 75
intermittent therapy trials, 37
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MRC Tuberculosis Chemotherapy 
Centre, 75, 76, 77
research conditions, xxi, 46






Medical Research Council (MRC)
Cardiothoracic Epidemiology 
Group, 71
chronic pulmonary tuberculosis 
trial, 11, 67
early tuberculosis studies, 10, 11, 15
East African collaborating unit, 8, 52
epidemiological study, 69
Madras studies, 46
patulin trial, 35, 36
research funding, 25–6, 73
short-course trials, 3, 18–22, 25–6, 
33, 69
spinal tuberculosis trials, 42
steroid studies, 48
streptomycin trials, xix, xx–xxi, 
33–4, 36, 64, 66
Tropical Medicine Research Board, 71
Tuberculosis and Chest Diseases 
Unit see Tuberculosis and Chest 
Diseases Unit
Tuberculosis Chemotherapy Centre,
Madras, 75, 76, 77
uptake of research findings, 32, 40–41
meningitis, tuberculous, 43–4, 45–6,
48, 50
Merrill-Dow, 24
miliary tuberculosis, 45, 107
mouse, 5
drug absorption, 56










Mycobacterium tuberculosis see tubercle
bacilli
National Institute for Clinical
Excellence (NICE), 71, 72
Nepal, 12, 51, 70–71
NICE see National Institute for
Clinical Excellence
nicotinamide, 10
nitric oxide (NO), 7
nomads, Algerian (Bedouin), 13, 47, 77
nurses, tuberculosis, 16, 68
ocular side-effects, 55
Overseas Development Agency (later
Department for International 
Development), 26, 73











PAS see para-aminosalicylic acid
Pasteur Institute, Paris, 6, 22
patient preferences, 29–30, 39
patulin trial, xx, 35–6
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penicillin, xx, 9, 64
pericarditis, tuberculous, 48, 49, 51, 77
peripheral neuropathy, 58, 59
pharmaceutical companies, 24, 25–6
PHLS see Public Health Laboratory
Service
PHS see Public Health Service
physicians
compliance with recommendations, 
41, 63, 69–70, 71–2
conservatism, 33–4, 67–8, 72–3
ensuring patient compliance, 61
see also chest physicians
placebo, 40, 54, 55
pleural effusion, tuberculous, 48, 51
pneumocystis, 60
Poland, xx, 25, 28
polypharmacy, 57–8
populations, bacterial, 5, 8
Prague, Czechoslovakia, 29, 37–8
prednisolone, 47, 49, 50, 51
prednisone, 47, 49




Public Health Laboratory Service
(PHLS), UK, 70
Public Health Service (PHS), US, 55
pulmonary tuberculosis, 77, 107
chronic, 11, 67
short-course trials, 18–25
steroid therapy, 47, 48–9
streptomycin trial, 64
pyrazinamide (Z)
adverse effects, 22, 30, 54–5, 56, 69
chemoprophylaxis, 56
duration of therapy, 7, 19, 20, 26
in extrapulmonary tuberculosis, 44, 
45–6
fixed dose combinations, 61, 62, 63
introduction into clinical practice, 
32, 69
mode of action, 4, 6–7
mouse experiments, 6, 9, 22
short-course regimens, xix, 27, 30, 
69, 77
short-course trials, xx, 18–26, 30, 69
pyrazinoic acid, 6
pyridoxine (vitamin B6), 58, 59
R see rifampicin
randomized controlled trials, 65
first, xx–xxi, 33–6
see also clinical trials
recommended short-course regimens, 
xix, 26–36, 69, 72–3
in HIV/AIDS, 27, 28, 40
intermittent dosing, 36, 38, 39, 41–2
introduction into clinical practice, 
32, 67–74
relapse, 10
long-course regimens, xix, 11–12, 
16–17
short-course studies, 24, 27, 30
renal tuberculosis, 49–50
research
integration of clinical and
laboratory, 3–10
introduction into practice, 32
laboratory, 3–5, 36–7
3RH regimen, 57, 108
rifampicin (rifampin) (R), 8





in extrapulmonary tuberculosis, 44, 
45, 46
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in HIV-positive patients, 28
intermittent therapy, 37, 40, 53–4




regimens, 27, 28, 30, 69
resistance, 28, 64, 65
short-course regimens, xix, 13, 77








Royal Brompton Hospital, London,
xix, 66, 77
Royal College of Physicians, London, 
34–5
Clinical Effectiveness Unit, 72
Journal, 71–2
Royal Postgraduate Medical School,








Madras trial, xx, 31–2, 33, 46, 65, 
66–7, 75




see also lymph node tuberculosis
sensitivity tests, antibiotic, 62–3, 65–6
short-course chemotherapy, 77
compliance advantages, 12–13
continuation phase see continuation
phase
in developing countries, 12
duration, 20, 27, 71
early trials, xx, 12, 13–14, 18–26
funding of trials, 24, 25–6, 73
introduction into clinical practice, 
32, 67–74
lymph node tuberculosis, 42–3




results in practice, 38–9
in spinal tuberculosis, 44
standard regimen, 20
silicotuberculosis, 55, 77
Singapore, xx, 12, 18, 76, 77
adverse drug reactions, 58
intermittent chemotherapy, 37, 39
short-course trials, 20, 21, 25, 30, 69
soil bacteria, 9, 10
South Africa, 44, 45, 48, 49, 57–8
spinal tuberculosis, 25, 42, 44, 77
sputum
culture-negative rates, 23, 24
drug resistance, 66
numbers of samples, 70, 72
viable bacillus counts, 5, 8, 9
St Mary’s Hospital, London, 43–4
statins, 57
Stellenbosch University, South Africa, 45
sterilizing action of drugs, 4, 5–6
steroids (corticosteroids)
in HIV and tuberculosis coinfection,
51
inhaled, 26
in tuberculosis management, 46, 
47–51
Stevens–Johnson syndrome, 14, 107
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Streptomyces, 10, 107
streptomycin (S), xx–xxi, 29–30
adverse effects, 25, 58, 64
discovery, 9
first clinical trial, xix, xx–xxi, 33–4, 
36, 64, 66
for fractious patients, 39
HIV transmission risk, 27
intermittent therapy, 37
isoniazid comparative studies, 14–15
long-course treatment, xix, 10, 13, 
16–17, 67
personal experience, xxi, 31
recommended short-course
regimens, 27, 40
resistance, xx–xxi, 64, 66
short-course regimens, xix, 13
short-course trials, 18–26, 68, 69
in tuberculous meningitis, 43–4
vs ethambutol, 27
Study A, 55
Study R, xx, 18, 20–22
Study U, 27
Study X, 20
supervised chemotherapy, 26, 51–2, 77
fully, 27, 38, 39, 75, 107
intermittent, 37–8, 39, 41
Madras trial, 66–7
in UK, 16, 68
surgery, lung resection, 11
Sweden, 16
Tanzania, 13, 28, 58, 72
TB see tuberculosis




short-course regimens, xix, 27, 28
toxicity, 13–14
thiazide diuretics, 57
Thiazina (isoniazid and thiacetazone), 13




toxicity, drug see adverse drug
reactions
transaminases, serum, 56
Transkei, South Africa, xx, 25, 49, 77
tubercle bacilli (Mycobacterium
tuberculosis), 107
early rapid killing by drugs, 5–6, 8
in mice, 7
pyrazinamide-mediated killing, 6–7
separate populations hypothesis, 5, 8




extrapulmonary see extrapulmonary 
tuberculosis




Tuberculosis and Chest Diseases Unit
(TCDU), MRC, 3, 18, 49, 70, 71, 
72, 77
Tuberculosis Chemotherapy Centre,
Madras, India, 75, 76, 77
Tuberculosis Research Unit see
Tuberculosis and Chest Diseases 
Unit
UK see United Kingdom
United Kingdom (UK), xx, 25, 76, 77
drug resistance, 60–63
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recommended regimens, 30, 36, 38,
68–9, 70, 72
results of long-course chemotherapy,
10–11, 16–17, 67
results of short-course 
chemotherapy, 38–9




hostility to short-course therapy, 73–4








urine testing, 42, 70, 75
US see United States
Vietnam, 48
vitamin B6 (pyridoxine), 58, 59
Wandsworth, London, chest clinic,
16–17
Wellcome Trust, London, 49
WHO see World Health Organization
World Health Organization (WHO),
xix, 12, 65, 72–3
DOTS, 31, 51, 52
isoniazid monotherapy, 16
Madras studies, 46, 59
recommended regimens, 27, 28, 34,
39, 41–2, 63–4, 73
X-rays, 47, 48, 49
Z see pyrazinamide
Zambia, xx, 20, 72
Zimbabwe, 15, 44, 51, 73
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